LabId,ID Sample,PatientId,consensus_sex,inferred_sex,inferred_ethnicity,centerID,CEBPA_Biallelic,ageAtDiagnosis,isRelapse,isDenovo,isTransformed,finalFusion,specificDxAtAcquisition_MDSMPN,nonAML_MDSMPN_specificDxAtAcquisition,priorMalignancyNonMyeloid,priorMalignancyType,cumulativeChemo,priorMalignancyRadiationTx,priorMDS,priorMDSMoreThanTwoMths,priorMDSMPN,priorMDSMPNMoreThanTwoMths,priorMPN,priorMPNMoreThanTwoMths,dxAtInclusion,specificDxAtInclusion,ELN2017,ELN2008,dxAtSpecimenAcquisition,specificDxAtAcquisition,ageAtSpecimenAcquisition,timeOfSampleCollectionRelativeToInclusion,specimenGroups,specimenType,rnaSeq,exomeSeq,totalDrug,rnaSeqAnalysis,analysisExomeSeq,analysisDrug,cumulativeTreatmentTypeCount,cumulativeTreatmentTypes,cumulativeTreatmentRegimenCount,cumulativeTreatmentRegimens,cumulativeTreatmentStageCount,cumulativeTreatmentStages,responseToInductionTx,typeInductionTx,responseDurationToInductionTx,mostRecentTreatmentType,currentRegimen,currentStage,mostRecentTreatmentDuration,vitalStatus,causeOfDeath,any_different_labs,any_different_labs_also_beataml,different_lab_ids,different_id_karyotype_interval,%.Basophils.in.PB,%.Blasts.in.BM,%.Blasts.in.PB,%.Eosinophils.in.PB,%.Immature.Granulocytes.in.PB,%.Lymphocytes.in.PB,%.Monocytes.in.PB,%.Neutrophils.in.PB,%.Nucleated.RBCs.in.PB,ALT,AST,Albumin,Creatinine,FAB/Blast.Morphology,Hematocrit,Hemoglobin,Karyotype,LDH,MCV,Other.Cytogenetics,Platelet.Count,Surface.Antigens.(Immunohistochemical.Stains),Total.Protein,WBC.Count,any_different_cgs,any_different_cgs_also_beataml,different_cgs_lab_ids,FLT3-ITD,NPM1
14-00231,BA2737,1533,Female,Female,White,2,n,57,FALSE,FALSE,FALSE,Complex,FALSE,FALSE,y,Ovarian cancer|Ovarian cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,57,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea",4,Consolidation|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,5,Supportive/Palliative Care,"Decitabine, Hydroxyurea",Supportive/Palliative Care,-1,Dead,Dead-Unknown,FALSE,FALSE,,0,0,76,79,0,,9,5,4,,45,41,3.2,,,28.6,9.6,"46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",64,"CD2(-), CD4(+), CD5(equivocal), CD7(-), CD11b(+), CD13(-), CD14(partial +), CD15(+), CD16(-), CD33 (bright +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56(+), CD64(+), CD117(partial +), HLA-DR(+)",6.3,19.5,FALSE,FALSE,,negative,negative
16-00547,BA2882,2723,Male,Male,HispNative,1,n,29,FALSE,FALSE,FALSE,MLLT3-KMT2A,FALSE,FALSE,y,Non-Hodgkins Lymphoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,29,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,19,Standard Chemotherapy,HiDAC,Re-induction,4,Dead,Dead-Unknown,FALSE,FALSE,,0,0.9,82,20,0,2.6,26.3,33.4,7.9,3.6,40,19,3.1,0.84,,27.3,9.1,"46,XY,t(9;11)(p22;q23)[20]",324,89.5,"94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, consistent with MLL rearrangement and the 9;11 translocation observed in the metaphase karyotype.",52,"CD11b, varibleCD13, CD14, brightCD33, CD64, and HLA-DR positive",6.7,3.88,FALSE,FALSE,,negative,negative
13-00655,BA2814,1394,Male,Male,White,3,n,62,FALSE,FALSE,FALSE,MLLT3-KMT2A,FALSE,FALSE,y,Prostate Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,62,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin) ",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, TBI",Allogeneic - Matched Unrelated Donor,-1,Dead,Dead-Disease,TRUE,TRUE,13-00654,-1,,93,58,,,,,,,,,,,M5a,,,"47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]",,,8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present,,"Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.",,14.66,TRUE,TRUE,13-00654,negative,negative
15-00633,BA2304,2241,Female,Female,White,3,n,52,FALSE,FALSE,FALSE,MLLT3-KMT2A,FALSE,FALSE,y,Breast Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,52,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, ATG, Methotrexate",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG, Methotrexate",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,-3,,,,,,,,,,,,,,,,,"46,XX,t(9;11)(p22;q23)[5]",,,11q23 (MLL): rearrangement present,,,,,FALSE,FALSE,,negative,negative
16-00494,BA2234,2705,Female,Female,White,1,n,72,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Non-Hodgkins Lymphoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,72,1,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Salvage,5,Dead,Dead-Disease,FALSE,FALSE,,0,0,90,94,1.9,0,4.6,89.8,3.7,0.2,,,2.8,0.93,M5,37.1,11.9,"46,XX,t(1;11)(p32;q23)[20]",,96.6,MLL: 94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal,33,"dim CD4, CD11b, partial CD13, partial CD14, CD15, CD33, partial CD56, CD58, bright CD64, partial CD123 and HLA-DR-positive",,104.44,FALSE,FALSE,,negative,negative
13-00500,BA2995,1248,Male,Male,White,2,n,71,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Prostate Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,55,Dead,Dead-Unknown,FALSE,FALSE,,0,0,76,58,2,,38,6,14,,27,25,3.1,,,25,8.5,"46,XY",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[29/200],(D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[11/200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",93,"CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial +), CD13(partial +), CD15(-), CD19(-), CD22(partial +), CD33(partial and variably +), CD34(variably +), CD36(partial +), CD38(variably +), CD45(partial +), CD56(-), CD64(partial +), CD117 (partial +), HLA-DR(+), TdT(partial +), MPO(-)",5.8,7.5,FALSE,FALSE,,negative,negative
14-00448,BA2302,1656,Female,Female,White,4,n,78,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Uterine Sarcoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,78,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Azacitidine, MLN4924",1,Induction,Refractory,Standard Chemotherapy,111,Standard Chemotherapy,"Azacitidine, MLN4924",Induction,111,Dead,Dead-Disease,TRUE,TRUE,14-00449,0,,78,77,,,,1,,,,,,,,,,"46,XX[20]",,,,,"CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR",,5.6,TRUE,TRUE,14-00449,negative,negative
16-00048,BA2174,2483,Female,Female,Asian,1,n,46,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Anaplastic Astrocytoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,46,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,7,"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG",4,Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),Refractory,Standard Chemotherapy,1,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG",Double Umbilical Cord Blood Transplant (DUCBT),-1,Dead,Dead-Disease,FALSE,FALSE,,0,0.9,25,26.7,1.7,4.3,6.1,32.2,48.7,0.2,14,15,3.1,0.64,,32,9.5,"46,XX,del(3)(p25),add(6)(p22),t(10;12)(p15;q13)[5]/46,XX[18]",440,80.6,Normal,92,"Immunophenotype: CD13, CD34, CD38, CD58, CD117, CD123, HLA-DR and TdT-positive; small subset of blasts also express CD19, CD22, and CD79a",6.8,42.57,FALSE,FALSE,,negative,negative
16-01185,BA2414,4252,Male,Male,White,5,n,50,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,50,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, Thiotepa, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1,Dead,Dead-Unknown,FALSE,FALSE,,0,0,75,82,2,,4,0,8,,39,45,3.7,,,20.1,6.5,"46,XY,add(1)(p11),del(5)(q15q33),del(7)(q22q36),der(11)t(1;11)(p31;p12-14)[20] ",,,Loss of 5q31 sequences for 99% of total cells,12,"Positive: CD38, CD56, CD13, CD34, CD45, CD117, HLA-DR",6.3,119.6,FALSE,FALSE,,positive,negative
16-00491,BA2726,2704,Female,Female,White,1,n,29,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Basal Cell Carcinoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,29,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,3,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,5,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib",3,Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,5,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,2,Dead,Dead-Disease,FALSE,FALSE,,-1,0,98,3.1,2,1,60,13,24,1.7,393,350,2.5,0.69,,27.2,9.4,"47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]",,105.4,Normal,18,"CD11b, CD13, CD14, CD33, CD56 and bright CD64+",5.4,2.42,FALSE,FALSE,,negative,positive
15-00593,BA2344,2225,Female,Female,White,3,n,71,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Follicular lymphoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,71,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone",4,Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,-1,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1,Dead,Dead-Disease,FALSE,FALSE,,-1,,82,66,,,,,,,,,,,,,,"46,XX,del(7)(q22q36)[20]",,,"ABNORMAL FISH RESULT 7cen (D7Z1), 7q31 (D7S486): deletion present",,"CD7, CD13, weak CD33, CD34, CD117, and HLA-DR",,133.7,FALSE,FALSE,,negative,negative
14-00289,BA2220,1561,Male,Male,White,1,n,23,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,mediastinum mass,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,23,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,"Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin) ",3,Consolidation|Induction|Experimental,Complete Response,Standard Chemotherapy,8,Targeted Therapy - Kinase Inhibitor(s),Trametinib,Experimental,197,Dead,Dead-Disease,TRUE,FALSE,14-00288,0,3.2,3,20.4,2.1,,25.8,1.1,36.6,43.4,32,131,3,0.91,,17.9,5.7,"48,XY,add(6)(p22),der(7)t(7;19)(p11.1;p12),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp20]",16499,95.2,Low-level tetraploidy or near-tetraploidy,24,,5.6,40.76,FALSE,FALSE,,negative,negative
16-00731,BA2721,3990,Female,Female,White,1,n,69,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Breast Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",69,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,7,"7+3 (Cytarabine, Idarubicin)|Azacitidine, Midostaurin|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924",4,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,6,Targeted Therapy - Other,ALRN-6924,Salvage,-1,Alive,Alive,FALSE,FALSE,,0,1.8,40,42.1,0.9,8.8,10.5,9.6,26.3,2.8,27,22,3.4,0.64,,23.5,7.1,"46,XX[20]",399,103.5,normal,12,"CD13, CD34, CD58, CD117, partial MPO and HLA-DR +",6.5,61.22,FALSE,FALSE,,positive,negative
15-00171,BA2520,2002,Male,Male,White,5,n,80,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,80,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),3,"Cytarabine|Decitabine|PF-04449913 (Hedgehog Inhibitor), LDAC",3,Consolidation|Salvage|Experimental,,,,Targeted Therapy - Kinase Inhibitor(s),Decitabine,Salvage,-1,Dead,Dead-Disease,FALSE,FALSE,,1,,80,86,,,,,,,,,,,,,,"46,XY,del(20)(q11.2q13.1)[15]/46,XY[5]",,,Positive for deletion of 20q12 in 11.5% of 200 cells,4,"positive for dim CD7, dim CD10, CD34, CD38, dim CD45, cCD79a, CD99, HLA-DR, TdT, dim PAX5",,,FALSE,FALSE,,negative,negative
15-00981,BA2846,2454,Male,Male,White,1,n,75,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Rectal Cancer,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,75,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Supportive/Palliative Care,2,Hydroxyurea|Decitabine,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,4,Dead,Dead-Disease,FALSE,FALSE,,0,0,90,90,0,0,5.1,0.8,0.9,1,23,51,2.9,0.97,,25.3,8.5,"46,XY[20]",728,91.3,Normal,28,"CD33, dim CD38, variable CD56, CD58, dim CD64, CD117, CD123, and MPO positive.",6.6,62.87,FALSE,FALSE,,negative,positive
15-00683,BA2355,2273,Female,Female,White,5,n,83,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Squamous cell carcinoma|Lung Cancer,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,83,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,n,y,n,n,1,Targeted Therapy - Other,1,AG-221,1,Experimental,,,,Targeted Therapy - Other,AG-221,Experimental,-1,Unknown,,FALSE,FALSE,,0,,45,,,,,,,,,,,,,,,"46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.1),del(19)(p13.3)[20]",,,"FISH assays were positive for findings consistent with trisomy 8 in 79% to 90% of assayed cells, and positive for loss of 16q22 sequences in 91.5% of assayed cells.",133,"positive for CD34, CD117, HLA-DR, and CD13, with aberrant loss of CD33, and with a subset of the blasts showing aberrant co-expression of CD34 and myeloperoxidase",,2.2,FALSE,FALSE,,negative,negative
13-00123,BA2104,1027,Male,Male,White,1,n,83,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Colon Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,83,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,Dead-Disease,FALSE,FALSE,,-1,0,,>90,0,,9,7,4,,242,341,1.9,2.48,M5,17.6,6.2,"47,XY,+8[6]/46,XY[13]",2037,94.5,trisomy 8,14,"Immunophenotype:  CD11b, CD13, dimCD14, CD15, dim CD16, CD33,     CD56,     CD58, CD64, CD123, and HLA-DR positive",3.6,85.9,FALSE,FALSE,,negative,positive
16-00004,BA2402,2462,Female,Female,White,1,n,82,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Breast Cancer,y,y,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,82,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,Dead-Disease,FALSE,FALSE,,0,0,50,,0,1.8,42.8,0,5.4,3.7,13,18,2.8,1.03,,27.7,9.2,"46,XX",279,91.1,trisomy 8 in 5 of 20 metaphase cells ,44,,7,1.36,FALSE,FALSE,,negative,negative
16-00113,BA2880,2521,Male,Male,White,5,n,85,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Not specified,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,85,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,TRUE,FALSE,16-00114,0,1.5,2,,24,,11.5,8,55,,4,8,3.7,1.2,,48.8,16.1,"46,XY[20]",,,Normal,141,,6.3,11.4,FALSE,FALSE,,negative,negative
15-00051,BA2789,1929,Female,Female,White,1,n,66,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,y,Breast Cancer,y,y,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,66,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Matched Unrelated Donor,2,Alive,Alive,FALSE,FALSE,,0,0,95,90.2,0,2.5,4.9,0.8,1.6,0.6,19,23,3,0.5,,18.9,6.1,,501,100.5,Normal,10,"CD13, CD33, dim CD71, CD117, CD123, and MPO",6.4,66.67,FALSE,FALSE,,negative,positive
13-00034,BA2712,958,Female,Female,White,2,n,61,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,y,Follicular lymphoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,61,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,Dead-Disease,FALSE,FALSE,,0,1,50,89,1,,0,0,0,,61,,2.5,0.84,,25.3,8.4,,,102.8,,24,"CD2(-), CD4(dim +), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +), CD15(variably and slightly bright +), CD16 (-), CD33(variably bright +), CD34(-), CD36(partial +), CD38(variably +), CD45(variably +), CD56(+), CD64(partial +), CD117(-), HLA-DR(partial dim +), MPO(+), TdT(-).",4.5,53,FALSE,FALSE,,negative,negative
15-00491,BA2691,2172,Male,Male,White,1,n,83,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,y,Prostate Cancer,y,y,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,83,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,Dead-Unknown,FALSE,FALSE,,0,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,negative,negative
14-00712,BA2872,1810,Male,Male,White,1,n,65,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Pancreatic adenocarcinoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,65,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Other,3,"3+7 (Cytarabine, Daunorubicin)|Decitabine|5+2 (Ara-C, Daunorubicin)",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Decitabine,Salvage,9,Dead,Dead-Disease,FALSE,FALSE,,0,0,18,12,0.9,32,7.4,35.2,18.5,4.8,44,165,2.9,1.65,,20.1,6.7,"46,XY,i(17)(q10)[20]",3923,81,"TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metaphase analysis.",40,"CD13, CD33, CD34, CD117, and HLA-DR positive",5.7,161.89,FALSE,FALSE,,negative,negative
14-00184,BA2906,1513,Male,Male,White,1,n,5,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,5,0,Initial Acute Leukemia Diagnosis|Post-Transplant,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"ADE (Cytarabine, Daunorubicin & Etoposide)|Cyclophosphamide, TBI|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Allogeneic - Sibling|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,9,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,0,0,,80,0,,33,0,0,0,12,32,3,0.44,M5,17.1,5.7,"46,XY[25]",1072,98.8,MLL rearrangement,34,"CD4, CD11b, CD15, CD33, bright CD34, CD38, CD58, CD64,CD71, CD117, CD123, HLA-DR and dim/partial MPO positive",7.4,95.2,FALSE,FALSE,,negative,negative
14-00597,BA2787,1604,Male,Male,White,3,n,58,FALSE,FALSE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,58,100,Post-Chemotherapy,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin) ",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,HiDAC,Consolidation,210,Alive,Alive,TRUE,FALSE,14-00596,0,,0.4,,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,,,29.18,FALSE,FALSE,,negative,negative
15-00081,BA2415,1757,Male,Male,White,3,n,48,FALSE,FALSE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,49,152,Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,6,"Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|FLAG-IDA, Gemtuzumab|Cytarabine, Methotrexate",5,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|CNS|Re-induction,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)",Allogeneic - Mismatched Unrelated Donor,-1,Dead,Dead-Disease,FALSE,FALSE,,-2,,,,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,,,,FALSE,FALSE,,negative,negative
15-00921,BA2934,2429,Female,Female,White,1,n,74,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Unknown,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",74,0,Post-Chemotherapy,Peripheral Blood,y,n,n,y,n,n,1,Standard Chemotherapy,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|MiDAC",2,Consolidation|Induction,Refractory,Standard Chemotherapy,8,Standard Chemotherapy,MiDAC,Consolidation,3,Alive,Alive,FALSE,FALSE,,-105,0.9,,,1.9,0.2,27.7,3.5,65.8,0,30,36,4.3,0.8,,38.7,13,"46,XX[20]",,102.9,normal,206,,7.3,4.26,FALSE,FALSE,,,
15-00929,BA2539,2433,Female,Female,White,3,n,50,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,50,0,Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)|MiDAC",4,Consolidation|Induction|Re-induction|Maintenance,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,Azacitidine,Maintenance,8,Dead,Dead-Treatment,TRUE,FALSE,15-00930,-1,,,,,,,,,,,,,,,,,"46,XX[20]",,,"""showed multiple RUNX1 signals as well as a 3rd RUNX1 signal at 7p consistent with t(7;21)(p22;q22).""",,,,10.08,FALSE,FALSE,,negative,negative
15-00140,BA2221,1721,Male,Male,White,2,n,68,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68,184,Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)",4,Consolidation|Induction|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,Azacitidine,Maintenance,-1,Alive,Alive,FALSE,FALSE,,0,,1,0,,,,,,,23,24,4.6,,,35.4,12,"46,XY",,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",61,"CD38(bright +), CD45(-), CD56(+), intracellular kappa(+), intracellular lambda(-)",7.5,2.6,FALSE,FALSE,,negative,negative
16-00875,BA2088,4052,Female,Female,Black,6,n,45,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",46,0,Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|CLAG (Cladribine, Cytarabine, Filgrastim)",4,Consolidation|Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,25,Standard Chemotherapy,"CLAG (Cladribine, Cytarabine, Filgrastim)",Salvage,23,Alive,Alive,FALSE,FALSE,,0,,3,,,,,4,,,,,,,,,,"45,XX,-7[4]/46,sl,+mar[2]/46,XX[14]",,,,69,MLL-PTD is not detected. FLT3-ITD not detected. FLT3-TKD mutation not detected. Pathogenic alterations are detected in the DNMT3A and IDH1 genes. Genomic alteration of uncertain significance is detected in the DNMT3A gene.,,1.3,FALSE,FALSE,,negative,negative
14-00608,BA2122,1749,Female,Female,White,4,n,75,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,77,716,Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,1131,Dead,Dead-Other,FALSE,FALSE,,-710,,,,,,,,,,,,,,,,,"46,XX[8]",,,,,,,,FALSE,FALSE,,negative,negative
16-01192,BA2079,4201,Female,Female,White,1,n,52,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,52,34,Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"MiDAC|FLAG-IDA plus Midostaurin|7+3 (Cytarabine, Idarubicin) plus Dasatinib ",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,FLAG-IDA plus Midostaurin,Salvage,-1,Alive,Alive,TRUE,TRUE,16-01143;16-01022,-6,1.4,,,0.2,,9.2,24.3,64.9,,119,151,3.2,0.76,,28.4,9.2,"46,XX[20] ",380,93.4,Normal,395,,6.6,6.5,TRUE,FALSE,16-01143;16-01146,negative,negative
15-00043,BA2348,1924,Female,Female,White,5,n,43,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,44,0,Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Induction|Re-induction,Refractory,Standard Chemotherapy,12,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,-46,,,,,,,,,,,,,,,,,"46,XX,add(3)(q21)[12]/52,sl,+6,+8,+10,+13,+20,+21[8]",,,Positive for an EVI1 rearrangement,,,,,FALSE,FALSE,,negative,negative
14-00815,BA2096,1814,Female,Female,White,2,n,32,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",32,46,Post-Chemotherapy,Bone Marrow Aspirate,y,n,y,y,n,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,Bu/Cy/ATG,Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,-7,0,2,0,0,,,44,56,,,,,,,23.2,7.7,"47,XX,+8[3]/46,XX[17].",130,89.9,"nuc ish(D8Z2x3,D20S108x2)[27/200]",113,,,0.9,TRUE,TRUE,14-00725,negative,negative
15-00821,BA2461,2343,Male,Male,White,1,n,66,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,66,0,Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Dead,Dead-Disease,FALSE,FALSE,,-20,0.8,0,0,0,2,18.6,9.3,69.3,0,,,,,,32.1,10.2,"46,XY[20]",,94.7,Normal,345,The analysis was performed by flow cytometry on the bone marrow aspiratespecimen. The analysis shows CD34+ blasts account for 1% of CD45+ events. Maturing myeloid precursors and monocytic cells demonstrate a normal pattern of myelomonocytic antigen expression.,,8.94,FALSE,FALSE,,negative,negative
16-01127,BA2244,2538,Male,Male,White,1,n,67,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68,261,Post-Chemotherapy,Leukapheresis,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,4,"AG-120|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC",4,Consolidation|Salvage|Induction|Experimental,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,-1,Alive,Alive,TRUE,TRUE,16-00157,-52,,,,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,,,,FALSE,FALSE,,negative,positive
16-00710,BA2855,2694,Male,Male,Black,6,n,50,FALSE,FALSE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,50,73,Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Unknown,Standard Chemotherapy,20,Standard Chemotherapy,HiDAC,Consolidation,182,Alive,Alive,FALSE,FALSE,,0,,0,,,,,0,,,,,,,,,,"46,XY[20]",,,RUNX1/RUNX1T1 fusion negative,126,No morphological evidence of acute leukemia,,7.7,FALSE,FALSE,,negative,negative
16-00702,BA2764,3976,Male,Male,White,7,n,77,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,79,0,Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,Decitabine,Induction,-1,Unknown,,FALSE,FALSE,,0,,,,,,,,,,,,,,,,,,,,Translocation between the long arm of chromosome 3 and short arm of chromosome 12.,,,,,FALSE,FALSE,,positive,positive
16-00087,BA2911,2495,Female,Female,White,1,n,24,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,FavorableOrIntermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,24,0,Post-Chemotherapy,Leukapheresis,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Other,3,"ATRA (Tretinoin)|HiDAC|3+7 (Cytarabine, Daunorubicin)",3,Consolidation|Induction|Experimental,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,HiDAC,Consolidation,114,Alive,Alive,FALSE,FALSE,,0,0,,97,0,0,1.9,0,1.9,0.2,14,18,2.7,0.51,,19.6,6.2,,364,108.3,normal,15,"CD13, CD33, CD38, CD58, CD117 and CD123 positive.",6.4,181.66,FALSE,FALSE,,positive,positive
13-00353,BA2446,1161,Female,Female,Asian,1,n,30,FALSE,FALSE,FALSE,MLLT3-KMT2A,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,30,0,Post-Chemotherapy|Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,6,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,31,Dead,Dead-Disease,FALSE,FALSE,,0,0,64,65,0,,28.9,25.4,19.3,1.7,48,33,3.6,0.64,,21.8,7.5,"46,XX,t(9;11)(p11;q34)[19]/46,XX[1]",,111.8,Disruption of MLL signal and t(9;11),29,"CD11b, CD13, CD14,  CD33, CD64, CD56, CD123 and HLA-DR positive",6.1,29.25,FALSE,FALSE,,negative,negative
15-00829,BA2695,2001,Female,Male,Black,2,n,67,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,68,254,Post-Chemotherapy|Post-DLI|Post-Transplant|Residual Disease,Peripheral Blood,y,y,y,y,y,y,4,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,4,"AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea",3,Salvage|Experimental|Supportive/Palliative Care,,,,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,-1,Dead,Dead-Disease,TRUE,FALSE,15-00797,-17,,,,,,,,,,18,25,4.1,,,20.4,6.8,"47,XX,+11[5]/48,idem,+19[15]",,,"nuc ish(DXZ1x2)[181]//(DXZ1,DYZ3)x1[19] nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[176/200],(PML,RARA)x2[196], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]",24,,7.4,27.5,TRUE,FALSE,15-00797,positive,negative
16-00477,BA3070,2695,Male,Male,Black,1,n,49,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,51,0,Post-Chemotherapy|Post-Transplant,Peripheral Blood,y,y,y,n,y,y,4,DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,7,"HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",6,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,13,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,115,Alive,Alive,FALSE,FALSE,,-55,0,,,0,0,19.8,12.9,53.5,5.3,44,29,2.8,,,30,10.3,"46,XY[20]",,87.7,,193,,6.8,4.53,FALSE,FALSE,,negative,negative
15-00071,BA3051,1962,Male,Female,White,2,n,53,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,56,0,Post-Chemotherapy|Post-Transplant,Bone Marrow Aspirate,y,y,n,n,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide",4,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,4,Dead,Dead-Disease,FALSE,FALSE,,0,0.9,1,0,3.5,,7.8,5.2,82.6,,9,16,2.7,1.14,,31.3,10.2,"45~49,X,-Y,add(5)(q11.2),+der(9;8)(q10;q10),+10,der(11)t(11;17)(p15;q11.2)del(11)(q21q22),add(12)(q12),del(13)(q12q22),-17,add(18)(p11.2),add(19)(q13.3),-20,+1~4mar[cp4]/46,XX[16]",,97.2,"nuc ish(RUNX1T1x3,RUNX1x2)[9/200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198](5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",365,"CD2(-), CD4(-), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(+), CD64(-), CD117(+), CD123(dim +), HLA-DR (+), MPO(few +), TdT(-).",4.9,7.5,FALSE,FALSE,,negative,negative
15-00169,BA2514,2001,Female,Female,Black,2,n,67,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,67,0,Post-Chemotherapy|Post-Transplant|Post-DLI|Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,4,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,4,"AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea",3,Salvage|Experimental|Supportive/Palliative Care,,,,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0,24,6,0,,77,10,7,,29,37,4.1,0.89,,30.1,9.9,"46,XX[20]",511,,"nuc ish(DXZ1x2)[182]//(DXZ1,DYZ3)x1[18]. nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2) [200]",288,"CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD33(variably +), CD34(+), CD36 (-), CD38(+), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+)",8,3.3,FALSE,FALSE,,negative,negative
14-00495,BA2735,1246,Male,Male,White,2,n,62,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,64,254,Post-Chemotherapy|Post-Transplant|Residual Disease,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide",5,Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,24,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,141,Dead,Dead-Unknown,FALSE,FALSE,,-28,,,,,,,,,,23,26,2.9,,,27.9,9.6,"45,XY,der(12;16)(q10;p10)[2]/46,XY[18]",,,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[31/200]",30,,5,27.4,FALSE,FALSE,,positive,positive
16-00481,BA2904,2699,Female,Female,White,3,n,60,FALSE,FALSE,FALSE,CBFB-MYH11,FALSE,FALSE,y,Adenocarcinoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,61,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|IDAC",2,Consolidation|Induction,UNKNOWN,Standard Chemotherapy,-1,Standard Chemotherapy,IDAC,Consolidation,-1,Dead,Dead-Disease,FALSE,FALSE,,0,,,,,,,,,,,,,,,,,"46,XX,inv(16)(p13q22)[20]",,,,,Increased atypical CD34+myeloblasts representing 80%of leukocytes suggestive of recurrent AML.,,,FALSE,FALSE,,negative,negative
13-00546,BA2413,1286,Male,Male,White,4,n,71,FALSE,FALSE,FALSE,GATA2-MECOM,FALSE,FALSE,y,Prostate Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,72,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,n,y,y,n,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",4,Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Dead,Dead-Disease,FALSE,FALSE,,2,,,,,,,,,,,,,,,,,"45,XY,-7,t(3;3)[20]",,,,,,,,FALSE,FALSE,,negative,negative
15-00942,BA2339,2437,Female,Female,Black,6,n,30,FALSE,FALSE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,31,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,n,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response i,Standard Chemotherapy,27,Standard Chemotherapy,HiDAC,Consolidation,93,Unknown,,TRUE,FALSE,15-00943,0,,27,43,,,12,40,5,,35,62,4.6,1.01,,26.1,8.5,"46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[19]/46,XX[1]",,90.6,"This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on previous sample.",5,"There are increased abnormal cells in the ""monocyte"" gate that stain positive for CD38, CD11b, CD14, CD64, CD33, with partial MPO, HLADR, CD13 expression.",7.3,5.3,FALSE,FALSE,,negative,negative
14-00757,BA2094,1495,Male,Male,White,3,n,75,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,75,265,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,n,n,y,n,n,1,Standard Chemotherapy,5,"7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,21,Standard Chemotherapy,"CLAG (Cladribine, Cytarabine, Filgrastim)",Consolidation,-1,Dead,Dead-Disease,TRUE,TRUE,14-00622;14-00152,-77,,,,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,,,9.7,FALSE,FALSE,,negative,negative
15-00275,BA3027,1992,Female,Female,White,5,n,53,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Ovarian cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,53,33,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,29,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Re-induction,17,Dead,Dead-Disease,TRUE,FALSE,15-00157,-33,,,,,,,,,,,,,,,,,"53~55,XX,+1,+2,der(5)t(5;13)(q13;q12),+6,add(7)(q32),+8,+11,-13,+14,i(17)(q10),+19,+19,+21,+mar[cp7]/46,XX[7]",,,Gain of 8 (4/301 cells); Gain of 8q22/21q22 (7.7/301 cells); Gain 11q23 (5/200 cells),,,,,FALSE,FALSE,,negative,negative
15-00371,BA2515,2113,Male,Male,White,2,n,74,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,75,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine",3,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,48,Dead,Dead-Unknown,FALSE,FALSE,,0,0,32,5,0,,69,8,18,,23,22,4.3,1.21,,32.9,11.1,"46,XY[18]",199,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[198],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",178,"CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial dim +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD22 (-), CD25(-), CD33(variably +), CD34(bright +), CD36(-), CD38(bright +), CD45(moderate/dim +), CD56(-), CD64(-), CD79a (-), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(partial +)",7.1,2.3,FALSE,FALSE,,negative,negative
15-00287,BA2251,2073,Male,Male,White,1,n,85,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,85,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,105,Dead,Dead-Disease,FALSE,FALSE,,2,0,,,2.5,0,14.6,2.4,0,0.5,14,15,3.5,0.98,,33.2,10.7,"46,XY[20]",289,89.5,Normal,8,,7.4,25.63,FALSE,FALSE,,negative,negative
16-00708,BA2989,3979,Male,Male,HispNative,2,n,70,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,71,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,Azacitidine|Decitabine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,98,Unknown,,FALSE,FALSE,,0,0,44,31,2,,46,0,14,,41,18,3.7,0.91,,21.6,7.1,"47,XY,+21[19]/46,XY[1]",91,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],",35,"CD2(-), CD4(dim +), CD7(-), CD10(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD22(-), CD19(partial +), CD33(partial +), CD34(+), CD36(-), CD38(bright and variably +), CD45(+), CD56(-), CD64(-), CD79a(-), CD117(+), HLA-DR(predominantly + and variable), TdT(partial +), and MPO(-)",7.7,5.05,FALSE,FALSE,,positive,negative
16-01017,BA2492,4043,Male,Male,AdmixedHispNative,6,n,25,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",26,28,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Unknown|Induction,Complete Response,Standard Chemotherapy,79,Standard Chemotherapy,Bu/Cy/ATG,Unknown,22,Alive,Alive,FALSE,FALSE,,0,,70,8,,,,4,,,,,,,,,,"46,XY,-3,del(5)(q31q35),der(7)t(7;?)(p11.2;?),+der(11)(q23),-12,+mar[20]",,,,10,"MONOBLASTS, 61%. These are dim45positive and also express CD13, CD33, CD11b, CD14, CD64  but lack CD16, CD34, CD117, HLADR ",,30.2,FALSE,FALSE,,negative,negative
14-00602,BA2756,1746,Male,Male,White,4,n,69,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,IntermediateOrAdverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,69,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,4,"CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,79,Standard Chemotherapy,"MEC, Lenalidomide",Salvage,5,Dead,Dead-Disease,FALSE,FALSE,,-8,,,,,,,,,,,,,,,,,"46,XY[22]",,,,,,,,FALSE,FALSE,,positive,negative
16-00733,BA2930,2119,Male,Male,White,1,n,76,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,77,472,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor),2,Consolidation|Induction,Complete Response,Standard Chemotherapy,35,Standard Chemotherapy,Incyte trial (azacitidine and JAK 1 inhibitor),Induction,77,Dead,Dead-Unknown,TRUE,FALSE,16-00732,0,0,54,13,6.9,,51.6,39.6,1.9,,20,23,3.2,1,,25.4,8.6,"47,XY,+8[cp15]/47,sl,der(22)t(1;22)(q11;p11.2)[2]/46,XY,dup(1)(q21q42)[cp2]",,92,"Seventeen of twenty cells examined were trisomy 8, previously observed.Two of the trisomy 8 cells had additional non-clonal abnormalities and two cells had an extra 1q attached to a chromosome 22 short arm, also previously observed.",22,"The myeloid blasts are CD13, CD34, CD38, CD117, and HLA-DR positive. Atypical monocytic cells comprise approximately 41% of analyzed events and are CD11b, CD13, CD14, CD64, and dim HLA-DR positive. T cells show a CD4:CD8 ratio of 6.9:1 without  aberrant antigen expression.",7.2,4.5,FALSE,FALSE,,negative,negative
13-00149,BA2360,1049,Male,Female,White,1,n,78,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Bladder Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,79,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,Decitabine,Induction,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0,87,72,1,,17,4,1,,19,41,3.4,0.75,,32.3,10.6,"45,X,-Y[19]/46,XY[1]",460,103.6,Normal,15,"CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO +",6.2,8.5,FALSE,FALSE,,negative,negative
16-00566,BA2705,2741,Male,Male,White,5,n,39,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,40,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,"GCLAC (GCSF, Clofarabine & Cytarabine)",1,Re-induction,,,,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Re-induction,-1,Unknown,,TRUE,FALSE,16-00565,0,0,41,14,0,,5,5,76,,12,17,3.6,0.83,,29.4,10.2,"46,XY[15]",,,Negative,24,Positive,5.9,3.6,TRUE,FALSE,16-00565,positive,positive
15-00147,BA3025,1981,Female,Female,HispNative,1,n,28,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,30,2,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,5,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) ",Salvage,5,Dead,Dead-Disease,TRUE,FALSE,15-00137,-27,0,,,0,0,4.1,0,2.1,32.3,54,37,3.7,0.3,NOS,27.3,9.2,"46,XX,t(2;9)(q31;p21)[17]/46,X,t(X;9)(q22;p21)[3]",,91.3,,8,,6.3,20.18,FALSE,FALSE,,negative,negative
13-00551,BA2701,1314,Male,Male,Black,2,n,51,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",51,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,-3,,,1,,,17,35,23,,16,14,3.7,0.8,,25,8.7,"46,XY[20]",,83.8,,16,,6.8,3.2,FALSE,FALSE,,negative,negative
16-00031,BA2850,2477,Male,Male,White,6,n,50,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",50,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Allogeneic - Sibling|Induction|Re-induction,Unknown,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,97,Alive,Alive,TRUE,FALSE,16-00030,0,,75,73,,,6,6,8,,44,20,3.5,1,,24.8,8,"46,XY[20]",,91.5,Not Available (no FISH done),26,"These are postive for CD34, CD117, HLADR, CD13 and CD33. These are negative for CD3, CD20, CD4, CD11b.",5.8,17.1,FALSE,FALSE,,positive,negative
16-00124,BA2993,2477,Male,Male,White,6,n,50,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",50,30,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Allogeneic - Sibling|Induction|Re-induction,Unknown,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,97,Alive,Alive,TRUE,FALSE,16-00123;16-00030,-30,,,68,,,12,,3,,20,11,3.8,0.81,,24.1,7.9,"46,XY[20]",,89.6,Not Available (no FISH done),39,,6.4,2.1,TRUE,FALSE,16-00123,positive,negative
13-00145,BA2921,1045,Male,Male,White,2,n,70,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,71,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,n,y,y,n,y,2,Standard Chemotherapy|Supportive/Palliative Care,2,"7+3 (Cytarabine, Idarubicin)|Azacitidine",2,Hypomethylating/Low Dose Cytarabine|Induction,Refractory,Standard Chemotherapy,-1,Supportive/Palliative Care,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Dead,Dead-Disease,FALSE,FALSE,,-22,,,78,,,12,5,3,,,,,1.12,,24.7,8.2,"46,XY,del(7)(q22q36)[7]/47,idem,+22[cp12]/46,XY[1]",,89.2,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[187/200], (D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",18,,,24.4,FALSE,FALSE,,positive,negative
15-00874,BA2674,1973,Male,Male,White,1,n,70,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,71,281,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",3,Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6,Supportive/Palliative Care,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Alive,Alive,FALSE,FALSE,,0,0,90,90,0,0,27.8,2.9,8.6,0.4,81,43,3.3,,,31.9,10.2,"47,XY,+4[2]/46,XY[18]",235,94.7,"Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.",91,"partial CD7 (~35%), CD13, partial dim CD33, CD34, CD38, variable CD56, and CD117",6.6,73.42,FALSE,FALSE,,negative,negative
16-00315,BA2809,1973,Male,Male,White,1,n,70,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,72,423,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",3,Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6,Supportive/Palliative Care,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Alive,Alive,TRUE,TRUE,15-00874,-142,0,,,0,0,15.5,6.9,5.2,0,79,38,3.1,0.8,,27.9,9.1,"47,XY,+4[2]/46,XY[18]",,87.7,"Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.",44,,6.3,50.58,FALSE,FALSE,,negative,negative
15-00883,BA2280,2416,Female,Female,White,1,n,72,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3,"7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib",2,Induction|Experimental,Refractory,Standard Chemotherapy,10,Targeted Therapy - Kinase Inhibitor(s),Ponatinib,Experimental,15,Dead,Dead-Disease,FALSE,FALSE,,0,0.9,90,78,0,0,2.7,3.6,17.3,1.4,28,23,2.8,0.56,,31.7,9.9,"46,XX[20]",261,98.1,Normal,211,"CD13, CD33, CD38, partial CD56, partialCD64, CD117, dimCD123, and MPO",6.5,24.01,TRUE,FALSE,15-00884,positive,positive
15-00967,BA2277,2416,Female,Female,White,1,n,72,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,40,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3,"7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib",2,Induction|Experimental,Refractory,Standard Chemotherapy,10,Targeted Therapy - Kinase Inhibitor(s),Ponatinib,Experimental,15,Dead,Dead-Disease,TRUE,FALSE,15-00933,-15,0,70,3.56,0,1.8,34.8,3.6,0.9,23.2,13,40,3.2,0.55,,22.7,7.5,"46,XX[5]",339,89.7,Normal,32,"CD13+, CD33+, CD38+, variable partial CD56+, partial CD64+, CD117+, dimCD123+, and MPO+",6.4,6.04,TRUE,FALSE,15-00933,positive,positive
13-00262,BA2032,1118,Female,Female,White,2,n,64,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5,"Crenolanib|MEC, plexifor, GCSF|Sorafenib|7+3 (Cytarabine, Idarubicin) plus LBH|Clofarabine, Cytarabine",4,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,21,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,124,Dead,Dead-Disease,FALSE,FALSE,,-1,,81,94,,,6,,,,87,47,2.8,0.53,,27.2,9.7,"46,XX,t(3;11)(q21;p11.2),t(15;15)(q15;q22)[19]/46,XX,t(2;14)(q21;q11.2)[2]",743,,"nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2 (5'MLL con 3'MLLx2)[198],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",11,"CD7(partial +), CD15(partial +), CD33(bright +), CD34(partial +), CD45(+), and CD117(variably +).",5.2,26,FALSE,FALSE,,positive,positive
15-00811,BA2829,2337,Male,Male,White,1,n,53,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,54,7,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea",4,Induction|Experimental|Re-induction|Maintenance,Unknown,Standard Chemotherapy,6,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,-1,Dead,Dead-Disease,TRUE,FALSE,15-00799,-7,0,,,1.7,0.9,6.1,8.8,43,0.4,38,29,3.4,0.71,,27,9.1,"46,XY,add(3)(p24)[cp4]/46,XY[14]",321,95.1,normal,170,,6.7,16.65,FALSE,FALSE,,positive,positive
15-00936,BA2249,2337,Male,Male,White,1,n,53,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,54,63,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea",4,Induction|Experimental|Re-induction|Maintenance,Unknown,Standard Chemotherapy,6,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,-1,Dead,Dead-Disease,TRUE,FALSE,15-00938;15-00799,2,1.8,,,3.6,6.2,23.2,18.7,17,1.3,29,41,3.6,1,,20.9,6.9,"46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]",,96.3,normal,21,,6.8,20.77,TRUE,FALSE,15-00938,positive,positive
15-00559,BA2589,2205,Female,Female,HispNative,5,n,42,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,42,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,3,"7+3 (Cytarabine, Idarubicin)|AG-221|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",3,Salvage|Induction|Experimental,Refractory,Standard Chemotherapy,-1,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,Dead-Unknown,TRUE,FALSE,15-00560,0,,50,51,,,,,,,,,,,,,,"46,XX[20]",,,Normal,256,"positive for CD13, CD34, CD38, dim CD45, CD117, HLA-DR, and MPO",,10.7,TRUE,FALSE,15-00560,negative,negative
14-00618,BA2080,1754,Male,Male,White,2,n,77,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Lung Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,78,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,5,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Bortezomib|Decitabine|Fludarabine, Cytarabine",4,Hypomethylating/Low Dose Cytarabine|Unknown|Induction|Experimental,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Unknown,,FALSE,FALSE,,0,,73,84,,,10,,6,,9,13,4.2,0.82,,,,"46,XY[20]",165,,,,,6.5,13.8,FALSE,FALSE,,negative,negative
15-00018,BA2423,1889,Male,Male,White,4,n,57,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",58,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Other,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Binimetinib (MEK162)",3,Consolidation|Induction|Experimental,Refractory,Standard Chemotherapy,-1,Targeted Therapy - Other,Binimetinib (MEK162),Experimental,-1,Dead,Dead-Disease,TRUE,FALSE,15-00017,0,,70,8,,,,10,,,,,,,,,,"46,XY[14]",,,,,,,7.1,TRUE,FALSE,15-00017,negative,negative
16-01201,BA2999,4260,Male,Male,White,1,n,53,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",54,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,7,"AG-120|7+3 (Cytarabine, Idarubicin)|Azacitidine|MGD006 (CD123 x CD3) |MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)",5,Salvage|Induction|Experimental|Re-induction|Maintenance,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Incyte trial (azacitidine and JAK 1 inhibitor),Salvage,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0,75,90,0,0,22.1,6.2,1.8,0,19,33,1.8,0.84,,25.5,8.1,"46,XY,t(4;12)(q12;p13)[10]/46,XY[10] ",706,91.4,"42/100 (42%) interphase cells scored were positive for  ETV6 rearrangement. Metaphase FISH showed part of the ETV6 signal (red) on  the long arm of chromosome 4. Based on the breakpoint, ETV6/CHIC2 fusion  is predicted, consistent with AML",25,"partial CD7, CD13, CD33, CD38, CD34, CD58, CD117, CD123,  HLA-DR positive ",6.6,118,FALSE,FALSE,,negative,negative
14-00064,BA2655,1444,Male,Male,White,2,n,58,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,59,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Other,8,"E7070, Idarubicin, Cytarabine|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|BL-8040|IGN523",4,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,-1,Dead,Dead-Disease,FALSE,FALSE,,0,1,10,6,0,,32.7,12.6,53.7,,45,19,3.7,0.69,,26.8,9.4,"46,XY[20]",88,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x1[47/200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",75,"CD2 (-), CD4(+), CD7(+), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(bright +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).",5.8,1.6,FALSE,FALSE,,negative,negative
16-00504,BA2228,2708,Female,Female,White,2,n,60,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Breast Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,60,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,5,"HiDAC|AG-221|3+7 (Cytarabine, Daunorubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)",4,Consolidation|Salvage|Induction|Experimental,Complete Response,Standard Chemotherapy,-1,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,Dead-Disease,FALSE,FALSE,,0,2,2,0,1,,12,12,71,,27,,4.4,0.99,,33.5,11.4,"46,XX[20]",,95.4,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",219,The study reveals a minute subset of myeloblasts with mild immunophenotypic variation; the significance of this finding is unclear and it is not diagnostic for recurrent or persistent myeloid neoplasia.,7.1,5.54,FALSE,FALSE,,negative,positive
16-00831,BA2817,4038,Male,Male,Black,2,n,73,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",77,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Supportive/Palliative Care|Targeted Therapy - Other,6,Vidaza|AG-221|Bortezomib|Cytarabine|Lenalidomide|Decitabine,3,Hypomethylating/Low Dose Cytarabine|Experimental|Supportive/Palliative Care,,,,Targeted Therapy - Other,AG-221,Experimental,267,Dead,Dead-Disease,FALSE,FALSE,,0,,95,48,1,,42,6,2,,14,14,3.5,1.1,,27.3,9.4,"88<4n>,XXYY,+del(1)(p22p36),i(2)(p10),-5,-7,-7,-21,-21[12]",453,,"nuc ish(RUNX1T1x4,RUNX1x2)[200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[200],(PML,RARA)x4[200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[174/200]",23,"92% population of variably-sized cells with the following immunophenotype: CD2(-), CD4(-), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(+), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(variably +), HLA-DR(partial +).",6.5,3,FALSE,FALSE,,negative,negative
15-00909,BA2950,2425,Female,Female,Black,6,n,44,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,47,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Targeted Therapy - Other,1,Radiation,1,Unknown,,,,Targeted Therapy - Other,Radiation,Unknown,14,Unknown,,TRUE,FALSE,15-00910,0,,90,45,0,,28,5,1,,30,41,3.3,0.82,,29.3,9.6,"46,XX[20]",,89.9,This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small precentage of tumor cells with chromosome abnormalities may not be detected due to the cells examined.,5,"The blasts are positive for HLA-DR, CD34, CD117 (PARTIAL), CD13, CD(PARTIAL/DIM), CD33, TDT (DIM, SUBSET) and are negative for CD11b, CD14, CD64, MPO and all B and T cell markers.",7.3,6.5,FALSE,FALSE,,positive,negative
16-01004,BA2417,4195,Male,Male,White,2,n,70,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,70,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Vidaza|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,Vidaza,Hypomethylating/Low Dose Cytarabine,4,Alive,Alive,FALSE,FALSE,,0,0,85,77.8,0,,7.4,0,11.1,,12,32,2.8,0.62,,21.8,7,,1195,,,103,,5.2,25.85,FALSE,FALSE,,negative,negative
16-01061,BA2994,4197,Female,Female,White,1,n,45,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47,14,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,32,Standard Chemotherapy,Sunitinib,Consolidation,2,Dead,Dead-Disease,TRUE,FALSE,16-01104,0,,,,,,,,,,,,,,,,,,,,Positive,,,,,FALSE,FALSE,,negative,positive
16-00459,BA2240,2687,Female,Female,HispNative,1,n,61,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea",4,Consolidation|Induction|Experimental|Re-induction,Complete Response,Standard Chemotherapy,7,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,55,Dead,Dead-Disease,FALSE,FALSE,,0,0,,,0,0,30.8,10.3,0,0.3,195,75,3.6,0.68,,25.4,8.2,,1033,95.5,,49,,6.7,73.28,FALSE,FALSE,,positive,positive
16-00886,BA3077,2704,Female,Female,White,1,n,29,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Basal Cell Carcinoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,29,126,Post-Chemotherapy|Residual Disease|Post-Transplant,Peripheral Blood,y,y,y,n,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,5,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib",3,Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,5,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,2,Dead,Dead-Disease,TRUE,TRUE,16-00491,-127,0,,,0,0,0,79.2,1,0.2,65,152,3.3,0.68,,28.2,9.7,"47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]",9928,90.4,Normal,43,,6.3,12.98,TRUE,TRUE,16-00765,negative,positive
13-00007,BA2452,29,Male,Male,White,1,n,34,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,36,574,Post-Chemotherapy|Residual Relapse,Bone Marrow Aspirate,y,n,y,y,n,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",4,Consolidation|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,43,Dead,Dead-Unknown,TRUE,FALSE,12-00161,0,1,90,30,0,,46,30,8,,43,11,2.8,0.92,,25.5,9.1,"46,XY,add(17)(p13)[19]/46,XY[1]",123,85,Normal,14,"partial CD7, CD13, CD33, CD38, dim CD45, dimCD58, CD117, CD123, and HLA-DR",5.8,0.6,FALSE,FALSE,,positive,positive
13-00493,BA3029,1246,Male,Male,White,2,n,62,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,63,0,Post-Chemotherapy|Residual Relapse,Peripheral Blood,y,y,y,y,y,n,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide",5,Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,24,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,141,Dead,Dead-Unknown,TRUE,FALSE,13-00494,0,0,81,59,0,,0,0,10,,34,15,4,,,30.2,10.7,"46,XY",,,,17,"CD2(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(variably +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD45(moderately +), CD56(-), CD64 (partial +), CD117(variably +), HLA-DR(-), MPO(+), TdT(-).",6,1.8,TRUE,FALSE,13-00494,positive,positive
14-00454,BA2595,1665,Male,Male,White,4,n,65,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",66,0,Post-Chemotherapy|Residual Relapse,Peripheral Blood,y,y,n,y,y,n,3,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,8,"HiDAC|AG-221|Gilteritinib (ASP2215)|3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|MEC, Lenalidomide|Clofarabine, Cytarabine",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction,Complete Response,Standard Chemotherapy,-1,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,Dead-Disease,TRUE,FALSE,14-00455,0,,96,85,,,,5,,,,,,,,,,"46,XY,t(4;15)(q31;q22),add(12)(p11~12)[cp7]/46~51,XY,del(7)(q11.2q36),add(12)(p11~12),add(20)(q11.2)[cp5]/46,XY,?inv(8)(p21q22)[cp7]/46,XY[cp2]",,,,,"CD38, CD33; WITH PARTIAL CD34, CD56, CD13, CD11C, CD2 AND CD15/CD117",,0.1,TRUE,FALSE,14-00455,negative,negative
13-00166,BA2245,1061,Male,Male,White,1,n,65,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,67,0,Post-Chemotherapy|Residual Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,8,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cladribine",6,Hypomethylating/Low Dose Cytarabine|Salvage|Consolidation|Unknown|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Cladribine,Unknown,5,Dead,Dead-Unknown,FALSE,FALSE,,0,0,,77,0,,15,1,3,,18,10,3.6,1.01,M2,28.1,9.3,,132,93.5,,22,,6.3,19.5,FALSE,FALSE,,negative,negative
13-00150,BA2802,1051,Male,Male,White,1,n,52,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",Adverse,Adverse,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",53,234,Post-Transplant|Post-Chemotherapy|Residual Disease,Peripheral Blood,y,n,y,y,n,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide",5,Salvage|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Decitabine,Salvage,80,Dead,Dead-Disease,FALSE,FALSE,,-2,0,,59,0,,9,2,29,,32,34,3.7,0.68,,34,11.1,"45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3]",167,102.8,Deleted 5q,152,,6.7,14,FALSE,FALSE,,negative,negative
16-00883,BA3072,2695,Male,Male,Black,1,n,49,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,51,129,Post-Transplant|Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,n,y,y,4,DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,7,"HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",6,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,13,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,115,Alive,Alive,TRUE,FALSE,16-00806,-22,0,,,6.1,0,7.9,0,6.1,0.1,30,26,3.1,,,26.2,8.9,"46,XY,t(6;19)(p23;q13.1)[11]/46,XY[9]",,84.5,Positive,32,,7,39.25,TRUE,TRUE,16-00477,negative,positive
13-00557,BA2677,1233,Male,Male,White,1,n,61,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62,43,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Decitabine,Salvage,126,Dead,Dead-Disease,FALSE,FALSE,,0,,17,2,,,32.2,,34.2,,34,15,3.7,0.3,,32.4,10.4,"46~49,XY,-21,+1~4mar[cp20]",,87.2,Monosomy 21,21,"CD11b, CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, HLA-DR and partial TdT positive; aberrant monocytic population: CD11b, CD13, CD14, bright CD33, dim CD56, CD64, and HLA-DR positive.",7,7.2,FALSE,FALSE,,negative,negative
15-00903,BA2394,2423,Male,Female;Male,White,3,n,73,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Lung Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,73,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,7,Dead,Dead-Disease,FALSE,FALSE,,-24,,,79,,,,,,,,,,,,,,"45,X,-Y[20]",,,Normal,,,,19.64,FALSE,FALSE,,negative,negative
13-00552,BA2634,1315,Male,Male,White,3,n,74,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,75,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Etoposide, Mitoxantrone",3,Hypomethylating/Low Dose Cytarabine|Salvage|Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,-1,Dead,Dead-Disease,FALSE,FALSE,,-7,,,,,,,,,,,,,,,,,"46,XY,add(1)(p34),del(7)(q22),del(20)(q11.2)[20]",,,"normal, no evidence of RUNX1T1/RUNX1 transloc or 11q23 or 16q22",,,,,FALSE,FALSE,,positive,negative
14-00083,BA2523,1989,Male,Male,White,4,n,46,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,46,0,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,5,"HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine",4,Consolidation|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Salvage,-1,Unknown,,FALSE,FALSE,,-2,,,,,,,,,,,,,,,,,"46,XY[20]",,,,,,,,FALSE,FALSE,,negative,positive
15-00701,BA2502,2280,Female,Female,White,1,n,50,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,50,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Other,6,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Other,Hydroxyurea,Hypomethylating/Low Dose Cytarabine,365,Dead,Dead-Unknown,FALSE,FALSE,,-111,0,,,0,2.6,8.8,17.6,2.6,0,,,,,M0,19.8,6.4,"48,XX,+11,+13[19]",,93.4,,31,,,206.64,FALSE,FALSE,,negative,negative
14-00676,BA2720,1561,Male,Male,White,1,n,23,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,mediastinum mass,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,24,163,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,"Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin) ",3,Consolidation|Induction|Experimental,Complete Response,Standard Chemotherapy,8,Targeted Therapy - Kinase Inhibitor(s),Trametinib,Experimental,197,Dead,Dead-Disease,TRUE,TRUE,14-00289,0,0,5,10,0,2.9,36.2,1.5,47.8,,30,146,3.4,0.82,,25.5,7.9,"48,XY,add(6)(p22),der(7)t(7;19)(p11.2;p12),del(9)(p13p22),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp2]/46~48,sl,add(17)(p1?3),add(22)(q13)[cp9]/46~48,sl,add(21)(p11.2)[cp6]/47~48,sl,add(1)(p36.1)[cp2]/48,sl,t(2;17)(p21;p11.2)[1]",,98.5,Low-level tetraploidy or near-tetraploidy,48,"A CD34 positive blasts population comprises approximately 4% of cellular gated events. Approximately 3% of cells are lymphocytes composed of 28% B cells, 45% T cells and 27% NK cells.",6.1,11.28,FALSE,FALSE,,negative,negative
16-00217,BA2659,2569,Male,Male,White,1,n,86,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,86,0,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,3,AG-221|Azacitidine|Hydroxyurea,3,Hypomethylating/Low Dose Cytarabine|Consolidation|Experimental,,,,Standard Chemotherapy,Hydroxyurea,Consolidation,55,Dead,Dead-Disease,FALSE,FALSE,,0,0,23,12.1,0,0.8,8.6,19,59.5,0,16,15,3.4,1.52,,27.8,9,"47,XY,+8[20]",398,97.5,"(FISH) was performed with a chromosome 8 probe, listed below. 95/100 (95%) interphase cells scored had three signals, consistent with trisomy 8 and the metaphase karyotype. ",299,"dimCD7, CD13, dimCD14, dimCD20, CD33, CD34, CD117, CD123, dim HLA-DR and MPO positive",7.6,10,FALSE,FALSE,,negative,negative
16-00538,BA2842,2694,Male,Male,Black,6,n,50,FALSE,FALSE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,50,21,Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Unknown,Standard Chemotherapy,20,Standard Chemotherapy,HiDAC,Consolidation,182,Alive,Alive,TRUE,TRUE,16-00474,-22,,8,0,0,,12,29,54,,19,9,2.3,0.51,,22.8,7.5,"46,XY,t(8;21)(q22;q22)[20]",,88.7,RUNX1/RUNX1T1 fusion positive in 6.5% of cells,224,,5.1,6.8,TRUE,TRUE,16-00474,negative,negative
16-00050,BA2004,2485,Female,Female,White,1,n,77,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,y,Breast Cancer,y,y,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,77,0,Residual Disease,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,253,Dead,Dead-Unknown,FALSE,FALSE,,0,0.8,,,2.5,0,15.8,0,70.9,0,62,28,3.3,1.01,,24.2,7.9,,241,87.7,"EGR-1/ D5S23, D5S721: 58/200 cells (29%) had a 1 red/ 2 green signal pattern, consistent with a deleted 5q. D7S522/CEP 7: 38/200 cells (19%) had a 1 red/ 2 green signal pattern, consistent with a deleted 7q. CBFB: 40/200 cells (20%) had a single signal indicating deleted 16q22. TP53/CEP 17: 12/200 c",16,,8,8.29,FALSE,FALSE,,negative,negative
16-00627,BA2663,2785,Male,Male,White,7,n,67,FALSE,FALSE,FALSE,Unknown,TRUE,FALSE,n,,y,n,n,n,n,n,y,y,MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,Adverse,Not Enough Information,MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,66,0,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,Cytarabine|Decitabine,2,Induction|Supportive/Palliative Care,UNKNOWN,Standard Chemotherapy,-1,Standard Chemotherapy,Cytarabine,Induction,-1,Unknown,,FALSE,FALSE,,0,,17,7,,,,,,,,,,,,,,,,,Trisomy 8,,,,,FALSE,FALSE,,negative,negative
16-00332,BA2801,2621,Male,Male,White,6,n,72,FALSE,FALSE,FALSE,Unknown,TRUE,FALSE,y,Lung Cancer,y,n,y,n,n,n,n,n,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",Adverse,Not Enough Information,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",73,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Vidaza,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Vidaza,Supportive/Palliative Care,268,Dead,Dead-Unknown,FALSE,FALSE,,0,,,4,1,,13,5,23,,13,57,2.5,1.83,,25,8.2,,,105.9,,32,,5.8,66.7,FALSE,FALSE,,negative,negative
16-00316,BA2288,2615,Male,Male,HispNative,7,n,72,FALSE,FALSE,FALSE,Unknown,FALSE,TRUE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,unknown,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,unknown,73,0,Residual Disease,Bone Marrow Aspirate,y,y,n,y,y,n,0,,0,,0,,,,,NONE,NONE,NONE,,Alive,Alive,FALSE,FALSE,,0,,20,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,negative,negative
13-00578,BA2334,1353,Female,Female,White,2,n,30,FALSE,FALSE,FALSE,DEK-NUP214,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,31,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib",3,Salvage|Induction|Experimental,Refractory,Standard Chemotherapy,-1,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,52,Dead,Dead-Disease,TRUE,TRUE,13-00581,3,,,47,,,,,,,49,31,4.2,0.85,,,,"47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]",329,,,10,,6.3,20.2,TRUE,TRUE,13-00581,positive,negative
13-00581,BA2050,1353,Female,Female,White,2,n,30,FALSE,FALSE,FALSE,DEK-NUP214,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,31,3,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,n,y,y,n,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib",3,Salvage|Induction|Experimental,Refractory,Standard Chemotherapy,-1,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,52,Dead,Dead-Disease,FALSE,FALSE,,0,,65,52,0,,10,0,28,,,26,3.9,0.87,,22.4,7.9,"47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]",,90.9,,20,"CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myeloid and lymphoid antigens(-).",,43.3,FALSE,FALSE,,positive,
13-00545,BA2308,1286,Male,Male,White,4,n,71,FALSE,FALSE,FALSE,GATA2-MECOM,FALSE,FALSE,y,Prostate Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,72,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",4,Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Dead,Dead-Disease,TRUE,TRUE,13-00546,2,,,,,,,,,,,,,,,,,"45,XY,-7,t(3;3)[20]",,,,,,,,TRUE,TRUE,13-00546,positive,negative
16-00010,BA2786,2437,Female,Female,AdmixedBlack,6,n,30,FALSE,FALSE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,31,25,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response i,Standard Chemotherapy,27,Standard Chemotherapy,HiDAC,Consolidation,93,Unknown,,TRUE,FALSE,16-00009;15-00943,0,,79,64,,,2,15,1,,44,53,4,0.52,,29.5,9.6,"46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[20]",,89.4,"This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on previous sample.",69,"POSITIVE FOR CD33, CD11B, CD64, CD4 AND MPO (SUBSET/DIM) AND ARE NEGATIVE FOR CD117, CD13, CD34, HLA-DR AND TDT",7.3,20.3,FALSE,FALSE,,negative,negative
13-00468,BA2329,1233,Male,Male,White,1,n,61,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,61,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Decitabine,Salvage,126,Dead,Dead-Disease,FALSE,FALSE,,0,,17,10,,,27.7,,39.2,,47,22,3.8,0.5,,25.8,8.5,"47~49,XY,-21,+1~4mar[cp21]/46,XY[2]",,86.6,Monosomy 21,40,"CD13, CD33, CD34. CD45, subset CD64, CD79a, CD117,HLA-DR, and subset TdT positive).",7.6,5.5,FALSE,FALSE,,negative,negative
16-01272,BA2406,4310,Male,Male,White,6,n,64,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6,Dead,Dead-Unknown,FALSE,FALSE,,0,,17,,,,,5,,,,,,,,,,"42,XY,-3,-7,der(12)t(12;?)(q24.3;?)-17,der(17)t(17;?)(p13;?),-21,der(22)t(22;?)(p11.2:?)[10]/46,XY[10] ",,,,43,"NOT DETECTED for the MLL partial tandem duplication (PTD). NOT DETECTED for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR). NOT DETECTED for the FLT3 TKD Mutation. Pathogenic alterations are DETECTED in the DNMT3A, NF1 and TP53 genes. ",,2.2,FALSE,FALSE,,negative,negative
13-00147,BA2003,819,Female,Female,AdmixedAsian,3,n,57,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,58,215,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Unknown,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,-1,Dead,Dead-Disease,TRUE,FALSE,12-00288,-14,,,,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,,,,FALSE,FALSE,,positive,positive
13-00420,BA2421,1194,Male,Male,White,2,n,75,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",75,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",4,Consolidation|Induction|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,Azacitidine,Maintenance,34,Dead,Dead-Disease,FALSE,FALSE,,-98,,,,,,,,,,,,,,,,,"47,XY,+8,inv(9)(p11q12)c[1]/48,idem,+3[5]/49,idem,+3,+15[1]/50,idem,+3,+8,+mar(8]/46,XY,inv(9}(p11q12)c[5]",,,"nuc ish (D8Z2x3~4)[134/200],(D15Z4x3)[114/200]",,,,,FALSE,FALSE,,negative,negative
16-00088,BA2256,2442,Female,Female,AdmixedBlack,6,n,25,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",26,49,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Cladribine, Cytarabine, Idarubicin",3,Consolidation|Induction|Re-induction,Unknown,Standard Chemotherapy,-1,Standard Chemotherapy,"Azacitidine, Sorafenib",Re-induction,67,Dead,Dead-Unknown,FALSE,FALSE,,0,,98,95,,,2,3,,,46,30,4.1,0.54,,27.2,8.9,"46,XX,t(7;12)(q22;p13)[12]/46,XX,t(7;17)(p10;q10),-9,+mar[7]/46,XX[1]",,90.4,This test has detected a translocation between 7 and 12 in 12 cells; a translocation between 7 and 17 with loss of a chromosome 9 and a marker in 7 cells.,81,"These are positive for CD34, CD117, HLADR, CD33 but negative for CD13 and CD11b. TdT and CD79a are partially expressed.",6.9,67.7,FALSE,FALSE,,positive,negative
13-00572,BA2019,1348,Male,Male,HispNative,3,n,39,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,39,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,7,"Nelarabine|POMP (Prednisone, Methotrexate, 6-MP, Vincristine)|3+7 (Cytarabine, Daunorubicin)|HyperCVAD|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)",5,Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance|Re-induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Re-induction,-1,Dead,Dead-Disease,FALSE,FALSE,,0,,59.3,28,,,,,,,,,,,,,,"46,XY,t(10;11)(p13;q14)[11]/45,sl,-Y[7]/46,sdl1,t(1;8)(q12;p21)[2]",,,Normal,,"Increased atypical myeloblasts (partial CD34+, weak CD7+, partial CD61+), representing approximately 91% of the leukocytes, consistent with persistent acute myeloid leukemia.",,1.7,FALSE,FALSE,,negative,negative
14-00672,BA2309,1786,Male,Male,White,7,n,64,FALSE,FALSE,FALSE,None,TRUE,FALSE,n,,y,n,n,n,n,n,y,n,MYELOPROLIFERATIVE NEOPLASMS,Essential thrombocythaemia,Intermediate,,MYELOPROLIFERATIVE NEOPLASMS,Essential thrombocythaemia,77,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,Ruxolitinib|Imatinib|Hydroxyurea,2,Induction|Re-induction,Refractory,Standard Chemotherapy,4626,Standard Chemotherapy,Ruxolitinib,Re-induction,-1,Alive,Alive,FALSE,FALSE,,0,,15,,,,,,,,,,,,,,,"47,XY,+der(1;9)(q10;p10)[17]/94,idemx2[2]/46,XY[1]",,,Nineteen of twenty metaphase cells examined had an extra derivative chromosome composed of a chromosome 1 long arm and a chromosome 9 short arm; two of these cells were in the tetraploid state with two copies of the derivative chromosome. ,,"dimCD7, CD13, dim CD33, CD34, CD71, and CD117 positive",,,FALSE,FALSE,,negative,negative
16-00770,BA2469,4007,Female,Female,White,6,n,50,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,51,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Busulfan, Fludarabine|5+2 (Cytarabine, Idarubicin)|HiDAC|7+3 (Cytarabine, Idarubicin, Bortezomib",3,Unknown|Induction|Re-induction,Unknown,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Unknown,-1,Alive,Alive,FALSE,FALSE,,0,,12,,,,,17,,,,,,,,,,"46,XX[20]",,,,16,"FLT3 (ITD) Not detected. Not detected for the FLT3 TKD Mutation. Pathogenic alterations are detected in the BCOR, IDH2 and WT1 genes. Positive for CD34, HLADR, CD117, CD13, CD33 and CD43 and negative for CD11B, CD14, CD64, TDT and MPO.",,1.5,FALSE,FALSE,,negative,negative
16-00771,BA2269,4008,Female,Female,HispNative,6,n,34,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,34,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Intrathecal,3,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Etoposide, Mitoxantrone",3,Unknown|Induction|Re-induction,Refractory,Standard Chemotherapy,35,Intrathecal,Cytarabine,Unknown,6,Dead,Dead-Unknown,FALSE,FALSE,,0,,15,,,,,12,,,,,,,,,,"46,XX[20]",,,,426,,,26.4,FALSE,FALSE,,negative,negative
14-00127,BA2822,1481,Male,Male,White,1,n,37,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,38,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,2,"7+3 (Cytarabine, Idarubicin)|Azacitidine",2,Induction|Maintenance,Refractory,Standard Chemotherapy,6,Supportive/Palliative Care,Azacitidine,Maintenance,-1,Dead,Dead-Disease,FALSE,FALSE,,-1,0,,95,0,,0.9,0,0,0.1,17,56,1.8,0.6,,23,7.9,"48~54,XY,add(2)(p13),+5,add(5)(q13),del(5)(q13),+10,+11,+13,+13,del(13)(q32),+14,-15,-16,del(17)(p12),-20,+21,+21,+22,+mar[cp9]/49~52,sl,-del(17)(p12)[cp8]/51~54,sl",,86.8,Extra chromosome 5,20,"CD10, CD13, CD33, CD34, CD56 and HLA-DR positive",5.3,38.47,FALSE,FALSE,,negative,negative
16-00264,BA2534,2225,Female,Female,White,3,n,71,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Follicular lymphoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,72,249,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone",4,Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,-1,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1,Dead,Dead-Disease,FALSE,FALSE,,-37,,>95,99,,,,,,,,,,,,,,"46,XX,del(7)(q22q36)[18]/46,sl,t(1;10)(p13;q24)[2]",,,"- 3 copies of the MECOM locus at 3q26.2, suggestive of a  rearrangement or gain of this locus, in 156/200 (78.0  percent) cells scored.  - deletion 7q31 involving the D7S486 locus in 162/200 (81.0  percent) cells scored.",,,,20.39,FALSE,FALSE,,positive,negative
15-00194,BA2153,1973,Male,Male,White,1,n,70,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,70,15,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",3,Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6,Supportive/Palliative Care,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Alive,Alive,TRUE,FALSE,15-00131,1,0,,,0,0,78.1,0.9,1.7,0,46,27,2,0.74,,24.4,8.1,"47,XY,+4[9]/46,XY[11]",,103.8,,23,,4.7,4.85,TRUE,FALSE,15-00131,negative,negative
14-00714,BA2526,1811,Female,Female,White,4,n,50,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,55,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,n,n,y,n,n,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine|MEC, Lenalidomide",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,6,Supportive/Palliative Care,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Dead,Dead-Disease,TRUE,TRUE,14-00715,0,,72,81,,,,,,,,,,,,,,"50,XX,del(1)(q32),+8,+9,t(15;16)(q15~21;q12~22),+19,+21[cp20]",,,,,"ABNORMAL CD34+ BLAST POPULATION, 72%, EXPRESSING DIM PARTIAL CD4, DIM PARTIAL CD7, DIM PARTIAL CD8, CD33, CD38, PARTIAL CD64, CD117, PARTIAL HLA-DR, AND DIM PARTIAL TdT",,3.8,TRUE,TRUE,14-00715,negative,negative
15-00864,BA2579,2337,Male,Male,White,1,n,53,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,54,30,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea",4,Induction|Experimental|Re-induction|Maintenance,Unknown,Standard Chemotherapy,6,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,-1,Dead,Dead-Disease,TRUE,FALSE,15-00863;15-00860;15-00799,0,0,8,1,4.7,0.9,40.6,10.4,43.4,0,40,34,3.8,0.73,,20.2,7.1,"46,XY[12]",235,93.5,normal,17,"dim variable CD7, dim CD11b, CD13, CD33, CD34, CD58, CD117, and CD123",6.8,1.06,TRUE,TRUE,15-00811;15-00863,positive,positive
16-00077,BA2837,2500,Male,Male,White,2,n,78,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Esophageal Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,80,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,5,"AG-120|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",4,Consolidation|Induction|Experimental|Maintenance,Complete Response,Standard Chemotherapy,7,Targeted Therapy - Other,AG-120,Experimental,-1,Dead,Dead-Disease,FALSE,FALSE,,-29,0,,70,0,,7,3,9,,11,57,2.6,1.28,,25.6,8.1,"45,XY,-7[2]/45,XY,t(6;8)(q21;q21.2),-7,del(10)(q24q26),t(12;15)(p13;q15)[19]",1897,,"nuc ish(D5S2064,D5S630,EGR1)x2 [200],(D7Z1x2,D7S522x1)[1/200]/(D7Z1,D7S522)x1[185/200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",23,"CD2(subset +), CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial +), CD38(variably +), CD45(+), CD56(partial +), CD64(-), CD117(+), HLA-DR(partial +).",4.3,240.43,FALSE,FALSE,,negative,negative
15-00912,BA2981,2426,Female,Female,White,6,n,76,FALSE,FALSE,FALSE,None,FALSE,FALSE,y,Breast Cancer,y,y,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,77,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Unknown,1,Azacitidine,1,Unknown,,,,Unknown,Azacitidine,Unknown,424,Dead,Dead-Unknown,FALSE,FALSE,,0,,86,50,1,,14,5,20,,32,20,2.9,0.62,,24.3,7.8,"48-51,XX,del(4)(q25),del(5)(q11.2),-17,-18,+22,+3-5mar[20]",,84.1,,27,"POSITIVE FOR DIM CD45, HLADR, CD34, CD117, CD13, CD33, CD43, CD81, CD58.",5.4,14.3,FALSE,FALSE,,negative,negative
13-00573,BA2412,1349,Male,Male,White,1,n,85,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,86,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,169,Dead,Dead-Disease,FALSE,FALSE,,0,0,,,0,,17,44,39,0,15,9,3.5,0.9,,25.7,8.2,,175,88,,18,,6.9,13.22,FALSE,FALSE,,negative,negative
16-01010,BA2450,4197,Female,Female,White,1,n,45,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,46,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,32,Standard Chemotherapy,Sunitinib,Consolidation,2,Dead,Dead-Disease,TRUE,FALSE,16-01104,0,0,,,0,0,20.4,0,66.7,1,58,44,3.3,1.04,,23.8,8.1,,401,88.5,Positive,14,,7.3,6.18,FALSE,FALSE,,positive,positive
16-01103,BA2824,4197,Female,Female,White,1,n,45,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47,23,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,32,Standard Chemotherapy,Sunitinib,Consolidation,2,Dead,Dead-Disease,TRUE,FALSE,16-01104,0,0,90,90,0,0,5,0,0,0,27,43,1.6,0.93,,22.5,7.9,,,82.1,Positive,43,"variable CD7, CD13, dim CD33, partial CD34, CD38,dim CD58, partial and variable CD117 and CD123 positive",5.1,18.38,FALSE,FALSE,,positive,positive
13-00619,BA2418,1373,Female,Female,White,2,n,47,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47,2,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,"Crenolanib|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Salvage|Experimental,,,,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,4,Dead,Dead-Unknown,TRUE,FALSE,13-00612,0,0,,72,0,,28,0,0,,10,17,2.8,0.56,,14.5,5.3,,291,,,10,,5.1,1.2,FALSE,FALSE,,negative,positive
13-00532,BA2248,1281,Male,Male,HispNative,2,n,21,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",22,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),13,"HiDAC|Crenolanib|Etoposide|Topotecan|Decitabine|Clofarabine|Thioguanine|7+3 (Cytarabine, Idarubicin)|Cyclophosphamide|Thiotepa|Sorafenib|Mitoxantrone|Vinorelbine",4,Induction|Experimental|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,5,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,15,Dead,Dead-Disease,FALSE,FALSE,,0,0,88,92,0,,8,0,0,,22,20,3.3,0.51,,25.8,9.1,,208,,,,,6.4,3.2,FALSE,FALSE,,negative,negative
15-00974,BA2727,1745,Female,Female,White,1,n,36,FALSE,FALSE,FALSE,GATA2-MECOM,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,38,494,Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant,Peripheral Blood,y,y,y,y,y,y,3,DLI|Standard Chemotherapy|Bone Marrow Transplant,7,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, Cyclophosphamide",5,Hypomethylating/Low Dose Cytarabine|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,4,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,4,Dead,Dead-Disease,FALSE,FALSE,,-11,0,,,0.9,0,13.9,0,0.9,0.4,59,28,2.8,,,32.6,10.3,"46,XX,inv(3)(q21q26)[5]",,99.4,FISH) was performed with a MECOM/RPN1 probe set. 125/200 (62.5%) interphase cells scored had a 1 red/ 1 green/ 2 yellow double fusion signal pattern reflecting MECOM/RPN1 fusion and the paracentric inversion of the long arm of a chromosome 3 observed in the metaphase karyotype.  FISH was also perfor,38,,6.7,7.08,FALSE,FALSE,,negative,negative
15-00309,BA3053,2075,Female,Male,White,3,n,63,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,64,0,Residual Disease|Post-Chemotherapy|Post-Transplant,Peripheral Blood,y,y,y,n,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),5,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Sorafenib",5,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental,Complete Response,Standard Chemotherapy,-1,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,-1,Dead,Dead-Disease,FALSE,FALSE,,-11,,,,,,,,,,,,,,,,,"46,XY[6]",,,,,,,25.7,FALSE,FALSE,,positive,positive
13-00537,BA3042,757,Female,Male,White,1,n,32,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,38,488,Residual Disease|Post-Transplant,Bone Marrow Aspirate,y,y,y,n,y,y,3,DLI|Standard Chemotherapy|Bone Marrow Transplant,9,"HiDAC|Decitabine, Sirolimus|Donor Lymphocyte Infusion|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, Cyclophosphamide",6,Consolidation|Salvage|Induction|Re-induction|Post-Transplant Relapse|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"Decitabine, Sirolimus",Salvage,127,Dead,Dead-Disease,TRUE,FALSE,13-00507,-18,,90,30,,,56.8,,9.9,,62,39,3.5,0.6,,30.6,10.2,"46,XX[19]/46,XY[1]",145,91.3,Normal,17,"CD7, CD13, CD33, CD34, dim CD45, CD56, CD117, CD123, and HLA-DR positive.",7.1,2,TRUE,FALSE,13-00507,negative,negative
16-00611,BA3071,2695,Male,Male,Black,1,n,49,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,51,46,Residual Disease|Post-Transplant|Post-Chemotherapy,Peripheral Blood,y,y,y,n,y,y,4,DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,7,"HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",6,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,13,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,115,Alive,Alive,TRUE,FALSE,16-00522,-32,0,,,0,0,4.2,1.7,6.8,0.6,91,102,3.5,,,29.9,10.8,"46,XY[19]",,85.4,Normal,31,,6.9,162.21,FALSE,FALSE,,negative,positive
16-00073,BA2483,2443,Female,Female,White,1,n,63,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64,44,Residual Relapse,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other,6,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea",6,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Maintenance|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,-1,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,29,Dead,Dead-Disease,TRUE,FALSE,15-00954,-44,1.5,,38.5,0,0,55,3.5,1.5,0,25,22,3.8,1.3,,21.1,7.1,"48,XX,+8,+21[16]/46,XX[4]",,91.3,"RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on banded chromosomes and the partner remains unkn",18,,7.7,19.76,FALSE,FALSE,,negative,negative
16-00118,BA3002,2443,Female,Female,White,1,n,63,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64,58,Residual Relapse,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other,6,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea",6,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Maintenance|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,-1,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,29,Dead,Dead-Disease,TRUE,FALSE,15-00954,-58,0,,,0,0,12.6,0,0,0.2,16,36,3.1,1.57,,20.9,7,"48,XX,+8,+21[16]/46,XX[4]",887,89.7,"RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on banded chromosomes and the partner remains unkn",21,,7.3,49.93,FALSE,FALSE,,negative,negative
15-00351,BA2986,2102,Female,Female,White,1,n,48,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",56,0,Residual Relapse|Post-Chemotherapy|Post-DLI|Post-Transplant,Bone Marrow Aspirate,y,y,n,y,y,n,3,DLI|Standard Chemotherapy|Bone Marrow Transplant,7,"7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Mitoxantrone|Busulfan, Cyclophosphamide",5,Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,5,Dead,Dead-Disease,FALSE,FALSE,,0,0,62,5,0,0,83.2,1.8,0,0,28,21,2.5,0.8,,24.1,8.3,"46,XX,t(1;11)(q44;q13),del(6)(p23)[9]/46,idem,t(17;20)(q25;q11.2)[11]",290,94.5,"All probe results were within normal laboratory limits.      *Note: while it was not disrupted, MLL (11q23) was observed on the end of      the derivative chromosome 1 on available metaphase cells, reflecting the      t(1;11).",53,"dim CD2, CD13, CD33, CD34, CD38, CD117, dim CD123, dim      HLA-DR, and TdT positive",6.5,1.46,FALSE,FALSE,,negative,negative
14-00044,BA2939,1153,Female,Female,White,4,n,35,FALSE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,37,160,Residual Relapse|Post-Chemotherapy|Post-Transplant,Peripheral Blood,y,n,y,y,n,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI",5,Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Re-induction,53,Dead,Dead-Treatment,TRUE,TRUE,13-00331,-159,,,,,,,,,,,,,,,,,"46,XX[5]",,,,,,,,FALSE,FALSE,,negative,positive
14-00742,BA2143,1821,Female,Female,White,2,n,51,FALSE,FALSE,FALSE,Complex,TRUE,FALSE,y,Breast Cancer,y,n,y,n,n,n,n,n,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",Adverse,Adverse,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",51,0,Unknown,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,Decitabine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,4,Unknown,,FALSE,FALSE,,0,0,9,11,0.8,,28.2,13.7,43.6,,19,28,2.6,0.7,,27.2,9.1,"44,XX,der(5)t(5;9)(p15;q22)del(5)(q11.2q15),-7,-9,-18,del(20)(q11.2q13.1),+mar[cp8]/43~44,XX,-der(5),del(7)(q11.2q32),add(11)(p15),del(12)(p11.2p13),der(15)t(15;17)(p12;q11.2),-16,-18,+mar[cp9]/43,XX,del(5)(q13q33),del(7),add(11),del(12),der(15),-16,-18,+mar[cp3].ishder(15)(PML+,RARA+)[1].",517,92.4,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[108/200]",74,"CD2 (-), CD4(- to dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD25(dim +), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), CD123(dim +), HLA-DR(variably+), MPO(-), TdT(-)",6.2,,FALSE,FALSE,,negative,negative
16-00564,BA2385,2740,Female,Female,White,6,n,81,FALSE,FALSE,FALSE,None,TRUE,FALSE,y,Rectal Cancer,y,y,n,n,y,n,n,n,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,Adverse,Adverse,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,81,0,Unknown,Bone Marrow Aspirate,y,y,y,n,y,y,1,Other,1,Radiation,1,Unknown,,,,Other,Radiation,Unknown,22,Alive,Alive,FALSE,FALSE,,0,,5,0,,,,2,,,,,,,,,,"45,X,-X,del(9)(q13)[12]/46,sl,i(X)(q10)[8]",,,9q deletion is present in all metaphase cells analyzed. All cells have also show either missing one X chromosome or an isochromosome for its long arm. It is most likely that the X chromosome abnormalities represent constitutional changes associated with Turner syndrome.,30,Not detected for the FLT3 Internal Tandem Duplication (ITD). Not detected for the FLT3 TKD Mutation. MLL partial tandem duplication (MLL-PTD) is not detected. Pathogenic alteration is detected in the TET2 gene. Genomic alterations of uncertain significance are detected in the EZH2 and NF1 genes.,,35.1,FALSE,FALSE,,negative,negative
14-00060,BA2860,1441,Male,Male,White,1,n,68,FALSE,FALSE,FALSE,None,TRUE,FALSE,n,,y,n,y,n,n,n,n,n,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",Adverse,,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",68,0,Unknown,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,Azacitidine,1,Induction,Unknown,Standard Chemotherapy,6,Standard Chemotherapy,Azacitidine,Induction,6,Dead,Dead-Unknown,FALSE,FALSE,,-13,0,,15,1.7,,38.7,3.4,30.3,0,27,23,3,1.18,,21,7,"45~48,XY,del(5)(q22q35),+8,del(13)(q12q14),- 20,der(21)t(20;21)(p11.2;p11.1),+der(22)t(?;22)(?;q11.2)[cp15]/46,XY[4]",1138,88.6,,26,"CD13, CD33, CD34, CD38, CD58, CD117, CD123 and HLA-DR positive",5.7,2.42,FALSE,FALSE,,negative,negative
13-00601,BA2481,1369,Male,Male,White,2,n,,FALSE,FALSE,FALSE,None,TRUE,FALSE,n,,y,n,y,n,n,n,n,n,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,Intermediate,,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,,4,Unknown,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Induction,Unknown,Standard Chemotherapy,60,Standard Chemotherapy,Decitabine,Induction,60,Dead,Dead-Unknown,FALSE,FALSE,,-3,,,,,,,,,,,,,,,,,"46,XY[20]",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,,,,FALSE,FALSE,,negative,negative
14-00376,BA2676,1614,Male,Male,White,1,n,48,FALSE,FALSE,FALSE,None,TRUE,FALSE,n,,y,n,y,n,n,n,n,n,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,Intermediate,,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,48,0,Unknown,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Decitabine|Busulfan, Cyclophosphamide",2,Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,116,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,0,17,5.3,0,,67.3,22.1,5.3,0,36,20,3.5,0.82,,32.5,10.2,"47,XY,+8[18]/46,XY[2]",155,83.5,Trisomy 8,105,"CD13, CD33, CD34, CD38, CD58, CD117, CD123, MPO+",7.9,0.94,FALSE,FALSE,,negative,negative
14-00458,BA2792,1662,Male,Male,White,1,n,51,FALSE,FALSE,FALSE,None,TRUE,FALSE,n,,y,n,y,n,n,n,n,n,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,Intermediate,,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,51,0,Unknown,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Fludarabine, Melphalan|Azacitidine, Lenalidomide",2,Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,117,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1,Dead,Dead-Treatment,FALSE,FALSE,,0,0,4,6,0,,38.9,1.1,56.7,,58,51,3.5,0.87,,22.4,7.5,"47,XY,+8[2]/46,XY[18]",438,93.7,Trisomy 8,20,CD34/CD117 positive myeloid blasts comprise about 4% of total CD45+ cells with possible partial TdT expression,5.9,2.23,FALSE,FALSE,,negative,negative
16-00339,BA3030,2626,Female,Female,White,1,n,70,FALSE,FALSE,FALSE,None,TRUE,FALSE,n,,n,n,n,n,n,n,y,n,MYELOPROLIFERATIVE NEOPLASMS,"Atypical chronic myeloid leukaemia, BCR-ABL1 negative",Intermediate,,MYELOPROLIFERATIVE NEOPLASMS,"Atypical chronic myeloid leukaemia, BCR-ABL1 negative",70,0,Unknown,Bone Marrow Aspirate,y,y,y,y,y,y,1,Targeted Therapy - Kinase Inhibitor(s),1,Hydroxyurea,1,Induction,Unknown,Targeted Therapy - Kinase Inhibitor(s),-1,Targeted Therapy - Kinase Inhibitor(s),Hydroxyurea,Induction,-1,Alive,Alive,FALSE,FALSE,,0,1.6,13,6.8,0.8,0,5.7,2.5,72.1,5.7,24,36,2.9,0.95,,29.1,8.9,"46,XX[20]",953,105.1,Normal,208,"CD13, CD33, CD34, partial CD117, CD123, HLA-DR",6.7,109.77,FALSE,FALSE,,positive,negative
12-00150,BA2172,722,Male,Male,AdmixedBlack,7,n,,FALSE,FALSE,FALSE,Unknown,FALSE,TRUE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,unknown,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,unknown,18,0,Unknown,Peripheral Blood,y,n,y,y,n,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,FALSE,FALSE,,0,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,negative,negative
13-00650,BA2656,2737,Male,Male,White,7,n,,FALSE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,20,2,Unknown,Peripheral Blood,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,FALSE,FALSE,,0,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,negative,positive
15-00837,BA2623,2350,Male,Male,White,3,n,72,FALSE,FALSE,TRUE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,72,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,Azacitidine|Momelotinib,2,Hypomethylating/Low Dose Cytarabine|Experimental,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Dead,Dead-Disease,FALSE,FALSE,,-141,,,58,,,,,,,,,,,,,,"46,XY,inv(16)(p13.1q22)[20]",,,,,,,8.21,FALSE,FALSE,,negative,negative
16-00755,BA2728,4001,Female,Female,White,1,n,58,FALSE,FALSE,TRUE,GATA2-MECOM,FALSE,FALSE,n,,y,n,y,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,58,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,2,"SWOG S0919 (Ida/Ara+Pravastatin) |Busulfan, Cyclophosphamide",2,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,70,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,0,Alive,Alive,TRUE,FALSE,16-00751,0,0,21,0,0,2.3,41.7,25.9,30.1,0.1,,,,,,35.1,11,"46,XX,t(3;3)(q21;q26)[20]",,107,Abnormal,360,"variable CD11b, CD13, dim CD33, CD34, CD58, CD117, CD123",,13.83,FALSE,FALSE,,negative,negative
16-00818,BA2951,4029,Female,Female,White,3,n,65,FALSE,FALSE,TRUE,GATA2-MECOM,FALSE,FALSE,n,,n,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,65,3,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,TRUE,FALSE,16-00813,-3,,,,,,,,,,,,,,,,,"47,XX,+X,inv(3)(q21q26.2),-7,+22[2]/48,sl,+21[18]",,,evidence of monosomy 7 in 191/200 (95.5 percent) cells scored,,,,,TRUE,FALSE,16-00813,negative,negative
14-00801,BA3049,1855,Male,Male,White,1,n,61,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,61,0,Post-Chemotherapy|Residual Disease|Post-Transplant,Bone Marrow Aspirate,y,y,y,n,y,y,3,DLI|Standard Chemotherapy|Bone Marrow Transplant,5,"Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,269,Alive,Alive,FALSE,FALSE,,1,0.6,3,0,7.2,0.4,31.8,13,47,0,51,76,3.3,0.94,,42.5,14,"46,XY[23]",753,87.6,Normal,188,maturing myeloid population. Myeloid blasts are about 2%. Monocytes are 6/7% and without antigen aberrancy.Lymphocytes are 10-11%. Mostly T cells and these have a 1:1 CD4:CD8 ratio.There are approximately 20% of lymphocytes as B cells and these are polyclonal. NK cells not increased,6.9,5.16,FALSE,FALSE,,negative,negative
13-00255,BA2134,1104,Male,Male,White,1,n,72,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72,8,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,1,"3+7 (Cytarabine, Daunorubicin)",1,Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,6,Dead,Dead-Unknown,TRUE,TRUE,13-00237,-8,0,,5,1,,3,77,8,,57,27,3.5,0.61,M4,26.3,8.7,"46,XY,del(12)(p11.2p13)[15]/46,XY[5]",324,92.8,12p deletion,19,,7.2,56.5,FALSE,FALSE,,negative,negative
15-00777,BA2089,2314,Male,Male,White,1,n,68,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,68,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Leukapheresis,y,y,y,y,y,y,1,Standard Chemotherapy,1,"3+7 (Cytarabine, Daunorubicin)",1,Induction,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,7,Dead,Dead-Unknown,FALSE,FALSE,,-1,0,,83,0,0.8,8.1,9.8,1.6,0.7,29,137,3.3,2.67,M5,35.5,11.4,"46,XY[20]",3615,92.4,normal,104,"CD11b, partial CD13, partial CD14, CD33, partial CD56, CD58, CD64, subset HLA-DR (20%) and partial MPO positive",6.4,140.18,FALSE,FALSE,,negative,negative
15-00939,BA2034,2314,Male,Male,White,1,n,68,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,68,72,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"3+7 (Cytarabine, Daunorubicin)",1,Induction,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,7,Dead,Dead-Unknown,TRUE,TRUE,15-00777,-39,0.8,,,0.9,0,9.3,0,0,0.5,12,14,2.5,0.9,,20.6,6.4,"46,XY[19]",,90.4,normal,60,,6.3,6.21,FALSE,FALSE,,negative,negative
16-00151,BA2273,2547,Male,Male,White,6,n,67,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",67,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"3+7 (Cytarabine, Daunorubicin)",1,Unknown,,,,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Unknown,-1,Unknown,,FALSE,FALSE,,0,,80,10,2,,68,4,8,,8,10,3.9,0.85,,21.2,7.2,"46,XY[20]",,110.4,The translocations commonly seen in AML are not detected. Loss of RARA and CBFB genes are detected in 14-39% of cells.,84,"These are positive for CD34, CD117, HLADR, CD33, CD13, CD14 and CD11b.",5.9,0.9,FALSE,FALSE,,negative,negative
13-00160,BA2858,967,Male,Male,White,1,n,70,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,73,93,Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|Azacitidine",2,Induction|Maintenance,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,Azacitidine,Maintenance,-1,Dead,Dead-Unknown,TRUE,FALSE,13-00049,-93,,,,,,,,,,,,,,,,,"46,XY[19]",,,Normal,,,,,FALSE,FALSE,,negative,negative
14-00761,BA2769,1833,Female,Female,White,4,n,72,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72,0,Residual Disease,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine, Midostaurin",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,186,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Re-induction,62,Alive,Alive,TRUE,FALSE,14-00760,-22,,,,,,,,,,,,,,,,,"46,XX[20]",,,,,,,,FALSE,FALSE,,negative,negative
15-00175,BA2441,1999,Male,Male,HispNative,1,n,50,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,50,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Salvage|Induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,4,Dead,Dead-Disease,FALSE,FALSE,,0,0,76,93,0,0,6.1,1.7,1.8,0,7,10,2.2,0.44,,18.8,6.3,"43~47,XY,del(1)(q42),r(2)(p2?3q37),t(3;5)(q27;q31),del(4)(q31),+del(5)(q31),add(5)(q11.2),-7,del(11)(q23),add(12)(p13),-22,+mar[cp11]/43~46,idem,add(14)(q24)[cp8]",,85.8,deleted 5q and three short arm signals;  monosomy 7 and the metaphase karyotype;  no evidence for MLL deletion or rearrangement,14,,5.9,50.74,FALSE,FALSE,,negative,negative
15-00084,BA2722,1953,Female,Female,White,1,n,82,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,82,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,122,Dead,Dead-Disease,FALSE,FALSE,,-21,7.6,,,4.2,8.5,28,6.8,12.7,0.1,24,22,3.1,0.96,,31.5,11,"43~46,XX,add(2)(q11.2),-4,del(5)(q23),add(7)(q32),+8,add(11)(q23),-16,del(17)(p12),-18,+22[cp19]/46,XX[1]",1304,86.8,,21,,7.3,17.63,FALSE,FALSE,,negative,negative
15-00353,BA2494,2104,Male,Male,White,5,n,60,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,n,n,y,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute megakaryoblastic leukaemia,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute megakaryoblastic leukaemia,60,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Dead,Dead-Disease,FALSE,FALSE,,-6,,13,rare,,,,,,,,,,,,,,"46,XY,del(13)(q12q14)[3]/46,XY[17]",,,Normal,136,"CD3  - Scattered cells positive, 5-10% of marrow cells CD20  - Scattered cells positive, 5-10% of marrow cells CD34  - Rare cells positive, <1% of marrow cells CD30  - Negative CD43  - Positive in >60% of marrow cells, including the clusters of immature cells",,3.1,FALSE,FALSE,,negative,negative
15-00650,BA2976,2251,Male,Male,White,1,n,85,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,85,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Induction,Refractory,Standard Chemotherapy,232,Standard Chemotherapy,Azacitidine,Induction,232,Dead,Dead-Unknown,FALSE,FALSE,,0,0,36,23.7,0,8.7,20.2,27.2,20.2,1.6,24,23,3.4,0.88,M4,31.5,9.6,"46,XY,del(12)(p11.2p13)[20]",200,95.7,"ETV6: 84% of cells were missing a signal for ETV6 (12p13), consistent with the deletion seen on metaphase analysis. ",46,"CD34, CD117, dim CD123, CD33, dim HLA-DR, CD13, and CD58.",7,40.53,FALSE,FALSE,,negative,negative
13-00281,BA2597,1131,Female,Female,White,4,n,79,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,79,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Azacitidine, Lenalidomide",1,Salvage,,,,Standard Chemotherapy,"Azacitidine, Lenalidomide",Salvage,137,Dead,Dead-Disease,FALSE,FALSE,,0,,73,56,,,,1,,,,,,,,,,"46,XX,del(16)(p11.2)[3]/46,XX[2]",,,,,"CD34, CD4(dim), CD7, CD11c(dim), CD13, CD33(dim),CD38, CD117, and HLA-DR",,8.7,FALSE,FALSE,,negative,negative
16-00132,BA2852,2526,Male,Male,White,6,n,74,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,75,0,Post-Chemotherapy,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,"Azacitidine, MLN4924",1,Induction,Complete Response,Standard Chemotherapy,498,Standard Chemotherapy,"Azacitidine, MLN4924",Induction,498,Unknown,,TRUE,FALSE,16-00131,0,,6,,3.8,,48.1,9.5,38.1,,41,25,4.4,0.73,,36.5,12.7,"48,XY,+8,del(20)(q11.2),+21[14]/46,XY[6]",,94.8,"This test has detected a 20q deletion, trisomy 8, and trisomy 21 in 14 cells. All these abnormalities are commonly seen in AML and MDS.",43,"These are positive for CD34, CD117, HLA-DR, and CD33.",6.4,2.1,FALSE,FALSE,,negative,negative
16-00007,BA2097,2464,Male,Male,White,4,n,77,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,77,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"Azacitidine, Sorafenib|Decitabine, Midostaurin",2,Induction|Re-induction,Refractory,Standard Chemotherapy,165,Standard Chemotherapy,"Azacitidine, Sorafenib",Re-induction,-1,Alive,Alive,TRUE,TRUE,16-00006,0,,41,18,,,,,,,,,,,,,,"46,XY[20]",,,"CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)",,"ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56",,2.2,TRUE,TRUE,16-00006,positive,negative
15-00014,BA2870,1877,Female,Female,White,1,n,77,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,77,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,2,Azacitidine|Decitabine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,6,Dead,Dead-Unknown,FALSE,FALSE,,1,0,95,9,0,0.9,53,0,28.7,0.8,10,16,4,1.02,M5,25.8,8.6,"47,XX,+1,add(1)(p22)[15]/47,XX,+1,i(1)(q10)[5]",601,97,"1p36/1q25: 81% of cells had three signals for 1q25 and two for 1p36, consistent with the larger clone above (ie. the clone with add(1)(p22). Another 13% of cells had four signals for 1q25 and two signals for 1p36, consistent with the smaller clone above (ie. the clone with the i(1)(q10)).",8,"CD4, CD11b, CD15, CD33, CD38, CD58, CD64, CD123 and partial HLA-DR positive",8.2,3.65,FALSE,FALSE,,negative,positive
14-00735,BA2902,1818,Male,Male,Asian,4,n,83,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,83,1,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,2,"Azacitidine|Decitabine, Midostaurin",2,Hypomethylating/Low Dose Cytarabine|Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"Decitabine, Midostaurin",Induction,-1,Dead,Dead-Disease,FALSE,FALSE,,-6,,,,,,,,,,,,,,,,,"46,XY[13]",,,,,,,,FALSE,FALSE,,positive,positive
14-00380,BA2948,1616,Male,Male,White,3,n,67,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,67,0,Post-Chemotherapy|Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,3,Azacitidine|Decitabine|Clofarabine,2,Hypomethylating/Low Dose Cytarabine|Induction,UNKNOWN,Standard Chemotherapy,-1,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Dead,Dead-Treatment,FALSE,FALSE,,-10,,,,,,,,,,,,,,,,,"42,X,add(Y)(p11.1),add(3)(q12),add(4)(q25),del(5)(q12q33),-7,add(8)(p11.2),-11,add(13)(p11.2),del(16)(q22),-17,add(19)(q12.3),-20,add(21)(p11.2),-22,+mar[20]",,,"43% del 5q31, 56% del 7q31, 58% del20q",,,,,FALSE,FALSE,,negative,negative
14-00581,BA2195,1731,Female,Female,Black,4,n,68,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,68,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,CPX-351 (Liposomal Cytarabine + Daunorubicin),1,Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,CPX-351 (Liposomal Cytarabine + Daunorubicin),Induction,-1,Dead,Dead-Disease,TRUE,FALSE,14-00580,-1,,33,37,,,,8,,,,,,,,,,"42~45,XX,-18[cp14]/43~45,idem,+2~3mar[cp3]/47,XX,+8[cp2]/45,X,-X[1]",,,,,"CD34+ BLAST POPULATION, 33%, EXPRESSING PARTIAL CD38, PARTIAL CD4, PARTIAL CD11C, HLA-DR, CD117, PARTIAL CD13, PARTIAL CD33, PARTIAL CD15, AND MPO",,29.1,TRUE,FALSE,14-00580,negative,negative
14-00800,BA3008,1854,Male,Male,White,1,n,68,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,69,0,Residual Disease|Post-Chemotherapy,Peripheral Blood,y,y,y,n,y,y,1,Standard Chemotherapy,2,"CPX-351 (Liposomal Cytarabine + Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,4,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,4,Dead,Dead-Disease,FALSE,FALSE,,-30,,,,,,,,,3.6,26,65,3.1,1.07,,20.9,7.2,"46,XY[20]",1004,90.1,,17,,5.4,53.76,FALSE,FALSE,,negative,negative
13-00660,BA2375,1398,Male,Male,Black,1,n,72,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,Decitabine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Alive,Alive,FALSE,FALSE,,0,2.6,41,,0,,15.3,9.3,28.8,0.6,36,31,3.8,1.66,,23.3,7.2,"46,XY,-7,+mar.ishder(7)del(7)(p11.2)del(7)(q11.2)(D7Z1+)[20]/45,XY,-7[2]/46,XY[3]",398,82,"Two of twenty-five metaphase cells examined were monosomy 7, shown by  fluorescent in situ hybridization (FISH) in  a companion study  (GLC-13-06587) to be a true clone.  Twenty cells appeared to be missing a  chromosome 7 with an additional small marker.",42,"CD13, dimCD19, partial CD33, partial CD34, CD38, CD58, dim cCD79a, CD117, and TdT positive.",6.6,12.44,FALSE,FALSE,,negative,negative
15-00767,BA2867,2311,Male,Male,White,2,n,78,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,78,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0.2,25,4,1,,25,10,60,,22,21,4.5,0.82,,47.3,15.3,"46,XY[20]",,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",15,"CD2(-), CD7 (-), CD10(-), CD11b(-), CD13(dim +), CD14(-), CD15(+), CD16(-), CD19(-), CD22(partial +), CD33(-), CD34(bright +), CD36 (-), CD38(variably +), CD45(partial dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(partial +), MPO(-) and TdT(+)",7.5,5.79,FALSE,FALSE,,negative,negative
15-00778,BA2224,2315,Male,Male,White,1,n,62,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,2,Decitabine|Hydroxyurea,2,Induction|Re-induction,Complete Response i,Standard Chemotherapy,-1,Standard Chemotherapy,Hydroxyurea,Re-induction,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0,21,2.5,1.7,0,68.3,1.7,25,0,22,9,3.2,0.81,,20.6,6.8,"46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]",,100.5,EGR1 (73.5%) ;  TP53: (85.5%),174,"CD7, CD34, CD117, HLA-DR, CD13, CD33, dim CD123, variable CD15 and subset MPO",5.8,3.74,FALSE,FALSE,,negative,negative
14-00021,BA2636,1408,Male,Male,White,4,n,74,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,4,"Hydroxyurea|Decitabine|Temozolomide, Vorinostat|Azacitidine, MLN4924",4,Salvage|Induction|Re-induction|Symptom Control,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,Decitabine,Salvage,-1,Dead,Dead-Disease,TRUE,FALSE,14-00022,-49,,,,,,,,,,,,,,,,,"46,XY",,,,,,,,FALSE,FALSE,,negative,negative
15-00766,BA2033,2310,Male,Male,White,5,n,71,FALSE,FALSE,TRUE,None,FALSE,FALSE,y,Non-Hodgkins Lymphoma,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,71,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,Lenalidomide|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Dead,Dead-Other,FALSE,FALSE,,0,,60,14,,,,7,,,,,,,,,,"45,XY,add(3)(p10),add(5)(q11.2),psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter)[1]/44,sl,-add(3)(p10), +der(3;13)(q10;q10)[2]/48,sdl1,+8,+14,+21,+22[8]/42-44,sl,-add(3)(p10),add(4)(p15),-7,-8, add(12)(p11.2),+mar,+1-2r[cp7]/80-82 < 4n > ,slx2,-2,add(4)(q22)x2,-6,+8,+8,add(8)(p23)x2,",,,"FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells.",17,"Flow cytometry was negative for increased myeloblasts. The flow showed a mild increase in   immature monocytic cells, but not to the degree seen in the marrow smears. This is likely   attributable to hemodilution of the sample received for flow cytometry.",,21.6,FALSE,FALSE,,negative,negative
16-00358,BA2473,2530,Female,Female,White,6,n,73,FALSE,FALSE,TRUE,None,FALSE,FALSE,y,Breast Cancer,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,73,56,Post-Chemotherapy,Bone Marrow Aspirate,y,n,y,y,n,y,1,Standard Chemotherapy,1,Ruxolitinib,1,Induction,Unknown,Standard Chemotherapy,28,Standard Chemotherapy,Ruxolitinib,Induction,28,Dead,Dead-Unknown,FALSE,FALSE,,1,,5,,,,,1,,,,,,,,,,"46,XX[20] ",,,This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited number of cells examined.,24,"CD34 positive blasts are rare, <1%",,1.8,FALSE,FALSE,,negative,positive
16-00836,BA2820,4039,Male,Male,White,1,n,73,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,73,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|Hydroxyurea",1,Induction,Refractory,Standard Chemotherapy,167,Standard Chemotherapy,"S0919 Trial (Pravastatin, Idarubicin, Cytarabine)",Induction,21,Dead,Dead-Disease,FALSE,FALSE,,0,0,88,38,0,1.7,20.9,60.9,1.7,0.1,27,40,3,1.2,,33,11.2,"46,XY[20]",,105.8,normal,55,Positive,7.5,58.97,FALSE,FALSE,,positive,positive
16-00249,BA2369,2581,Male,Male,White,6,n,75,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",75,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Vidaza,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Vidaza,Supportive/Palliative Care,-1,Alive,Alive,FALSE,FALSE,,0,,60,50,,,,2,,,,,,,,,,"46,XY[20]",,,,,"These are positive for HLA-DR, CD34,CD117, CD33, CD11B, CD64 but Negative for CD13, CD14, CD16, MPO, TDT and all B and T cell markers",,25,FALSE,FALSE,,negative,negative
16-00150,BA2685,2546,Male,Male,White,6,n,67,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,67,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,4,"Vidaza|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Decitabine",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,Decitabine,Salvage,106,Alive,Alive,FALSE,FALSE,,0,,60,,,,,0,,,,,,,,,,"46, XY, del (3) (q12q21) [2]/47, idem, +8[11]/47, idem, der (15) t (1;15) (q21;p11.2) [7]",,,Trisomy 8 is detected in 28% of cells.,,"Positive for CD34, CD117, HLADR, CD33, CD13 and Negative for CD11b and CD64",,,FALSE,FALSE,,negative,negative
16-00145,BA2212,2533,Male,Male,Asian,2,n,75,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,75,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Vidaza|Decitabine|Fludarabine, Cytarabine",2,Salvage|Supportive/Palliative Care,,,,Standard Chemotherapy,"Fludarabine, Cytarabine",Salvage,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0,27,2,0,,60.2,8.4,29.4,,12,15,4.8,0.98,,30.7,9.3,"46,XY,t(1;12)(p32;p13)[3]/46,XY[17]",215,,"nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[194],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]",121,"CD2(-), CD4(-),CD7(-), CD10(partial +), CD11b(-), CD13(dim +), CD14(-), CD38(variably +/small subset -), CD45(dim to moderately +), CD56(-), CD64(-), CD117(variably +), HLA-DR(variably +).",7.5,3.09,FALSE,FALSE,,negative,negative
15-00870,BA3010,2364,Male,Male,White,6,n,71,FALSE,FALSE,TRUE,None,FALSE,FALSE,y,Non-Hodgkins Lymphoma,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,71,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,Vidaza|Rituximab|Decitabine,2,Consolidation|Maintenance,,,,Standard Chemotherapy,Decitabine,Maintenance,86,Dead,Dead-Disease,FALSE,FALSE,,0,,20,10,1,,22,48,16,,6,33,3.7,1.57,,26,8.1,"46,XY[20]",,91.9,,13,"Positive for CD34, CD117, HLADR, CD33, CD13 but negative for CD14, CD64, CD11b, CD19, and CD3",7,44.8,FALSE,FALSE,,negative,negative
13-00558,BA2937,1341,Male,Male,White,1,n,61,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,61,0,Residual Disease|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide",5,Allogeneic - Sibling|Salvage|Induction|Re-induction|Symptom Control,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Dead,Dead-Treatment,FALSE,FALSE,,0,0,25,20,13,,6,12,55,0.9,45,34,3.1,0.8,,31.1,9.8,"42~44,XY,t(1;10)(q12;q21),-5,-7,-11,add(13)(p11.1),der(18)t(11;18)(q14;q21.1),add(20)(q12),+1~3mar[cp4]/41~44,sl,add(4)(q23)[cp9]/41~44,sl,del(4)(q21q?27)[cp5]/41~42,",,88.9,Monosomy 5,243,"CD13, CD33, CD34, CD117, and MPO+.",6.4,96.64,FALSE,FALSE,,negative,negative
16-00701,BA2347,2747,Male,Male,White,6,n,62,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,y,n,n,n,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,62,34,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,n,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Azacitidine|Fludarabine, Melphalan, ATG",2,Unknown|Allogeneic - Matched Unrelated Donor,,,,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,TRUE,FALSE,16-00578,-34,,,1,0,,22,28,42,,37,29,4.7,1.03,,38.2,12.4,"46, XY [20]",,91,The abnormalities normally seen in MDS are not detected.,237,,7.8,16.4,FALSE,FALSE,,negative,negative
16-00822,BA2379,2747,Male,Male,White,6,n,62,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,y,n,n,n,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,62,81,Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Azacitidine|Fludarabine, Melphalan, ATG",2,Unknown|Allogeneic - Matched Unrelated Donor,,,,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,TRUE,FALSE,16-00578,0,,9,,,,,7,,,,,,,,,,"46,XY[12]",,,The abnormalities normally seen in MDS are not detected.,,A very dim/negative CD45 population was also detected by the flow analysis. This population is negative for all the myeloid and lymphoid markers including CD34. This is mentioned here for documentation purposes but we believe that they do not represent blasts.,,,TRUE,TRUE,16-00701,negative,negative
16-00479,BA2765,2697,Female,Female,White,3,n,39,FALSE,FALSE,TRUE,None,FALSE,FALSE,y,Leiomyosarcoma,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,40,0,Residual Disease|Post-Chemotherapy|Post-Transplant,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)",5,Allogeneic - Sibling|Salvage|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,30,Standard Chemotherapy,Azacitidine,Salvage,4,Unknown,,FALSE,FALSE,,0,,,,,,,,,,,,,,,,,"46,XX,der(7)t(3;7)(q26;q21)[9]/46,XX[11]",,,,,"Increased atypical CD34 positive, CD7 positive myeloblasts",,,FALSE,FALSE,,negative,negative
15-00608,BA2229,2232,Female,Female,White,5,n,61,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,61,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Cyclophosphamide, Fludarabine, TBI|7+3 (Cytarabine, Idarubicin) plus Sorafenib",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Cyclophosphamide, Fludarabine, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1,Alive,Alive,TRUE,FALSE,15-00606,1,,40,28,,,,,,,,,,,,,,"46,XX,del(5)(q31q33),der(21)(qter->q22::p11.2->qter),del(21)(q22)[19]",,,"65% Loss 5q31; 14.5% Gain of 8 centromere, trisomy; Trisomy for 21q22  (40.5%), and trisomy for 8q22 and 21q22 (7.0%)",26,"positive CD13, CD34, dim CD45, CD117 and HLA-DR",,4.8,TRUE,FALSE,15-00606,negative,negative
13-00522,BA2681,1261,Female,Female,White,3,n,68,FALSE,FALSE,TRUE,None,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,y,y,MYELOPROLIFERATIVE NEOPLASMS,Secondary myelofibrosis,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,68,49,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Cyclophosphamide, Fludarabine, TBI|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine",3,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Dead,Dead-Other,FALSE,FALSE,,0,,29,40,,,,,,,,,,,,,,"46,XX,der(9)t(9;12)(p13;q13),del(11)(q21q25),der(12)add(12)(p11.2)add(12)(q13),del(13)(q14q22)[9]/46,idem,add(12)(q24.3),+13,-del(13)[9]/46,idem,add(17)(p13)[2]",,,,,,,11.36,FALSE,FALSE,,negative,negative
16-00820,BA2163,4032,Male,Male,White,1,n,67,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,67,0,Residual Disease,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Fludarabine, Melphalan|Azacitidine|Hydroxyurea|Idarubicin and Cytarabine",3,Allogeneic - Sibling|Induction|Re-induction,Refractory,Standard Chemotherapy,1932,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,0,2.6,42.5,54,0.9,0,44.2,2.7,0.9,0,21,15,2,2.62,,23.1,7.9,"45,XY,+5,dic(5;8)(q11.2;p12)x2,del(7)(q22q32),-18,del(20)(p11.2)[cp20]",,91.7,"5p/5q: 88/100 (88%) cells had one signal for EGR1 (5q31) and three signals for 5p, consistent with the metaphase karyotype; 5 cells (5%) had one EGR1 signal and four 5p signals, consistent with a previous sideline with three copies of the dicentric 5;8 chromosome.  ",22,Positive,5.3,1.27,FALSE,FALSE,,negative,negative
16-01191,BA2697,4256,Female,Female,White,3,n,65,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,65,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Vidaza|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)",3,Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,TRUE,FALSE,16-01190,0,,,,,,,,,,,,,,,,,"45,XX,-7[20]",,,"7cen (D7Z1), 7q31 (D7S486): monosomy present ",,,,,TRUE,FALSE,16-01190,negative,negative
16-00466,BA3067,2685,Male,Male,White,1,n,59,FALSE,FALSE,TRUE,None,FALSE,FALSE,y,Bladder Cancer,y,n,y,y,n,n,n,n,MYELODYSPLASTIC SYNDROMES,Primary myelofibrosis,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,59,6,Post-Transplant|Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Peripheral Blood,y,y,y,n,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),3,"Fludarabine, Melphalan|Azacitidine|Sorafenib",4,Induction|Allogeneic - Mismatched Unrelated Donor|Experimental|Re-induction,Refractory,Standard Chemotherapy,153,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,56,Dead,Dead-Disease,TRUE,FALSE,16-00467,0,0,30,25,0.9,0,23.2,11.6,36.6,0,39,22,2.7,,,27.3,8.6,"45,X,-Y,der(2)t(2;5)(q37;p13),-5,-18,add(19)(p13.3),+21,+21[cp13]/45,sl,-der(2)t(2;5)(q37;p13),add(2)(q11.2),add(12)(q15)[7]",,97.2,"EGR-1/ D5S23, D5S721/CEP 8: 64/100 cells (56%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q,",11,"CD13, dim CD33, CD43, CD117",6.8,4.54,TRUE,FALSE,16-00467,negative,negative
16-00533,BA3068,2685,Male,Male,White,1,n,59,FALSE,FALSE,TRUE,None,FALSE,FALSE,y,Bladder Cancer,y,n,y,y,n,n,n,n,MYELODYSPLASTIC SYNDROMES,Primary myelofibrosis,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,59,27,Post-Chemotherapy|Post-Transplant|Residual Disease,Peripheral Blood,y,y,y,n,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),3,"Fludarabine, Melphalan|Azacitidine|Sorafenib",4,Induction|Allogeneic - Mismatched Unrelated Donor|Experimental|Re-induction,Refractory,Standard Chemotherapy,153,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,56,Dead,Dead-Disease,TRUE,FALSE,16-00467,-21,0.9,70,50,0.9,0,22.8,2.6,36.8,0.2,16,43,2.5,1.62,,20.4,6.8,"45,X,-Y,der(2)t(2;5)(q37;p13),-5,-18,add(19)(p13.3),+21,+21[cp13]/45,sl,-der(2)t(2;5)(q37;p13),add(2)(q11.2),add(12)(q15)[7]",1805,91.5,"94/100 cells (94%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q, as previously observed. There was no evidence for the previous trisomy 8.",8,"CD13, dim CD33, partial CD34, dim CD117",7.4,8.35,TRUE,FALSE,16-00467,negative,negative
14-00670,BA2489,1787,Male,Male,Black,2,n,63,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,3,"AG-221|Azacitidine|Fludarabine, Melphalan, TBI, ATG",3,Hypomethylating/Low Dose Cytarabine|Experimental|Allogeneic - Child,,,,Bone Marrow Transplant,"Fludarabine, Melphalan, TBI, ATG",Allogeneic - Child,-1,Alive,Alive,FALSE,FALSE,,0,0,20,0,0,,76,0,24,,18,16,4.1,1.24,,24.9,8.3,"46,XY[20]",148,100.4,,72,,7.4,1.8,FALSE,FALSE,,negative,negative
14-00780,BA2592,1098,Female,Female,White,2,n,31,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,38,1496,Post-Chemotherapy|Post-Transplant|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,4,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),9,"Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide",7,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Experimental|Re-induction,Complete Response,Standard Chemotherapy,-1,Targeted Therapy - Kinase Inhibitor(s),Dasatinib,Experimental,24,Dead,Dead-Unknown,TRUE,TRUE,13-00294,-480,,7,1,,,,,,,15,21,4.2,,,31.9,11,"46,XX",,,nuc ish(DXZ1x2)[200],45,,6.2,2.2,FALSE,FALSE,,negative,negative
15-00539,BA2670,2196,Female,Female,White,2,n,72,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,73,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Other,4,"Lenalidomide|Azacitidine|Decitabine|Clofarabine, Cytarabine",2,Hypomethylating/Low Dose Cytarabine|Maintenance,,,,Other,"Clofarabine, Cytarabine",Hypomethylating/Low Dose Cytarabine,-1,Dead,Dead-Disease,FALSE,FALSE,,-79,0,,25,0,,2,54,18,,41,34,3.6,0.58,,27.5,8.8,"46,XX,+1,der(1;21)(q10;q10)[6]/46,XX[14]",,,"nuc ish(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200]",,,6.2,58.2,FALSE,FALSE,,negative,negative
15-00231,BA2657,1727,Male,Male,HispNative,1,n,45,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,46,196,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Supportive/Palliative Care,5,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",4,Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) ",Salvage,4,Dead,Dead-Disease,TRUE,TRUE,14-00803,-86,0,,,0,1.7,7.8,51.3,18.3,0,29,19,3,0.52,,20.6,7,"47,XY,der(7)t(1;7)(q10;p10)+8[20]",,87.3,,5,,5.8,11.13,FALSE,FALSE,,negative,negative
16-00724,BA2261,3986,Female,Female,White,2,n,62,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"Vidaza|7+3 (Cytarabine, Idarubicin)|Lenalidomide|Hydroxyurea",3,Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,7,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0.8,34,3.3,1.6,,14.9,5,68.6,,13,11,2.6,0.5,,32.4,10.7,"46~47,XX,del(5)(q15q35),i(8)(q10),add(11)(q23),add(17)(p11.2),add(21)(q22),+2~3mar[cp3]/47~49,idem,add(7)(q11.2),-add(11),+11,+14,-20[cp4]/45~49,idem,del(7)(q22q36),-add(11),+11,+14,-20[cp2]/45~48,idem,der(7)del(7)(q22q31)dic(7;20)(q36;q11.2),-add(11),+11,+14[",304,,"nuc ish(D5S2064x2,D5S630x2,EGR1x1)[184/200],(D7Z1x2,D7S522x1)[115/200],(D8Z2x2,D20S108x1)[142/200],(RUNX1T1x3,RUNX1x2)[180/200],(5'MLL amp,3'MLL amp)(5'MLL con 3'MLL amp)[66/200],(PML,RARA)x2[197],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",36,"CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+),CD56(+), CD64(-), CD117(partial +), HLA-DR(partial +).",5.3,8.35,FALSE,FALSE,,negative,negative
16-00226,BA2363,2503,Male,Male,White,1,n,79,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,79,35,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other,4,Azacitidine|Decitabine|Hydroxyurea|V212,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,,,,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1,Alive,Alive,TRUE,FALSE,16-00092,-35,1.7,,35,0,0,0.9,64.4,8.7,0.2,9,22,3.1,2.11,,25.5,7.8,"46,XY[22]",722,95.5,Normal,438,"CD13, dim CD33, bright CD34, CD38, CD117, dim HLA-DR positive",5.8,116.52,FALSE,FALSE,,negative,negative
13-00515,BA2100,1257,Male,Male,White,2,n,73,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),7,"Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)",6,Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,39,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,33,Dead,Dead-Unknown,FALSE,FALSE,,0,1,32,67,2,,8,3,14,,15,30,4.1,,,32.8,11,"46,XY,+1,dic(1;15)(q12;p11.2)[2]/46,XY[18]",,,"18].nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",90,"CD4(partial dim +), CD7(-), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variably +), CD34(+), CD36(-), CD38(variably +), CD45 (variably +), CD56(-), CD64(-), CD79a(-)",5.8,24.2,FALSE,FALSE,,positive,negative
13-00593,BA2953,1257,Male,Male,White,2,n,73,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74,37,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),7,"Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)",6,Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,39,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,33,Dead,Dead-Unknown,FALSE,FALSE,,0,6,66,40,2,,19,20,8,,22,36,4.3,,,34.7,11.6,"46,XY",,,"nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]",67,"CD2(-), CD4(-), CD7(-), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variable and bright +), CD34(variably +)",6.2,13.9,FALSE,FALSE,,positive,negative
12-00066,BA2496,559,Male,Male,White,1,n,70,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,y,y,n,n,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,70,34,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"Dasatinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine",4,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,153,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,4,Dead,Dead-Disease,TRUE,FALSE,12-00032,0,5,36,9,5,,21,38,22,,19,22,3.6,1.18,M4,28.7,9.7,"46,XY[20]",231,99.6,Normal,47,"CD11b, CD13, CD14, CD15, variable CD16, dim CD33, CD58, bright CD64, HLA-DR positive",7.1,21,TRUE,FALSE,12-00262,positive,negative
16-00392,BA2840,2664,Female,Female,White,1,n,78,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,78,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3,Ruxolitinib|Hydroxyurea|Decitabine,2,Consolidation|Experimental,,,,Targeted Therapy - Kinase Inhibitor(s),Ruxolitinib,Experimental,7,Dead,Dead-Unknown,FALSE,FALSE,,-1,0,,,0,1.6,43.7,9.4,29.7,5.5,27,39,2,0.41,M7,26.2,8.2,"46,XX,t(7;13)(q22;q12),del(20)(q11.2)[1]/46,sl,dup(1)(p25),del(2)(q21q23),add(8)(q13q22)[3]/46,sdl,add(5)(p15)[8]/46,sdl,add(12)(p13)[3]/46,sdl,add(12)(p13),add(13)(p12)[4]/46,XX[1]",1024,89.4,RUNX1T1 (8q21.3): 35% of cells had three signals for RUNX1T1 on 8q. No evidence for t(8;21).,17,,5.5,6.28,FALSE,FALSE,,negative,negative
15-00312,BA2292,1967,Male,Male,White,5,n,69,FALSE,FALSE,TRUE,None,FALSE,FALSE,y,Squamous cell carcinoma,y,y,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,70,55,Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Other,3,"7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Rituximab",2,Induction|Experimental,Unknown,Standard Chemotherapy,-1,Targeted Therapy - Other,Rituximab,Experimental,-1,Unknown,,TRUE,FALSE,15-00082,-54,,,,,,,,,,,,,,,,,"46,XY[18]",,,Normal,,,,,FALSE,FALSE,,positive,negative
15-00534,BA2804,2195,Male,Male,White,5,n,87,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,87,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,2,AG-120|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Experimental,,,,Targeted Therapy - Other,AG-120,Experimental,-1,Dead,Dead-Disease,FALSE,FALSE,,1,,60,39,,,,2,,,,,,,,,,"47,XY,+21[3]/46,XY[9]",,,9.5% gain 21q22,43,"A distinct blastic population, expressing CD7, CD13, CD15, CD33, CD34, CD38, dim CD45, CD64, MPO, and HLA-DR",,139.9,FALSE,FALSE,,negative,negative
15-00976,BA2618,2453,Male,Male,White,1,n,83,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,83,0,Residual Relapse|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,2,"AG-221|Azacitidine, SGN-CD33A",2,Induction|Experimental,Refractory,Standard Chemotherapy,-1,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0.3,12,3,0,9.4,26.9,24.5,38.9,0,42,47,3.2,1.3,,21.1,6.8,"46,XY[20]",,87.9,Normal,213,"CD13, CD33, CD34, CD38, dim CD58, CD117, and dim HLA-DR positive",6,3.72,FALSE,FALSE,,negative,negative
15-00626,BA2905,2239,Male,Male,White,5,n,77,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,77,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Other,3,AG-221|Azacitidine|Decitabine,3,Hypomethylating/Low Dose Cytarabine|Induction|Experimental,Refractory,Standard Chemotherapy,212,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,Dead-Disease,FALSE,FALSE,,0,,70,72,,,,,,,,,,,,,,"47,XY,+11[8]/46,XY[12]",,,35% gain of 11q23,174,"CD34, CD117, HLA-DR, CD13, and CD33. A subset of the myeloblasts showed aberrant co-expression of CD34 and myeloperoxidase.  A subset of the myeloblasts showed aberrant expression of CD56.",,33.1,FALSE,FALSE,,negative,negative
15-00057,BA2694,1933,Male,Male,White,5,n,76,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,76,0,Residual Disease,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,2,AG-221|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Experimental,,,,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,Dead-Disease,TRUE,TRUE,15-00056,0,,70,55,,,,,,,,,,,,,,"46,XY[20]",,,Normal,46,"positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers",,4.5,TRUE,TRUE,15-00056,negative,negative
12-00258,BA2923,799,Female,Female,White,1,n,81,FALSE,FALSE,TRUE,None,FALSE,FALSE,y,Anal carcinoma|Breast Cancer|Breast Cancer,y,y,n,n,y,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,81,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,n,y,y,n,y,1,Supportive/Palliative Care,1,Azacitidine,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Azacitidine,Supportive/Palliative Care,42,Dead,Dead-Disease,FALSE,FALSE,,-112,0,,,0,,12,33,7,,60,64,3.2,1.08,M5,26.6,8.8,"46,XX,t(8;16)(p11.2;p13.3)[8]/46,XX,del(7)(q11.2q22),del(20)(q13.1q13.3)[cp3]/46,XX[12]",2700,92.4,,46,,6.3,37.1,FALSE,FALSE,,negative,negative
16-00109,BA2744,2511,Male,Male,White,1,n,76,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,n,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,76,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,y,y,y,y,y,1,Supportive/Palliative Care,1,Hydroxyurea,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,7,Dead,Dead-Unknown,FALSE,FALSE,,-1,0,96,93.3,0,0.7,4.7,0,1.3,0.6,23,43,2.3,0.46,,31,10.4,"46,XY[20]",839,93.9,Normal,17,"CD13, CD33, CD38, variable CD56, CD58, CD117 and MPO positive",5.1,230.05,FALSE,FALSE,,positive,positive
16-01225,BA2776,4274,Female,Female,White,1,n,61,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,n,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Supportive/Palliative Care,1,Hydroxyurea,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1,Dead,Dead-Disease,FALSE,FALSE,,-2,,,,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,,,,FALSE,FALSE,,positive,positive
15-00383,BA2970,2127,Male,Male,Black,2,n,63,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,n,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,63,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Supportive/Palliative Care,2,Ruxolitinib|Hydroxyurea,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,103,Dead,Dead-Disease,FALSE,FALSE,,0,1,9,15.4,2.9,,20.2,16.3,42.3,,,,,0.6,,22.7,7,"46,XY[20]",1086,,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",126,"CD34(+), CD7(partial +), CD13(+), CD33(+), CD38(partial +), CD45(moderately +), CD56 (+), CD117(+), HLA-DR(variably +), other myeloid and lymphoid antigens(-).",,73.4,FALSE,FALSE,,positive,positive
16-00766,BA2715,4006,Male,Male,White,2,n,81,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,n,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,81,0,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,1,Supportive/Palliative Care,2,Vidaza|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,,,,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,3,Dead,Dead-Disease,FALSE,FALSE,,-32,,33,8,4,,28,24,44,,22,20,4.1,1.07,,27.5,9.5,"45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]",333,,"nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5CBFB con 3CBFB dimx1,5CBFB con 3CBFBx1)[200]",28,"CD4(+), CD5(partial +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(predominantly -), CD16(-), CD33(+), CD34(+), CD36(-),CD38(variably +), CD45(variably +), CD56(predominantly -), CD64(partial +), CD117(+), HLA-DR(predominantly + and variable),MPO(-), TdT(-).",6.6,2.2,FALSE,FALSE,,negative,negative
16-00882,BA2116,4006,Male,Male,White,2,n,81,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,n,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,81,41,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Supportive/Palliative Care,2,Vidaza|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,,,,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,3,Dead,Dead-Disease,TRUE,TRUE,16-00766,-73,0,,70,0,,3,1,36,,25,33,4.1,1.26,,24.1,8.1,"45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]",853,98,"nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5CBFB con 3CBFB dimx1,5CBFB con 3CBFBx1)[200]",74,negative,,39.12,FALSE,FALSE,,negative,negative
15-00075,BA2583,1964,Male,Male,White,5,n,80,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,n,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,80,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Targeted Therapy - Other,1,AG-221,1,Experimental,,,,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,Dead-Disease,FALSE,FALSE,,1,,90,48,,,,,,,,,,,,,,"46,XY,del(20)(q11.2q13.1)[12]/45,sl,-7[3]/45,XY,-7[5]/46,XY[2]",,,Tetrasomy 5p/q; Monosomy 7; Loss 20q12 (15.5%); Tetrasomy 8cen and 20q12 (7,65,"positive for CD13, dim CD33, CD34, CD38, dim CD45, CD117, HLA-DR and TdT",,6.6,FALSE,FALSE,,negative,negative
16-00307,BA2798,2612,Male,Male,White,6,n,71,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,n,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,0,,0,,0,,,,,NONE,NONE,NONE,,Alive,Alive,TRUE,FALSE,16-00306,0,,75,26,2,,15,8,43,,118,53,3.8,1.26,,22.9,7.7,"46,XY,del(7)(q32),add(13)(p11.2)[15]",,81.8,"This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies.",24,"These are positive for CD34, CD117, HLADR, CD33 and CD13",8.7,5,FALSE,FALSE,,negative,negative
16-00483,BA2883,2612,Male,Male,White,6,n,71,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,n,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71,57,Post-Chemotherapy|Residual Disease,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Alive,Alive,FALSE,FALSE,,0,,33,,,,,8,,,,,,,,,,"46,XY,del(7)(q32),add(13)(p11.2)[20]",,,"Not Available. Pathogenic alterations are DETECTED in the ASXL1, IDH1, JAK2 and RUNX1 genes. Genomic alterations of uncertain significance are DETECTED in the CEBPA and TET2 genes (not seeing specific mutations or MAF)",22,"They are positive for CD34, HLADR, CD117, CD13 and MPO and negative for TDT.",,,FALSE,FALSE,,negative,negative
13-00186,BA2667,1072,Male,Male,White,1,n,74,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,n,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,Dead-Unknown,FALSE,FALSE,,0,0,60,29,1,,26,18,24,,250,160,3.2,0.59,,22,7.1,"46,XY[20]",399,87.4,,107,"partial CD7, CD13, CD33, CD34, CD38, CD58, CD117, CD123, TdT, and HLA-DR positive",7,11.8,FALSE,FALSE,,negative,negative
15-00417,BA2839,2135,Male,Male,White,2,n,44,FALSE,FALSE,TRUE,None,FALSE,FALSE,n,,n,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,44,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,FALSE,FALSE,,0,0,62,19,1,,18,35,25,,24,90,1.8,0.73,,22.4,7.2,"47,XY,+21[19]/46,XY[1]",,,"nuc ish(RUNX1T1x2,RUNX1x3)[140/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",18,"CD2(-), CD7(dim + to -), CD11b(-), CD13(+), CD14(-), CD15 (partial +), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(variably +)",7.1,8,FALSE,FALSE,,positive,negative
13-00544,BA2832,1285,Male,Male,White,2,n,68,FALSE,FALSE,TRUE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",68,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,5,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,5,Dead,Dead-Disease,FALSE,FALSE,,0,,,41,,,,,,,,,,,,,,,,,,,,,9.5,FALSE,FALSE,,negative,negative
14-00514,BA2499,1696,Male,Male,White,2,n,71,FALSE,FALSE,TRUE,Unknown,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,71,0,Post-Chemotherapy|Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,107,Dead,Dead-Disease,FALSE,FALSE,,0,0,,50,1,,17,1,13,,19,42,3.2,1.83,,23.7,7.7,,766,92.2,,11,,7.1,45.6,FALSE,FALSE,,negative,negative
13-00250,BA2429,1111,Male,Male,White,1,n,78,FALSE,FALSE,TRUE,Unknown,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,78,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,2,Azacitidine|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Induction,Unknown,Standard Chemotherapy,-1,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Dead,Dead-Disease,FALSE,FALSE,,0,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,negative,negative
16-00356,BA2903,2633,Male,Male,HispNative,6,n,59,FALSE,FALSE,TRUE,Unknown,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,59,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"Lenalidomide|3+7 (Cytarabine, Daunorubicin)",2,Unknown|Supportive/Palliative Care,,,,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Unknown,-1,Dead,Dead-Unknown,FALSE,FALSE,,0,,,1,9,,1,6,58,,135,44,3.2,0.79,,21.6,7.3,,,85,,22,,5.9,9.1,FALSE,FALSE,,negative,negative
16-00139,BA2133,2530,Female,Female,White,6,n,73,FALSE,FALSE,TRUE,Unknown,FALSE,FALSE,y,Breast Cancer,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,73,0,Post-Chemotherapy,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Ruxolitinib,1,Induction,Unknown,Standard Chemotherapy,28,Standard Chemotherapy,Ruxolitinib,Induction,28,Dead,Dead-Unknown,FALSE,FALSE,,0,,,,0.5,,39.2,7.5,52.5,,10,21,4.5,0.87,,34.1,10.9,,,92.4,,6,,7.6,3.8,FALSE,FALSE,,negative,positive
14-00026,BA2169,1410,Male,Male,HispNative,2,n,38,FALSE,FALSE,TRUE,Unknown,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Intermediate,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,39,0,Post-Chemotherapy|Residual Disease,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Supportive/Palliative Care,4,"7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)",4,Salvage|Unknown|Induction|Maintenance,Refractory,Standard Chemotherapy,5,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Unknown,6,Unknown,,FALSE,FALSE,,0,,,16,,,20,10,54,,152,49,4.3,0.77,,30.5,10.6,,340,,,215,,7,4.01,FALSE,FALSE,,negative,negative
13-00338,BA2427,1157,Female,Female,White,4,n,53,TRUE,FALSE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,60,0,Post-Chemotherapy|Relapse,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,5,"7+3 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Azacitidine, Gemtuzumab|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Cytarabine",2,Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"Azacitidine, Gemtuzumab",Re-induction,-1,Alive,Alive,TRUE,FALSE,13-00337,0,,82,25,,,,19,,,,,,,M4eo,,,"47,XX,t(16;16)(p13;q22),+22[20]",,,Positive,,,,4.3,TRUE,FALSE,13-00337,negative,negative
14-00528,BA2463,1533,Female,Female,White,2,n,57,TRUE,FALSE,FALSE,Complex,FALSE,FALSE,y,Ovarian cancer|Ovarian cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,58,111,Post-Chemotherapy|Relapse,Peripheral Blood,y,n,y,y,n,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea",4,Consolidation|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,5,Supportive/Palliative Care,"Decitabine, Hydroxyurea",Supportive/Palliative Care,-1,Dead,Dead-Unknown,TRUE,TRUE,14-00231,-111,0,,58,0,,14,3,19,,24,116,3.7,,,21.4,7.7,"46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",10,"CD2(-), CD4(+), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +),CD15(variably +), CD16(-), CD33(variably +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56 (variable +), CD64(partial +), CD117(-), HLA-DR(+).",6,11.2,FALSE,FALSE,,negative,negative
12-00426,BA2922,50,Male,Male,White,1,n,11,TRUE,FALSE,FALSE,DEK-NUP214,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,14,950,Relapse|Post-Transplant|Post-Chemotherapy,Bone Marrow Aspirate,y,n,y,y,n,y,5,DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)|Intrathecal,13,"Cyclophosphamide, TBI|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Cytarabine, Mitoxantrone, Sorafenib|ADE (Cytarabine, Daunorubicin & Etoposide)|Donor Lymphocyte Infusion|Cytarabine|Sorafenib|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)|Methotrexate|Etoposide, Cytarabine",8,Allogeneic - Sibling|Consolidation|Unknown|Induction|Experimental|Intensification|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,9,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,187,Dead,Dead-Disease,TRUE,FALSE,12-00403,0,0,80,0,3,,78,3,16,,42,38,4.3,0.66,M2,41.6,14.3,"48,X,-Y,+4,t(6;9)(p22;q34),+8,+10,del(15)(q11.2q15)[20]",,102.9,"DEK/NUP probe set; 70/100 (70%) interphasecells scored had a 1 red/ 1 green/ 2 yellow fusion signal pattern,consistent with DEK/NUP fusion and the 6;9 translocation observed in themetaphase karyotype.",50,"CD13, CD33, CD34, CD38, CD117,  CD123, dim HLA-DR, partial MPO",7.6,2.2,FALSE,FALSE,,positive,
14-00015,BA2025,1161,Female,Female,Asian,1,n,30,TRUE,FALSE,FALSE,MLLT3-KMT2A,FALSE,FALSE,y,Not specified,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,31,147,Relapse|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,6,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,31,Dead,Dead-Disease,FALSE,FALSE,,0,0,75,35,0,,9.9,9.9,37.2,0.8,37,39,3.1,0.56,,22.1,7.7,"46,XX,t(9;11)(p22;q23)[20]/46,XX[1]",,89.8,MLL disruption and t(9;11),39,"dim/partial CD13, CD33, CD38, CD56, CD58, CD64, partialCD117, CD123 and HLA-DR positive",6,43.72,FALSE,FALSE,,negative,negative
13-00342,BA2841,1159,Male,Male,Asian,4,y,31,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,32,0,Relapse|Post-Chemotherapy,Bone Marrow Aspirate,y,y,n,y,y,n,4,DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,7,"7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Fludarabine, Cyclophosphamide, TBI ",6,Allogeneic - Sibling|Consolidation|Salvage|Unknown|Induction|Re-induction,Complete Response,Standard Chemotherapy,8,Supportive/Palliative Care,Decitabine,Salvage,-1,Alive,Alive,FALSE,FALSE,,0,,28,23,,,,6,,,,,,,,,,"46,XY[20]",,,,,"CD34, CD117, CD38, MPO, CD11c (dim),CD13, CD33, CD15, and HLA-DR,CD7 and CD56 (partial)",,4,FALSE,FALSE,,negative,negative
15-00482,BA2065,1532,Female,Female,White,1,n,46,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47,424,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,Azacitidine,Consolidation,339,Alive,Alive,FALSE,FALSE,,0,0,70,64.6,3.5,0.9,17.7,0,13.3,0,184,77,2.8,0.72,,37,12.6,"46,XX[20]",,94.4,Normal,138,"CD13, CD33, partial CD34, partial CD38, dim partial  CD64, CD117 and CD123 positive",5.7,16.95,FALSE,FALSE,,negative,positive
13-00118,BA2236,685,Male,Male,White,1,n,54,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,57,349,Relapse|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,7,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",5,Consolidation|Salvage|Induction|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,Decitabine,Re-induction,160,Dead,Dead-Disease,TRUE,FALSE,12-00109,-349,3,71,83,2,,5,10,4,,35,31,3.9,0.81,M4,33.7,11.7,"47,XY,+21[15]/46,XY[5]",438,100.6,Trisomy 21,119,"CD13, CD33, CD38, CD58, dim CD64, CD117, and CD123",7.1,33.8,FALSE,FALSE,,negative,positive
16-01094,BA2879,2254,Female,Female,White,2,n,52,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",53,462,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,-1,Dead,Dead-Disease,TRUE,TRUE,15-00653,-463,,76,1,,,,,,,,,,,,,,"46,XX[20]",,,"nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,,,,FALSE,FALSE,,negative,negative
14-00061,BA2707,202,Male,Male,White,1,n,68,TRUE,FALSE,FALSE,None,FALSE,FALSE,y,Lung Cancer|Lung Cancer|Lung Cancer|Lung Cancer|Lung Cancer|Lung Cancer,y,y,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,72,1207,Relapse,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|MiDAC|Decitabine",3,Consolidation|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,9,Dead,Dead-Disease,FALSE,FALSE,,-2,0,,,0,,14.9,0.8,2.5,0,,,,,,22.7,7.6,"47,XY,del(9)(q22),+13[18]/48,idem,+mar[2]",556,93.8,Missing ABL and ASS signal,32,,,47.2,FALSE,FALSE,,negative,negative
15-00755,BA2200,2304,Male,Male,White,3,n,59,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59,0,Relapse|Post-Chemotherapy,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Azacitidine, Sorafenib|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Azacitidine, Sorafenib",Re-induction,-1,Dead,Dead-Treatment,FALSE,FALSE,,-1,,93.2,47.5,,,,,,,,,,,,,,"46,XY,t(3;4)(p21;q25)[3]/46,XY[17]",,,,,"CD4, CD7, CD11b, CD13,  CD33, partial CD34, CD117, HLA-DR, partial weak TdT and  partial CD64",,42.91,FALSE,FALSE,,positive,positive
16-01097,BA2577,2116,Female,Female,White,1,n,10,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,12,568,Post-Chemotherapy|Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,33,Standard Chemotherapy,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Re-induction,-1,Alive,Alive,FALSE,FALSE,,0,0,46,,0,0,81.3,8.3,10.4,18.1,31,27,3.8,0.53,,30.5,10.2,"47,XX,+10[19]/46,XX[1]",,96.8,Normal,11,"variable CD7, dim CD13, CD33, CD34 bright CD38,CD56, CD58, CD117, HLA-DR positive",7,1.93,FALSE,FALSE,,negative,negative
16-00548,BA2758,2119,Male,Male,White,1,n,76,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,77,417,Post-Chemotherapy|Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor),2,Consolidation|Induction,Complete Response,Standard Chemotherapy,35,Standard Chemotherapy,Incyte trial (azacitidine and JAK 1 inhibitor),Induction,77,Dead,Dead-Unknown,TRUE,FALSE,16-00557,6,0,,,0.9,,60.3,38.5,0.3,,19,19,3.2,1,,24.2,8.6,"47,XY,+8[cp14]/47,sl,der(21)t(1;21)(q11;p11.1)[2]/46~47,sl,der(22)t(1;22)(q11;p11.2)[cp2]/46,XY[1]",261,102.5,"Eighteen of twenty-one cells examined were trisomy 8, previously observed.Two of these cells also had an extra 1q attached to a chromosome 21 short arm, and two other cells had an extra 1q attached to a chromosome 22 short arm. These are new clonal changes. One cell appeared normal male.",7,,7.2,3.4,FALSE,FALSE,,negative,negative
16-01138,BA2470,2315,Male,Male,White,1,n,62,TRUE,FALSE,TRUE,None,FALSE,FALSE,n,,y,n,y,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,412,Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,Decitabine|Hydroxyurea,2,Induction|Re-induction,Complete Response i,Standard Chemotherapy,-1,Standard Chemotherapy,Hydroxyurea,Re-induction,-1,Dead,Dead-Disease,TRUE,TRUE,15-00778,-412,0.9,,,0,0,7.8,1.7,4.3,0.1,18,21,2.8,1.43,,25,8.2,"46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]",564,102.5,EGR1 (73.5%) ;  TP53: (85.5%),139,,6.6,46.79,FALSE,FALSE,,negative,negative
16-00705,BA2209,3978,Male,Male,White,5,n,59,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64,0,Relapse,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, TBI ",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Double Umbilical Cord Blood Transplant (DUCBT),-1,Dead,Dead-Disease,FALSE,FALSE,,0,0,59.5,12,0,,55,3,29,,37,22,4.1,,,25.2,8.3,"47,XY,+13[2]/94,slx2[2]/46,XY[19]",,,"5p15.2/5q31(EGR1), 7 centromere/7q31, 8 centromere/20q12, 12 centromere/13q14 D13S319/13q34 (13qter)",46,Negative,6.4,,FALSE,FALSE,,negative,negative
13-00331,BA2106,1153,Female,Female,White,4,n,35,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,37,1,Post-Chemotherapy|Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI",5,Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Re-induction,53,Dead,Dead-Treatment,FALSE,FALSE,,0,,92,97,,,,,,,,,,,M5,,,"46,XX[5]",,,,,"CD45, DIM CD64, DIM CD13, DIM CD33, CD15, CD38, MPO, CD11C, DIM CD4, DIM PARTIAL CD19, CD117, AND HLA-DR",,140,FALSE,FALSE,,negative,positive
16-01118,BA3075,2611,Female,Male,HispNative,5,n,56,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,56,224,Post-Transplant|Relapse,Bone Marrow Aspirate,y,y,y,n,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI",4,Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,27,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Salvage,-1,Dead,Dead-Disease,TRUE,TRUE,16-00303,-224,,90,,,,,,,,,,,,,,,"46,XX[19]",,,Normal,,,,,FALSE,FALSE,,positive,positive
14-00045,BA2168,1435,Female,Female,HispNative,2,n,47,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,48,0,Post-Chemotherapy|Post-Transplant|Relapse,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide",4,Allogeneic - Sibling|Consolidation|Salvage|Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,-1,Dead,Dead-Unknown,FALSE,FALSE,,0,0,62,66,0,,7,0,13,,24,40,3.4,,,35.5,12.1,"46,XX",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",29,"CD2(-), CD4(partial +), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(variably +), CD56(partial +), CD64(-), CD117(partial +), HLA-DR(partial dim +)",5.8,58.5,FALSE,FALSE,,positive,negative
16-00765,BA3076,2704,Female,Male,White,1,n,29,TRUE,FALSE,FALSE,None,FALSE,FALSE,y,Basal Cell Carcinoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,29,82,Post-Transplant|Post-Chemotherapy|Relapse,Peripheral Blood,y,y,y,n,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,5,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib",3,Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,5,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,2,Dead,Dead-Disease,TRUE,TRUE,16-00491,-83,,,,,,,,,,,,,,,,,"47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]",,,Normal,,,,,TRUE,TRUE,16-00491,negative,positive
15-00692,BA2155,2277,Female,Female,White,2,n,72,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,73,0,Post-Chemotherapy|Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1,Supportive/Palliative Care,Azacitidine,Hypomethylating/Low Dose Cytarabine,112,Dead,Dead-Disease,TRUE,FALSE,15-00690,0,0,81,43,0,,51,3,2,,11,16,4.5,0.99,M0,28.2,9.6,"46,XX,der(3)t(3;17)(q29;q21)[19]/46,XX,t(3;21)(q26.2;q22)[2]",,,"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1, D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",10,"CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD19 (-/few dim +), CD25(-), CD33(partial +), CD34(partial +), CD36(-), CD38(bright and variably +), CD45(+), CD56(variably +), CD64(-), CD117(variably +), CD123(-/few +), MPO(+), TdT(-/few dim +)",6.9,35,FALSE,FALSE,,negative,negative
12-00372,BA2480,555,Male,Male,Asian,1,n,56,TRUE,FALSE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60,309,Relapse|Post-Chemotherapy,Peripheral Blood,y,n,y,y,n,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),8,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Sorafenib|Clofarabine|Clofarabine, Cytarabine",5,Consolidation|Salvage|Induction|Experimental|Re-induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,Cytarabine,Consolidation,64,Dead,Dead-Disease,TRUE,TRUE,12-00371;12-00224,-121,0,77.5,75,1,,16,1,4,,,,,,NOS,26.3,9.3,"46,XY[4]",,87.8,Normal,9,"CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive",,7.9,FALSE,FALSE,,positive,positive
16-01227,BA2218,4275,Female,Female,HispNative,6,n,39,TRUE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,40,0,Post-Chemotherapy|Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,39,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,Alive,FALSE,FALSE,,0,,,91,,,9,,,,21,34,3.8,0.49,,29.3,9.9,,,93.6,,66,,5.8,73,FALSE,FALSE,,negative,positive
16-00846,BA2723,4043,Male,Male,White,6,n,25,TRUE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",26,0,Post-Chemotherapy|Relapse,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,3,"Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Unknown|Induction,Complete Response,Standard Chemotherapy,79,Standard Chemotherapy,Bu/Cy/ATG,Unknown,22,Alive,Alive,FALSE,FALSE,,0,,,14,8,,17,2,54,,39,49,3.2,0.79,,19.3,6.5,,,101,,33,,4.9,1.6,FALSE,FALSE,,negative,negative
16-01047,BA2552,4205,Female,Female,White,6,n,67,TRUE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,69,0,Post-Chemotherapy|Relapse,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,2,Cytarabine|Idarubicin and Cytarabine,2,Consolidation|Induction,Complete Response,Standard Chemotherapy,9,Standard Chemotherapy,Cytarabine,Consolidation,40,Alive,Alive,FALSE,FALSE,,0,,,94,0,,3,0,1,,18,52,3.2,1.03,,24.6,8.6,,,93.5,,28,,5.7,108.9,FALSE,FALSE,,positive,positive
15-00764,BA3064,2308,Male,Male,White,3,n,38,TRUE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,40,0,Relapse|Post-Chemotherapy|Post-Transplant,Peripheral Blood,y,y,y,n,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6,"Azacitidine, Sorafenib|Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Sorafenib|Cladribine, Cytarabine, Idarubicin",7,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Experimental|Intensification|Re-induction,Refractory,Standard Chemotherapy,-1,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,38,Dead,Dead-Disease,FALSE,FALSE,,0,,71,46,,,,,,,,,,,,,,,,,Normal,,"CD4,  CD11b, dim CD13, variable CD15, CD33, partial CD34  (approximately 25%), variable CD64 (dim to bright), CD117,  HLA-DR, and myeloperoxidase",,34,FALSE,FALSE,,positive,negative
13-00450,BA2910,1224,Female,Female,White,2,n,79,TRUE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,79,0,Post-Chemotherapy|Relapse,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,"7+3 (Cytarabine, Idarubicin)|Crenolanib",2,Induction|Experimental,Complete Response,Standard Chemotherapy,4,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,14,Dead,Dead-Disease,FALSE,FALSE,,0,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,positive,positive
16-01270,BA2830,4317,Female,Female,White,1,n,72,TRUE,FALSE,FALSE,Unknown,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,74,0,Relapse,Peripheral Blood,y,y,y,y,y,y,1,Targeted Therapy - Kinase Inhibitor(s),1,Dasatinib,1,Experimental,,,,Targeted Therapy - Kinase Inhibitor(s),Dasatinib,Experimental,16,Unknown,,FALSE,FALSE,,0,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,negative,negative
14-00193,BA2956,1519,Male,Male,White,2,n,56,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,57,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,3,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,3,Dead,Dead-Disease,FALSE,FALSE,,0,0,,54,0,,38,8,0,,15,23,3,1.3,,,,"46,XY,del(5)(q15q35),inv(16)(p13.1q22)[20]",409,,"nuc ish(D5S721x2,D5S23x2,EGR1x1)[182/200],(D7Z1,D7S522)x2[199], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[192],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB sep 3'CBFBx1)[176/200]",,,6.6,8.2,FALSE,FALSE,,negative,negative
14-00798,BA2575,1852,Female,Female,White,1,n,36,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,36,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,6,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6,Dead,Dead-Other,FALSE,FALSE,,0,0,74,82,1.7,1.7,6.7,82.3,3.4,0,45,36,2.7,0.68,M4,20.4,7.1,"46,XX,inv(16)(p13.1q22)[20]",,87.6,"CBFB; 76/100 cells (76%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement. ",12,,5.8,117.53,FALSE,FALSE,,negative,negative
15-00850,BA2426,2357,Male,Male,White,5,n,62,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,62,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,-1,Unknown,,FALSE,FALSE,,1,,50,20,,,,,,,,,,,,,,"46,XY,inv(16)(p13.1q22)[20]",,,positive for rearrangement of CBFB in 60.5% of cells.,32,"positive for CD13, CD33, HLA-DR, CD34, and CD117, with partial aberrant expression of CD7.",,52.8,FALSE,FALSE,,negative,negative
16-01082,BA2101,4226,Male,Male,White,1,n,68,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,68,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,-1,Unknown,,FALSE,FALSE,,0,0,,10,0.9,0,81.8,4.6,10.9,0,27,26,4.1,1,,33.6,11.9,"46,XY,del(7)(q22),inv(16)(p13.1q22)[18]/46,XY[2]",330,106.7,"CBFB, D7S486/ CEP 7",106,"CD5, CD19, dim CD20, dim CD22, CD23 and light chain negative",6.9,2.16,FALSE,FALSE,,negative,negative
15-00303,BA2828,2069,Male,Male,White,1,n,64,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,64,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",2,Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Re-induction,5,Alive,Alive,FALSE,FALSE,,-8,0,,,0,0.9,48.7,30.1,5.3,0,10,7,2.6,1.33,,23.2,7.7,"46,XY,inv(16)(p13q22)[17]/46,XY[3]",,87.2,c/w karyotype,53,,5.9,8.69,FALSE,FALSE,,negative,negative
13-00487,BA2072,1243,Female,Female,White,1,n,35,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,35,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,HiDAC,Consolidation,94,Alive,Alive,FALSE,FALSE,,0,0,49.4,28.6,1.8,,19.6,37.5,7.1,0,20,17,3.1,0.88,M4,14.3,4.8,"46,XX,t(16;16)(p13.1;q22)[16]/47,idem,+22[4]",505,100.7,Trisomy 22,36,"Myeloid blasts (21%): CD13, CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive. Promonocytic/monocytic cells (55%): CD11b, CD13, CD14, CD33, dim/partial CD34, CD38, CD58, CD64, variable CD123, HLA-DR, and MPO-positive.",7.8,49.4,FALSE,FALSE,,negative,negative
13-00496,BA2733,1247,Female,Female,White,2,n,33,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,33,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,103,Alive,Alive,TRUE,TRUE,13-00497,0,0,72,18,0,,38,26,3,,85,30,3.4,,,25.9,9,"47,XX,inv(16)(p13.1q22),+22",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x3, D20S108x2)[7/200],(RUNX1T1,RUNX1)x2[197],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198], (CBFBx2)(5CBFB sep 3CBFBx1)[140/200]",18,"CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(variably +), CD16(-), CD33(+), CD34(variably +), CD36(-), CD38(+), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(+)",6.1,26.3,TRUE,TRUE,13-00497,negative,negative
15-00702,BA2322,2281,Female,Female,White,1,n,35,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,35,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,10,Standard Chemotherapy,HiDAC,Consolidation,112,Alive,Alive,FALSE,FALSE,,0,1.7,42,29.6,0.9,0,40,18.3,7.8,0.2,54,23,3.5,0.6,,20.3,6.8,"46,XX,inv(16)(p13.3q22)[21]",319,102.5,"CBFB: 83/100 cells (83%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting CBFB rearrangement and consistent with the inverted  chromosome 16 in the metaphase karyotype.",63,"Partial CD2, CD33, CD34, CD38, CD117, CD123, partial HLA-DR, dim MPO and partial TdT positive.",6.7,12.78,FALSE,FALSE,,negative,negative
16-01109,BA2507,4235,Male,Male,Black,5,n,33,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,33,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,Alive,TRUE,FALSE,16-01108,0,0,72,95,0,,3,0,1,,29,24,3.4,,,19.8,6.5,"46,XY,inv(16)(p13.1q22)[20]",,,Positive for CBFB rearrangment for 91% of cells,31,Positive,6.6,93.2,TRUE,FALSE,16-01108,negative,negative
13-00454,BA2148,1226,Female,Female,HispNative,2,n,31,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,31,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response i,Standard Chemotherapy,5,Standard Chemotherapy,HiDAC,Consolidation,95,Unknown,,FALSE,FALSE,,0,,,45,3,,25,20,7,,,,,1.04,,22,7.4,"46,XX,inv(16)(p13.1q22)[11]/47,idem,+22[4]/46,XX[5]",229,,"nuc ish(D4Z1,D10Z1)x2[199],(SCFD2,LNX,PDGFRA/KIT)x2[200],(5'PDGFRB,3'PDGFRB)x2(5'PDGFRB con 3'PDGFRBx2)[200],(5'FGFR1,3'FGFR1)x2([200],(RUNX1T1,RUNX1)x2[200](ABL1x2,BCRx3)[63/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(ETV6,RUNX1)x2[198],(PML,RARA)x2[200],(CBFBx2)(5CBFB sep 3CBFBx1)[147/200]",30,"CD2(-), CD4(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial+), CD16(-), CD22(few +), CD33(dim + to -), CD34(+), CD36(-), CD38(variably +), CD41(-), CD45(variably +), CD56(-), CD61(-), CD64(-), CD117(variably +), HLA-DR(partial +), Gly-A(-), MPO(+), TdT(partial +)",,13.63,FALSE,FALSE,,negative,negative
14-00613,BA2053,1752,Male,Male,White,2,n,31,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,31,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,HiDAC,Consolidation,5,Unknown,,FALSE,FALSE,,-1,,80,56,2,,17,21,3,,63,39,3.9,0.91,,28.8,10.2,"46,XY,inv(16)(p13.1q22)[7]/46,idem,add(17)(p11.2)[13]",434,,"nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[198],(CBFBx2)(5CBFB sep 3CBFBx1)[164/200]",34,"CD2(partial +), CD4(partial +), CD5(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CDCD33(variably +), CD34(variably +), CD36(few +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(partial +),CD117(+), CD123(variably +), HLA-DR(partial +), MPO(+), TdT(few +).",8.2,41.35,FALSE,FALSE,,negative,negative
14-00359,BA2260,1604,Male,Male,White,3,n,58,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,58,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin) ",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,HiDAC,Consolidation,210,Alive,Alive,TRUE,FALSE,14-00360,-2,,,,,,,,,,,,,,,,,"48,XY,+8,inv(16)(p13.1q22),+22[18]/49,sl,+21[2]",,,8q22 (RUNX1T1): gain present  16q22 (CBFB): rearrangement present  21q22 (RUNX1): gain or rearrangement present,,,,,FALSE,FALSE,,negative,negative
12-00301,BA2055,829,Male,Male,White,1,n,65,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,65,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,n,n,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,MiDAC,Consolidation,108,Dead,Dead-Other,FALSE,FALSE,,-4,0,,15,0,,11,71,2,,71,48,2.7,1.54,M4,25.9,8.8,"46,XY,inv(16)(p13q22)[20]",454,95.9,CBFB rearrangement,14,,6.1,20.7,FALSE,FALSE,,negative,negative
13-00270,BA2564,1123,Female,Female,White,1,n,18,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,18,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",2,Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",Re-induction,-1,Alive,Alive,FALSE,FALSE,,0,0,50,22,0,,24,49,20,,13,15,3.6,0.77,M4,21,7.4,"46,XX,inv(16)p13.1q22)[4]/47,idem,+22[15]/46,XX[1]",415,97.8,CBFB rearrangement and inv(16),23,"Blast phenotype:  CD13, CD33, CD34, CD38, CD58, dim CD123,     HLA-DR-positive               - Monocytic phenotype:  CD11b, CD13, CD14, CD33, CD58, CD64, HLA-DR-positive",7.6,8.8,FALSE,FALSE,,negative,negative
14-00125,BA2482,1477,Female,Female,White,1,n,10,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,10,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,1,Standard Chemotherapy,1,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",3,Induction|Intensification|Re-induction,Complete Response,Standard Chemotherapy,10,Standard Chemotherapy,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",Intensification,29,Alive,Alive,FALSE,FALSE,,-2,0.8,,,0,,10.5,21,7.3,0.5,,,2.1,0.41,,24.7,8.3,"46,XX,inv(16)(p13q22)[17]/46,XX[3]",702,88.5,CBFB rearrangement and inverted 16,31,,,55.35,FALSE,FALSE,,negative,negative
15-00045,BA2709,1925,Female,Female,White,2,n,30,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,30,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,40,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,-1,Alive,Alive,FALSE,FALSE,,0,0,36,22,0,,12,44,5,,61,44,4.2,0.59,,31.8,11,"46,XX,inv(16)(p13q22)[20]",441,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(RUNX1T1,RUNX1)x2[200],(PML,RARA)x2[200], (5'CBFBx2,3'CBFBx1)(5CBFB sep 3'CBFBx1)[195/200],(ABL1,BCR)x2[200]",33,"CD34, CD13, partialCD15, CD38, CD45, CD117, CD123, HLA-DR, dimMPO",7,55,FALSE,FALSE,,negative,negative
14-00279,BA2992,1558,Female,Female,HispNative,4,n,52,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,52,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,SWOG S1203 (7+3 +/- Vorinostat),1,Induction,Complete Response,Standard Chemotherapy,8,Standard Chemotherapy,SWOG S1203 (7+3 +/- Vorinostat),Induction,8,Alive,Alive,FALSE,FALSE,,0,,91,79,,,,0,,,,,,,,,,"46,XX,inv(16)(p13.1q22)[cp20]",,,,,"CD34, PARTIAL CD117, CD15, CD38, PARTIAL CD13, CD33, CD64, PARTIAL CD14(SUBSET), PARTIAL CD11c, DIM CD4, HLA-DR AND BRIGHT MPO",,28.1,FALSE,FALSE,,negative,negative
14-00423,BA2524,1644,Female,Female,White,4,n,51,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,51,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Stanford Protocol 9022 (BU/CY)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,7,Bone Marrow Transplant,Stanford Protocol 9022 (BU/CY),Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,TRUE,FALSE,14-00422,0,,74,61,,,,1,,,,,,,M4eo,,,"46,XX,inv(16)(p13q22)[20]",,,,,"CD34+ EXPRESSING CD38, CD13, CD33, PARTIAL DIM CD2, PARTIAL CD64; DIM PARTIAL CD11C, PARTIAL DIM CD4, COEXPRESSION OF CD117 AND CD15, HLA-DR, MPO, AND PARTIAL DIM TDT",,34.4,TRUE,FALSE,14-00422,negative,negative
15-00331,BA2051,2091,Male,Male,White,5,n,60,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,60,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"HiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, Thiotepa, TBI",3,Consolidation|Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, Thiotepa, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1,Dead,Dead-Disease,FALSE,FALSE,,0,,33,23,,,,,,,,,,,,,,"46,XY,inv(16)(p13.1q22)[18]/47,sl,+22[2]",,,FISH positive for CBFB rearrangement in 49% of cells,42,"Flow cytometry shows the large majority of analyzed cells fall within the monocyte gate, which are predominantly mature as evidenced by coexpression of CD14 and CD64. A smaller subset of cells within the monocyte gate consists of immature monocytes with decreased expression of CD14 and/or CD64.",,29,FALSE,FALSE,,negative,negative
13-00163,BA3038,1058,Male,Male,HispNative,1,n,24,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,24,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine, Methotrexate|Busulfan, Cyclophosphamide",4,Allogeneic - Sibling|Consolidation|Unknown|Induction,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,0,0,50,6,0,,19,52,16,,,,,,M4,26.3,9.2,"47,XY,inv(16)(p13q22),+22[20]",,91.5,inv(16),53,"- 14% Myeloid blasts: CD13, CD34, CD38, CD58, partial CD64,     CD117, CD123,          HLA-DR, and MPO positive     - 30% Monoblasts/promonocytes: CD11b, CD13, CD14, CD38, CD58, bright CD64,     HLA-DR, and MPO",,13.8,FALSE,FALSE,,negative,negative
15-00819,BA2587,2342,Male,Male,White,1,n,64,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,64,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Intrathecal,4,"7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|Cytarabine, Methotrexate",3,Consolidation|Induction|CNS,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,MiDAC,Consolidation,82,Alive,Alive,FALSE,FALSE,,0,0.9,90,25.2,4.3,0.9,9.6,44.3,13.9,0.1,31,45,2.6,0.79,M5,22.7,7.7,"46,XY,inv(16)(p13q22)[20]",1151,93.8,CBFB,10,"dim CD2, variable CD5, CD13, CD33, CD34, CD38, variable CD64, CD117, dim CD123, HLA-DR, and MPO",5.5,24.64,FALSE,FALSE,,negative,negative
16-00001,BA2639,2460,Female,Female,White,1,n,36,FALSE,TRUE,FALSE,CBFB-MYH11,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,36,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|Hydroxyurea",3,Consolidation|Induction|Experimental,Refractory,Standard Chemotherapy,1,Standard Chemotherapy,HiDAC,Consolidation,122,Alive,Alive,FALSE,FALSE,,-2,0,40,60,1.7,0,33.4,5.1,18.8,0.1,38,28,3.2,0.53,,22.9,7.6,"46,XX,t(16;16)(p13.2;q22)[20]",508,99.6,"CBFB: 191/200 cells (95.5%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement, consistent with the 16;16 translocation observed in the metaphase karyotype.",24,"Immunophenotype: CD13, partial CD15, dim CD33, CD34, CD38, dim CD45, CD58, variable CD64, variable CD117, CD123, and dim HLA-DR positive.",7.3,20.44,FALSE,FALSE,,negative,negative
14-00041,BA2511,1434,Female,Female,White,4,n,71,FALSE,TRUE,FALSE,GATA2-MECOM,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,71,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,AG-221,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,AG-221,Hypomethylating/Low Dose Cytarabine,-1,Alive,Alive,TRUE,FALSE,14-00042,0,,22,8,,,,10,,,,,,,M4,,,"46,XX,inv(3)?(q21q25)[21]",,,,,"CD34, CD117, CD38, CD56 (minor subset), partial CD13, partial CD33, CD11c, and HLA-DR",,2.6,TRUE,FALSE,14-00042,negative,negative
14-00053,BA2505,1438,Male,Male,White,4,n,71,FALSE,TRUE,FALSE,GATA2-MECOM,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,71,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,n,y,n,n,1,Standard Chemotherapy,3,"CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Induction|Re-induction,Refractory,Standard Chemotherapy,23,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,4,Dead,Dead-Unknown,TRUE,TRUE,14-00052,-14,,,,,,,,,,,,,,,,,"45,XY,inv(3)(q21q26),-7[20]",,,,,,,,TRUE,TRUE,14-00052,negative,negative
16-00510,BA2037,2712,Male,Male,HispNative,1,n,34,FALSE,TRUE,FALSE,GATA2-MECOM,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,34,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5,"7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|anti-CD33|Azacitidine",3,Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,6,Targeted Therapy - Kinase Inhibitor(s),anti-CD33,Experimental,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0,60,28.9,0,2.1,44.3,8.2,16.5,5.5,117,61,3.9,1,,35.6,11.7,"46,XY,t(3;3)(q21;q26),der(7)del(7)(p11.1)del(7)(q11.1)[13]/45,idem,-der(7)[6]/46,XY[1]",424,96,D7S522/CEP 7: 65/100 cells (65%) had a signal pattern consistent with the deleted chromosome 7 long arm from the small marker observed in the metaphase karyotype; 9 cells (9%) had a signal pattern consistent with the monosomy 7 sideline observed in the metaphase karyotype.,916,,7.7,6.13,FALSE,FALSE,,negative,negative
13-00513,BA2069,1255,Male,Male,White,1,n,55,FALSE,TRUE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,55,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,4,Dead,Dead-Disease,FALSE,FALSE,,-274,1.4,75,,8.5,,11.4,8.5,34,0.2,62,31,3.8,1.44,M5,38.1,12.2,"46,XY,t(9;11)(p22;q23)[20]",497,87.6,MLL rearrangement and t(9;11),32,,7.9,10.21,FALSE,FALSE,,positive,positive
15-00296,BA2952,2079,Female,Female,White,1,n,16,FALSE,TRUE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,16,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",1,Induction,Complete Response,Standard Chemotherapy,10,Standard Chemotherapy,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",Induction,10,Alive,Alive,FALSE,FALSE,,0,0,93,0,0,0,33,67,0,0,,,,0.72,M5,18.2,6.1,"46,XX,t(9;11)(p22;q23)[3]/50,sl,+6,+8,+der(9)t(9;11),+19[14]/51,sdl1,+5[3]",934,100,"MLL:  14% of cells had a 1 red / 1 green / 1 fused split pattern consistent with the t(9;11) seen on metaphase analysis. An addition 65% of cells had two red / 1 green / 1 fused signal pattern, consistent with the clone with the +der(9).",39,"CD11b, dim CD13, dim CD15, CD33, CD38, dim CD45, CD56,      CD58, bright CD64, dim CD117, CD123, HLA-DR, and variable MPO positive",,24.72,FALSE,FALSE,,negative,negative
14-00434,BA2540,1648,Female,Female,White,4,n,69,FALSE,TRUE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,69,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Hydroxyurea,1,Induction,Unknown,Standard Chemotherapy,365,Standard Chemotherapy,Hydroxyurea,Induction,365,Alive,Alive,FALSE,FALSE,,0,,94,83,,,,0,,,,,,,M5a,,,"46,XX[1]",,,,,"CD38, CD56, slightly dim CD4, CD33, dim CD13, CD64, CD11c, CD15 and partial CD117",,137.6,FALSE,FALSE,,negative,negative
13-00425,BA2087,1197,Female,Female,White,2,n,40,FALSE,TRUE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,40,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,5,Alive,Alive,FALSE,FALSE,,-1,,84,29,,,63,3,5,,21,23,3.7,0.65,,35,12,"46,XX,t(9;11)(p22;q23)[20]",613,,"nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1) [179/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",34,"brightCD4, partialCD11b, brightCD15, brightCD33, partialCD36, partialCD38, CD45, brightCD64, partialCD117, HLA-DR",6.5,9.1,FALSE,FALSE,,negative,negative
14-00504,BA2377,1693,Male,Male,White,2,n,35,FALSE,TRUE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,35,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Cyclophosphamide, Thymoglobulin",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,-2,,,,,,,,,,,,,,,,,"46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1]",,,"nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]",,,,,FALSE,FALSE,,positive,positive
14-00447,BA2928,1655,Female,Female,HispNative,1,n,48,FALSE,TRUE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,48,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Fludarabine, Melphalan|Idarubicin and Cytarabine",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,0,,,0,,9.5,0,6,0,51,152,3.1,0.85,M5,30.4,9.7,"47,XX,+8,t(9;11)(p22;q23)[20]",4484,80.4,MLL rearrangement,87,,6,49.29,FALSE,FALSE,,negative,negative
14-00464,BA2651,1664,Female,Female,White,4,n,22,FALSE,TRUE,FALSE,MLLT3-KMT2A,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,22,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,4,"ATRA (Tretinoin)|Cyclophosphamide, TBI|3+7 (Cytarabine, Daunorubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)",4,Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,7,Bone Marrow Transplant,"Cyclophosphamide, TBI",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,,65,90,,,,0.1,,,,,,,M1,,,"46,XX,t(9;11)(p22;q23)[22]",,,,,"CD34, CD38 (dim partial), CD13, CD33 (dim partial), CD11c, CD4 (dim partial), HLA-DR, CD117 and MPO",,40.2,FALSE,FALSE,,negative,negative
13-00028,BA2887,953,Male,Male,White,1,n,24,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,24,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,3,DLI|Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Busulfan, Cyclophosphamide",5,Consolidation|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,DLI,Donor Lymphocyte Infusion,Unknown,0,Alive,Alive,FALSE,FALSE,,0,0,88,94,0,,3,40,3,,13,14,2.8,0.62,M4,31.7,10.9,"47,XY,+10[18]/46,XY[2]",419,86.3,Normal,89,"CD11b, dim CD13, dim CD14, CD33, CD34, dim CD38, partialCD56, CD58, partial CD64, CD117, CD123, dim HLA-DR, and MPO",5.8,21.7,FALSE,FALSE,,negative,negative
14-00240,BA2006,1540,Female,Female,Black,2,n,78,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,78,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,n,y,y,1,Other,1,Azacitidine,1,Supportive/Palliative Care,,,,Other,Azacitidine,Supportive/Palliative Care,-1,Dead,Dead-Disease,FALSE,FALSE,,-17,,,1,,,6,49,35,,9,15,2.9,1.09,,26.1,8.3,"45,XX,+i(5)(p10),psudic(12;5)(p13;q11.2),-16,del(17)(p11.2p13)[5]/44,idem,-i(5)[3]/46,XX[12]",342,,"nuc ish(D5S721x2,D5S23x2,EGR1x1)[57/200]/(D5S721x4,D5S23x4,EGR1x1)[29/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[83/200]",50,,6.7,51.64,FALSE,FALSE,,negative,negative
12-00423,BA2286,923,Male,Male,White,1,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,1,Standard Chemotherapy,1,"3+7 (Cytarabine, Daunorubicin)",1,Induction,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,7,Unknown,,FALSE,FALSE,,0,0,46,66,1,,24,5,4,,18,34,3.2,1.05,M2,26.4,8.8,"46,XY[20]",551,89.1,Normal,72,"CD13, CD33, CD34, CD117, dim CD123, HLA-DR,partial MPO (+)",7,16.5,FALSE,FALSE,,negative,negative
14-00599,BA2420,1739,Male,Male,White,1,n,69,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,69,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,3,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,MiDAC,Consolidation,63,Dead,Dead-Disease,FALSE,FALSE,,0,0,,,0,0,78.5,15.1,6.4,2.9,21,15,3.1,1.01,M0,23.5,7.5,"47,XY,+8[2]/46,XY[18]",,101.7,Consistent with karyotype,47,"dim CD13, dimCD33, CD34, dim CD38, CD58, dimCD64, CD117, CD123, dim HLA-DR, TdT positive",6.7,2.05,FALSE,FALSE,,negative,negative
14-00901,BA2629,1870,Male,Male,White,1,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,MiDAC,Consolidation,44,Dead,Dead-Unknown,FALSE,FALSE,,-2,0,,,0,0,45.5,0.8,0,0.3,14,18,2.4,0.73,,21.3,6.9,"46,XY,t(1;4)(q21;p14)[20]",178,103.4,Normal,57,,7,13.68,FALSE,FALSE,,negative,negative
15-00858,BA3004,2362,Female,Female,White,1,n,76,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,76,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"5+2 (Cytarabine, Idarubicin)|Decitabine",2,Induction|Re-induction,Refractory,Standard Chemotherapy,8,Standard Chemotherapy,"5+2 (Cytarabine, Idarubicin)",Re-induction,4,Dead,Dead-Disease,FALSE,FALSE,,0,0,95,0,0,0.9,16.8,3.5,24.8,1.1,23,22,3.5,1.33,,31.5,10.3,"46,XX[22]",244,92.6,Normal,29,"dimCD13, CD33, CD45, CD56, dimCD117 and MPO positive",7,27.17,FALSE,FALSE,,positive,positive
15-00572,BA2198,2213,Male,Male,White,3,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,-1,Alive,Alive,TRUE,TRUE,15-00571,0,,84,91,,,,,,,,,,,M2,,,"46,XY[20]",,,Normal,,"partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)",,25,FALSE,FALSE,,negative,negative
15-00717,BA2376,2295,Male,Male,White,1,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6,Alive,Alive,FALSE,FALSE,,0,0.4,68,0,0.1,3,17,62.6,16.9,0.1,29,17,3.7,1.51,M5,27.7,8.9,"46,XY[20]",296,104.9,Normal,74,"dim CD4, CD11b, partial CD14, CD15, dim CD33, CD38, CD56, CD58, CD64 and HLA-DR positive",8,16.84,FALSE,FALSE,,negative,positive
16-00075,BA3040,2498,Male,Male,White,4,n,69,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,69,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,7,Alive,Alive,FALSE,FALSE,,0,,39,11,,,,,,,,,,,,,,"45,XY,add(1)(p13),del(5)(q13q33),add(6)(q13),-7,del(7)(q11.2),der(9)t(1;9)(p13;q22),add(12)(p13),-15,-16,-17,+3mar[19]/43~45,idem,der(3)t(3;17)(p21;q11.2),-17[cp3]",,,"COMPLEX DEL(5q)/DEL(7q)/-7 CLONE OBSERVED, CONSISTENT WITH AML",,Positive,,1.6,FALSE,FALSE,,negative,negative
13-00266,BA2162,1119,Male,Male,White,1,n,77,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,77,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,7,Dead,Dead-Disease,FALSE,FALSE,,1,,,47,,,,,,,,,,,,,,"46,XY,-7,+13,i(17)(q10)[20]",,,Monosomy 7,,"CD13, CD33, CD34, CD117, dim CD123, and HLA-DR-positive",,25.3,FALSE,FALSE,,negative,negative
16-00273,BA2312,2595,Female,Female,White,3,n,62,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,62,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,7,Dead,Dead-Disease,FALSE,FALSE,,-2,,,,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,,,,FALSE,FALSE,,negative,negative
16-00292,BA2171,2607,Female,Female,White,1,n,73,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,73,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,3,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,3,Dead,Dead-Disease,FALSE,FALSE,,0,0,90,98.4,0,0,0.8,0,0.8,0.1,18,36,2.9,1.44,,25.9,8.2,"46,XX[20]",,90.6,Normal,19,"CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, and MPO",7.7,122.89,FALSE,FALSE,,positive,positive
16-00699,BA2570,3975,Male,Male,HispNative,2,n,46,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",46,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,6,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6,Dead,Dead-Treatment,FALSE,FALSE,,0,,92,75,,,5,19,1,,,,2.8,1.13,,18.4,6.2,"46,XY[20]",,113.6,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",31,"CD2(+), surface CD3(-),  cytoplasmic CD3(dim +), CD4(-), CD7(partial +), CD11b(partial +),  CD13(variably +), CD14(few +), CD15(-), CD16(-),  CD33(-), CD34(partial +), CD36(-), CD38(bright +), CD45(dim  +), CD56(small subset +), CD64(-), CD117(+), HLA-DR(partial +), MPO(partial +), TdT(partial dim+)",,151.6,FALSE,FALSE,,negative,negative
14-00817,BA2593,1865,Male,Male,White,3,n,53,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,53,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,n,y,y,n,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,-1,Unknown,,TRUE,FALSE,14-00818,-1,,66,56,,,,,,,,,,,,,,"46,XY[20]",,,Normal,123,"large population of atypical CD117 positive myeloblasts (partial CD34+, weak CD4+, weak partial CD7+, partial CD64+), representing approximately 57% of the leukocytes and increased   promonocytes/monoblasts representing approximately 13% of the total leukocytes",,180,TRUE,FALSE,14-00818,positive,negative
15-00595,BA2459,2226,Male,Male,White,2,n,55,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,Intermediate,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,55,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,8,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,8,Unknown,,FALSE,FALSE,,0,0,91,61,0,,46.1,1.7,9.4,,391,343,2.8,0.74,M1,22.8,7.1,"92<4n>,XXYY[13]/46,XY[7]",,,"nuc ish(D5S2064,D5S630,EGR1)x3~4[193/200],(D7Z1,D7S522)x3~4[194/200],(D8Z2, D20S108)x3~4[195/200],(RUNX1T1,RUNX1)x3~4[191/200],(ABL1,BCR)x3~4[191/200],(5'MLL,3'MLL)x3~4(5'MLL con 3'MLLx3~4)[193/200],(PML,RARA)x3~4[191/200],(5'CBFB,3'CBFB)x3~4(5CBFB con 3CBFBx3~4)[192/200]",34,"CD2(-), CD4(partial dim +), CD7(-), CD11b (variably +), CD13(variably +), CD14(predominantly -), CD15(predominantly -/few scattered +), CD16(-), CD20(small subset +), CD33(partial +), CD34(variably +), CD36(small subset +), CD38(variably +), CD45(variably +), CD56(-), CD61 (-), CD64(-), (cont.above)",5.8,9.4,FALSE,FALSE,,positive,negative
16-00540,BA2442,2721,Female,Female,White,3,n,66,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",66,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,UNKNOWN,Standard Chemotherapy,6,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6,Unknown,,FALSE,FALSE,,0,,,16,,,,,,,,,,,,,,"47,XX,+8[18]",,,Normal,,"Large population of CD117 pos myeloblasts, representing 80% of leukocytes, consistent w/ AML.",,129.5,FALSE,FALSE,,positive,negative
15-00320,BA2410,2084,Female,Female,White,2,n,57,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,57,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin) plus Crenolanib",1,Induction,Complete Response i,Standard Chemotherapy,-1,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin) plus Crenolanib",Induction,-1,Dead,Dead-Treatment,FALSE,FALSE,,0,,55,47,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,"It reveals 0.23% CD34 (+) myeloid blasts with the following immunophenotype: CD2(-), CD7(-), CD13(+), CD15(-/few +), CD33 (bright +), CD36(few +), CD38(partial +), CD45(+), CD64(-), CD117(+), HLA-DR(-), MPO (partial +).",,26.5,FALSE,FALSE,,positive,positive
15-00674,BA2760,2269,Female,Female,White,5,n,54,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,54,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin) plus Sorafenib",1,Induction,Complete Response,Standard Chemotherapy,19,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin) plus Sorafenib",Induction,19,Dead,Dead-Other,FALSE,FALSE,,0,,75,,,,,39,,,,,,,,,,"50,XX,+8,+10,+12,+21[20]",,,- Gain of chromosome 8 in 55% of cells - Gain of 8q22 (ETO) sequence in 77.8% of cells; 21q22 (AML1) gain in 12% and loss in 77.8% cells,9,"CD11b, CD13, CD14 (subset), CD33, CD34 (subset), CD38, CD45, CD64 (subset), HLA-DR and MPO",,37.2,FALSE,FALSE,,negative,negative
14-00081,BA2125,1453,Female,Female,White,1,n,71,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,71,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Decitabine",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"Azacitidine, Lenalidomide",Re-induction,28,Unknown,,FALSE,FALSE,,0,0,46,49.1,0,,20.5,8,17,0.9,32,39,3.3,0.73,M2,20.7,6.4,"42~45,XX,add(5)(q13),der(17)add(17)(p11.2)add(17)(q11.2),-18,-22[cp6]/43~44,sl,add(13)(q32),add(14)(q11.2),+mar[cp12]/43~44,sl,add(14)(q11.2),-21,",685,79,5q deletion,11,"partial CD7, CD13, partial CD33, CD34, partial CD38, CD58, CD117, dim/partial CD123, partial TdT, HLA-DR positive.",6.6,12.87,FALSE,FALSE,,negative,negative
14-00228,BA2474,1532,Female,Female,White,1,n,46,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,46,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,Azacitidine,Consolidation,339,Alive,Alive,FALSE,FALSE,,0,0,80,45,1.6,,9.9,14.9,10.7,0,52,28,2.5,0.77,M4,25.2,8.4,"46,XX[20]",550,88.1,Normal,107,"dim CD11b, CD13, CD33, partial CD34, dim CD45, dim CD64, CD117, CD123, and dim HLA-DR+",6.3,57.23,FALSE,FALSE,,negative,positive
14-00152,BA2561,1495,Male,Male,White,3,n,75,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,75,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,5,"7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,21,Standard Chemotherapy,"CLAG (Cladribine, Cytarabine, Filgrastim)",Consolidation,-1,Dead,Dead-Disease,FALSE,FALSE,,-1,,64,7,,,,,,,,,,,M4,,,"46,XY,add(8)(p21),t(8;19)(p11.2;q13.3)[18]/46,XY[2]",,,Normal,,"Large population of atypical myelomonocytic cells (CD4+, bright CD64+, MPO positive, partial CD14), representing 85% of the total leukocytes",,4.67,FALSE,FALSE,,negative,negative
14-00681,BA2908,1797,Male,Male,White,1,n,65,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,65,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|Cytarabine",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,Cytarabine,Consolidation,133,Alive,Alive,FALSE,FALSE,,0,0,,,0,0,31.2,0.9,0,0,19,25,3.3,0.78,M1,21.4,7.4,"46,XY,del(13)(q12q2?1)[14]",509,103.4,"all 100 interphase cells scored (100%) were missing one set of 13S319 and RB1 probe signals, consistent with deleted 13q and the metaphase karyotype",17,"CD13, partial/dim CD33, CD38, CD58, CD117 and MPO",6.6,5.39,FALSE,FALSE,,negative,negative
14-00473,BA2619,1666,Female,Female,White,1,n,62,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Salvage|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"HAM (Cytarabine, Mitoxantrone)",Salvage,7,Dead,Dead-Other,TRUE,FALSE,14-00468,0,6.1,22,17.4,5.2,16.5,31.3,1.7,21.8,0.2,13,11,3.2,0.78,,29.5,9.5,"59~62,XX,+X,+1,+2,del(5)(q13q34),+6,+8,+8,+9,+11,+11,i(11)(q10),+12,+14,+16,+19,+22,+mar[cp19]/46,XX[1]",444,101.4,Trisomy 9,34,"CD13, CD34, CD58 and CD117",7,10.75,TRUE,FALSE,14-00468,negative,negative
14-00001,BA2485,1400,Male,Male,HispNative,1,n,56,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,56,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,n,y,n,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,HiDAC,Consolidation,111,Alive,Alive,FALSE,FALSE,,0,0.8,95,95,0,,25.6,0,0,0.7,27,16,3.4,0.97,,11.1,3.7,"46,XY[20]",314,95.7,Normal,20,"CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive",7.1,13.26,TRUE,TRUE,14-00004,positive,positive
14-00273,BA2915,1554,Female,Female,HispNative,4,n,34,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,34,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,n,y,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,24,Standard Chemotherapy,HiDAC,Consolidation,105,Alive,Alive,TRUE,TRUE,14-00272,-1,,87,87,,,,0,,,,,,,,,,"46,XX[20]",,,,,"CD34, CD117,partial CD13, CD33, CD38, partial CD64, dim CD7, variable CD15, HLA-DR and bright MPO",,99.3,TRUE,TRUE,14-00272,negative,negative
16-00003,BA2775,2461,Male,Male,White,3,n,26,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,27,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,16,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,Alive,FALSE,FALSE,,-7,,,,,,,,,,,,,,,,,"46,XY[15]",,,Normal,,,,,FALSE,FALSE,,negative,positive
16-00129,BA2301,2519,Female,Female,White,5,n,42,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,42,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,Alive,FALSE,FALSE,,0,0,90,,0,,17,,20,,17,13,3.6,0.98,,21.7,7.3,"46,XX[19]",,,Normal,71,Positive,6.6,18.3,FALSE,FALSE,,negative,positive
16-00344,BA2588,2628,Male,Male,White,1,n,59,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,HiDAC,Consolidation,96,Alive,Alive,TRUE,FALSE,16-00345,0,0,30,10.5,0,0,19.7,0.9,71.4,0,77,27,3.4,1.01,,26.4,8.9,"46,XY[20]",479,96.4,Normal,101,"CD13, CD33, CD117, CD123, and HLA-DR",6.4,4.4,FALSE,FALSE,,negative,positive
16-00351,BA2296,2630,Female,Female,HispNative,1,y,46,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,46,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,HiDAC,Consolidation,120,Alive,Alive,FALSE,FALSE,,-3,,,,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,,,,FALSE,FALSE,,negative,negative
16-01219,BA2217,4271,Male,Male,White,1,y,47,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,47,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,Alive,FALSE,FALSE,,0,0,83,82,3.4,0,23.1,3.4,0,1.6,23,11,3.5,0.95,,31.1,10.2,"46,XY[20]",290,88.9,,24,"CD7, CD13, CD33, CD34, CD38, partial CD56,  CD58, dim CD64, CD117, CD123, HLA-DR, and cMPO ",6.5,18.71,FALSE,FALSE,,negative,negative
16-01254,BA2914,4299,Female,Female,White,1,n,38,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,38,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,Alive,FALSE,FALSE,,0,,47,21.7,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,"CD117, dimCD4, heterogeneous CD13, CD33, dimCD64 and  MPO positive ",,46.27,FALSE,FALSE,,negative,positive
15-00269,BA2836,2053,Male,Male,White,2,n,59,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,HiDAC,Consolidation,107,Dead,Dead-Unknown,FALSE,FALSE,,-1,0,35,27.4,0,,36.8,6.6,29.2,,13,25,2.9,1.4,,23.6,7.6,"46,XY[20]",383,,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",35,,6,3.6,FALSE,FALSE,,negative,positive
14-00331,BA2772,1586,Male,Male,HispNative,2,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,HiDAC,Consolidation,5,Unknown,,TRUE,FALSE,14-00330,0,1,81,68,,,5,2,2,,85,52,3.1,0.85,,28.8,10.1,"46,XY[20]",1205,,"nuc ish(D4Z1,D10Z1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200]",20,"CD2(-),CD4(partial dim +), CD7(-), CD11b(few +), CD13(+), CD14(-), CD15(partialCD22(-), CD25(appears partial dim +), CD33(bright +), CD34(few +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(partial +), CD79a(-), CD117(+), CD123(partial +), HLA-DR(partial +), MPO(+), TdT(-).",6.2,152.75,TRUE,FALSE,14-00330,negative,positive
15-00248,BA2844,2033,Male,Male,HispNative,2,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine",3,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Unknown,,FALSE,FALSE,,0,0,64,47.4,1.7,,23.3,27.6,0,,29,26,3.7,1.01,,32.9,10.3,"46,XY[20]",578,99.7,"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",20,"CD2(-), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD19(few appear very dim +), CD25(-), CD33(variably +), CD34(variably +), CD36(subset +), CD38(+), CD45 (variably +), CD56(+), CD64(partial +), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(-).",7.2,20.8,FALSE,FALSE,,negative,negative
14-00559,BA2901,1721,Male,Male,White,2,n,68,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)",4,Consolidation|Induction|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,Azacitidine,Maintenance,-1,Alive,Alive,FALSE,FALSE,,0,0,79,54,,,10,42,30,,8,26,4,,,20.8,6.8,"46,XY",,,IGH-MYEOV and IGH-CCND1 rearrangement; MAF unlisted,61,"CD2(-), CD4(equivocal), CD7(partial +), CD11b (equivocal), CD13(+), CD14(-), CD15(-), CD16(equivocal), CD33(-), CD34(bright +), CD36(-), CD38(dim +), CD45(+), CD56(equivocal), CD64(-), CD117(+), CD123(equivocal), HLA-DR(dim +), MPO(partial +), TdT(-)",7.1,41.4,FALSE,FALSE,,negative,positive
15-00653,BA2386,2254,Female,Female,White,2,n,52,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",52,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,-1,Dead,Dead-Disease,FALSE,FALSE,,-1,0,83,48.6,0,,9.4,0.9,40.2,,21,47,3.3,0.55,M1,25.3,8.3,"46,XX[20]",,,"nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",48,"CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+ and dim +), CD14(-), CD15(+), CD16(-), CD25(-), CD33(slightly bright +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(small subset +), CD64(-), CD117(dim and variably +), CD123(variably +), HLA-DR(+), TdT(-), MPO(+).",6.6,22.1,FALSE,FALSE,,negative,positive
13-00098,BA2068,1011,Female,Female,Black,2,n,64,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,64,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Induction,5,Unknown,,FALSE,FALSE,,0,1.4,76,0,0.1,,94.3,1.5,2.7,,22,20,3.6,0.48,,32.6,10.9,"46,XX[14]",184,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],",32,"CD4(few +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(partial +), CD16(-), CD34(-), CD36(-), CD38(+), CD45(+), CD56(few +), CD64(-), CD117(partial +), HLA-DR(-), MPO(+) and TdT (+)",7.5,1.5,FALSE,FALSE,,negative,positive
14-00496,BA2856,1683,Male,Male,White,3,n,55,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,55,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin) ",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,129,Unknown,,TRUE,FALSE,14-00497,-1,,37,20,,,,,,,,,,,,,,"46,XY[20]",,,Normal,283,"Increased atypical CD117 positive myeloid blasts (weak CD7  positive, HLA-DR negative), representing 18% of the total  leukocytes, consistent with a myeloid neoplasm",,16.11,TRUE,FALSE,14-00497,negative,positive
16-00220,BA2124,2571,Male,Male,White,3,n,67,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,67,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|IDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,IDAC,Consolidation,-1,Alive,Alive,FALSE,FALSE,,0,,71.5,56,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,"CD33, CD38, CD56, CD117, and myeloperoxidase",,16.24,FALSE,FALSE,,negative,positive
15-00782,BA2046,2320,Male,Male,White,2,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,-1,Unknown,,FALSE,FALSE,,0,0,45,48,2,,69,4,2,,12,15,3.8,,,22.7,7.6,"46,XY[19]",,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]",27,"CD2(-), CD4(-), CD7(subset +), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).",6.8,1.39,FALSE,FALSE,,negative,negative
13-00157,BA2235,1054,Female,Female,White,1,n,60,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,MiDAC,Consolidation,104,Alive,Alive,FALSE,FALSE,,0,0,80,32,0,,11,13,23,,32,50,2.9,0.64,,41.1,13.4,"46,XX[20]",660,86.1,normal,228,"partial CD7, partial CD11b, CD13, CD33, dim CD45, CD58,     partial CD64, partial CD117, CD123, dimHLA-DR,  MPO positive",7.4,53.9,FALSE,FALSE,,negative,positive
13-00195,BA2239,1078,Male,Male,White,1,n,66,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,66,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,MiDAC,Consolidation,74,Alive,Alive,FALSE,FALSE,,0,0,90,24,0,,14,61,1,,19,14,2.4,1.13,M5,23.9,7.9,"46,XY[20]",387,103.6,normal,122,"CD11b, dim/partial CD13, CD14, CD33, CD38, CD58, CD64,     partial CD117, dim/partial CD123, and HLA-DR positive",6.3,28,FALSE,FALSE,,negative,positive
13-00658,BA2631,1396,Male,Male,White,1,n,60,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,MiDAC,Consolidation,114,Alive,Alive,FALSE,FALSE,,0,0.8,30,42.4,4.5,,19.7,8.3,15.9,0.3,49,23,3.5,1.22,,30.6,10.6,"46,XY[21]",536,95.6,Normal,141,"CD7, CD13, CD33, partial CD34, CD38, CD58, CD117, CD123,HLA-DR, and MPO positive",7.2,11.93,FALSE,FALSE,,negative,positive
14-00781,BA2497,1847,Male,Male,White,1,n,71,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,71,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,MiDAC,Consolidation,5,Dead,Dead-Disease,FALSE,FALSE,,0,0,95,80,0,2,21,4,1,0.8,29,282,3.2,1.61,M5,31.8,10,"47,XY,t(1;11)(p32;q23),+8[cp20]",7759,102.3,c/w karyotype,59,"CD11b, CD13, partial CD14, CD15, CD33,CD38, CD45, CD56, CD58, CD64, HLA-DR and MPO-positive",6.1,71.19,FALSE,FALSE,,negative,negative
15-00839,BA2024,2347,Male,Male,White,1,n,48,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,48,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,"ADE (Cytarabine, Daunorubicin & Etoposide)",1,Induction,Unknown,Standard Chemotherapy,7,Standard Chemotherapy,"ADE (Cytarabine, Daunorubicin & Etoposide)",Induction,7,Dead,Dead-Disease,FALSE,FALSE,,0,0.2,13,,0,0.5,10.2,4.4,84.7,0,84,28,3.9,0.95,,42.1,14,"46,XY[20]",231,89.2,Normal,330,"CD33, CD117 positive, negative for CD34 and HLA-DR",8.2,6.3,FALSE,FALSE,,positive,positive
15-00975,BA2132,2452,Female,Female,White,6,n,70,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",70,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Induction,Unknown,Standard Chemotherapy,37,Standard Chemotherapy,Azacitidine,Induction,37,Unknown,,FALSE,FALSE,,0,,90,17,,,20,18,2,,24,26,3.8,0.76,,25,8.2,"46,XX,del(5)(q22q35)[20]",,87.7,Positive for 5q deletion in 91% of cells.,35,"POSITIVE FOR CD34, HLA-DR, CD117 AND CD33, AND NEGATIVE FOR MPO, TdT, CD13, CD19, CD20 AND CD10.",6.2,7.7,FALSE,FALSE,,positive,negative
13-00365,BA2525,1171,Female,Female,White,4,n,72,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"Azacitidine, Lenalidomide|Temozolomide, Vorinostat",2,Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"Temozolomide, Vorinostat",Re-induction,-1,Dead,Dead-Unknown,TRUE,FALSE,13-00366,-13,,,,,,,,,,,,,,,,,"46,XX,del(5)(q31q35),inv(7)(p15q32),del(12)(q?15)[2]/45~46,idem,add(3)(q27),-9,-del(12)(q?15),+add(12)(q13),-16,-17,+mar1,+mar2x2[cp16]/46,XX[2]",,,,,,,,TRUE,FALSE,13-00366,positive,positive
16-00289,BA2211,2606,Female,Female,White,1,n,65,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib",2,Consolidation|Induction,Complete Response i,Standard Chemotherapy,45,Standard Chemotherapy,Azacitidine,Consolidation,34,Dead,Dead-Disease,FALSE,FALSE,,0,0,95,92.9,0,0.7,3.6,1.4,1.4,0.1,101,55,3.2,0.83,,37,12.4,"46,XX[20]",697,95.1,normal,42,"CD13, CD33, CD38, CD56, CD58, partial CD64, CD117, CD123, and MPO positive",6.3,166.91,FALSE,FALSE,,positive,positive
14-00135,BA2594,1485,Male,Male,White,1,n,72,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,Azacitidine|Decitabine,3,Consolidation|Induction|Maintenance,Unknown,Standard Chemotherapy,38,Standard Chemotherapy,Azacitidine,Maintenance,36,Dead,Dead-Disease,FALSE,FALSE,,0,0,55,46,0,,27.8,27,20.6,0,32,31,2.2,1.37,M4,20.6,6.6,"43~44,X,-Y,t(3;11)(p21.3;p11.2),del(5)(q11.1;q31.1),add(12)(p11.2),-21[cp17]/44~45,idem,-t(3;11),+9[cp4]",435,85.8,Previous FISH results were consistent with the deleted 5q and trisomy 9,33,"CD13, CD33, CD34, partial CD56,variable CD117, dim CD123, and dim HLA-DR+",5.9,20.82,FALSE,FALSE,,negative,negative
15-00377,BA2748,2116,Female,Female,White,1,n,10,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,10,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,33,Standard Chemotherapy,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Re-induction,-1,Alive,Alive,FALSE,FALSE,,0,0,80,75,1.7,6.1,17.4,7.8,11.3,0.7,24,22,3.7,0.51,,30.3,9.1,"46,XX[20]",688,83.7,Normal,74,"variable CD7, variable CD13, CD33, partial CD34, bright CD38, partial CD56, CD58, variable CD71, CD117, CD123, HLA-DR, and MPO positive",7.3,39.69,FALSE,FALSE,,negative,negative
15-00395,BA2622,2119,Male,Male,White,1,n,76,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,76,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,3,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor),2,Consolidation|Induction,Complete Response,Standard Chemotherapy,35,Standard Chemotherapy,Incyte trial (azacitidine and JAK 1 inhibitor),Induction,77,Dead,Dead-Unknown,FALSE,FALSE,,0,0,50,<5,2,0.2,52.2,37.1,8.5,0,18,16,3.7,1.45,M0,22.3,7.6,"47,XY,+8[3]/46,XY[17]",,118.6,5% trisomy 8 (c/w karyotype),104,"#1 Immunophenotype: CD13, CD34, CD38, dim CD45, CD58, CD117, HLA-DR and TdT positive",7.7,4.48,FALSE,FALSE,,negative,negative
16-00102,BA2233,2508,Male,Male,White,4,n,72,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Hydroxyurea,1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,CPX-351 (Liposomal Cytarabine + Daunorubicin),Induction,-1,Alive,Alive,FALSE,FALSE,,0,,97,96,,,,,,,,,,,M1,,,"46,XY[5]",,,"D5S721, EGR1 del(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q)   ",,"CD117, MPO,CD38(PARTIAL), CD33(DIM) AND NOT EXPRESSING CD34 AND HLA-DR",,125.9,FALSE,FALSE,,negative,positive
16-01102,BA2175,4232,Female,Female,White,2,n,72,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,-1,Alive,Alive,FALSE,FALSE,,0,,30,5,,,,,,,37,93,,,,,,"45,XX,der(5)inv(5)(p13q15)del(5)(q15q33),-16,-17,der(17)t(17;17)(p13;q11.2),der(18;22)(q10;q10),+22,+r[cp20] .ish r(MLL+)[2]",,,"nuc ish(D4Z1,D10Z1)x2[200],(D5S2064x2,D5S630x2,EGR1x1)[196/200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[197],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3) [142/200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[200]",16,,,44.63,FALSE,FALSE,,negative,negative
16-01237,BA2135,4291,Female,Female,HispNative,6,n,73,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,73,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,-1,Alive,Alive,TRUE,FALSE,16-01238,0,,71,3,1,,68,8,11,,11,23,2.9,0.51,,24.9,7.8,"46,XX,del(1)(p22),der(15)t(15;?)(q15;?),-17,+mar[19]/46,XX[1]",,110.7,Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells.,95,"blasts 55% of all events; they are positive for cd34, hla-dr, cd117, cd13, cd33, and  negative for cd11b, cd14, cd64, tdt and mpo.",4.8,63.4,FALSE,FALSE,,negative,negative
14-00564,BA2275,1719,Male,Male,White,1,n,57,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,57,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,Decitabine,1,Induction,Unknown,Standard Chemotherapy,10,Standard Chemotherapy,Decitabine,Induction,10,Dead,Dead-Unknown,FALSE,FALSE,,0,0,45,,0.9,27.8,18.2,12.2,40.9,0,32,19,2,0.83,,26.9,9.1,"44~48,XY,-5,del(7)(q22),+11,idic(11)(p11.2)x2,-12,der(13)t(1;13)(p13;p12),add(17)(q25),der(18)t(12;18)(q13;q11.2),-22,+2mar[cp14]/44~47,sl,-9,+16[cp3]/46~47,sl,der(1)t(1;3)(q21;q21),der(3)t(1;3)(q21;q21)ins(3)(3;?)(p21;?),-idic(11)(p11.2)[cp4]/46,XY[1]",,97.1,"EGR1/5p; 88% of cells were missing a signal for both probes, consistent with monosomy 5 ",77,"CD13, CD33, CD34, CD71, CD117, dim CD123 and HLA-DR+",6.7,5.92,FALSE,FALSE,,negative,negative
15-00246,BA2123,2032,Male,Male,White,2,n,65,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,1,Decitabine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,214,Dead,Dead-Unknown,FALSE,FALSE,,0,,10,1,0,,80,2,17,,24,27,4.3,1.48,,20.4,7.2,"46,XY[20]",275,93.3,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199](RUNX1T1, RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",23,"CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33 (bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR (+), GLy-A(-), MPO(partial +), TdT(-).",6.9,1.6,FALSE,FALSE,,negative,positive
15-00688,BA2113,2276,Female,Female,White,1,n,63,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Induction,Unknown,Standard Chemotherapy,9,Standard Chemotherapy,Decitabine,Induction,9,Dead,Dead-Other,FALSE,FALSE,,0,1.8,41,2.6,0.9,0,79.6,0.9,14.2,0,21,19,2.7,0.98,,27.7,9.4,"45~46,XX,add(1)(q42),del(5)(q31q35),del(6)(q13),del(9)(q13q34),del(17)(p13),i(21)(q10)[cp12]/46~47,idem,+mar[cp6]/46,XX[2]",404,88.5,"EGR1 (5q31): 73% of cells were missing a signal for EGR1 (5q31), consistent with the deletion seen on metaphase analysis.  TP53 (17p13.1): 71% of cells were missing a signal for TP53 (17p13.1), consistent with the deletion seen on metaphase analysis.  RUNX1 (21q22): 77% of cells had three signals fo",6,"CD13, dimCD33, CD34, CD38, CD58, partial CD64, CD117, CD123, and HLA-DR positive.",7.6,1.61,FALSE,FALSE,,negative,negative
16-01223,BA2454,4273,Male,Male,White,2,n,73,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",73,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,-1,Dead,Dead-Unknown,FALSE,FALSE,,0,,83,59,,,,,,,21,23,,,,,,"46,XY[20]",,,"nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[195],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",22,,,24.23,FALSE,FALSE,,negative,negative
16-00078,BA2724,2499,Female,Female,White,2,n,67,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,67,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,-1,Unknown,,FALSE,FALSE,,0,0.8,85,7.7,0,,5.1,42.7,40.2,,27,41,1.9,0.66,,28.7,9.5,"46,XX[20]",670,102.5,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",42,"CD2(-), CD4(partial dim +), CD7(few dim +), CD11b(-), CD13 (variably +), CD14(-), CD15(partial +), CD16(-), CD19(partial dim +), CD33(variably +), CD34(-), CD36(-), CD38(+), CD45 (moderate +), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+), MPO(+).",5.7,56.03,FALSE,FALSE,,negative,positive
15-00029,BA2276,1919,Male,Male,White,2,n,80,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",80,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,2,"Decitabine, ABT-199|Hydroxyurea",2,Unknown|Supportive/Palliative Care,,,,Standard Chemotherapy,"Decitabine, ABT-199",Unknown,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0,21,47,0,,5,10,41,,25,52,4.1,1.26,,35,11.1,"46,XY[20]",639,90.4,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",110,"CD2(-), CD4(-), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(few +), CD16 (-), CD33(variably +), CD34(+), CD36(-), CD38(partial + with an unusual pattern of expression vs. CD34), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), HLA-DR(dim +).",7.5,64.6,FALSE,FALSE,,negative,negative
14-00141,BA2747,1488,Male,Male,Asian,4,n,85,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,85,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Decitabine, Midostaurin",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Decitabine, Midostaurin",Induction,-1,Dead,Dead-Disease,TRUE,FALSE,14-00142,-15,,,,,,,,,,,,,,,,,"46,XY[14]",,,,,,,,TRUE,FALSE,14-00142,negative,negative
14-00774,BA2843,1843,Male,Male,White,4,n,84,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,84,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Decitabine, Midostaurin",1,Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"Decitabine, Midostaurin",Induction,-1,Dead,Dead-Disease,FALSE,FALSE,,0,,85,88,,,,,,,,,,,M0,,,"46,XY[20]",,,,,"CD34, CD38, CD117, CD13, CD4, HLA-DR, AND TDT",,30,FALSE,FALSE,,positive,negative
15-00024,BA2682,1916,Female,Female,White,4,n,75,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,75,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,1,"Decitabine, Midostaurin",1,Induction,Refractory,Standard Chemotherapy,206,Standard Chemotherapy,"Decitabine, Midostaurin",Induction,206,Dead,Dead-Unknown,TRUE,FALSE,15-00027,-6,,,,,,,,,,,,,,,,,"46,XX,t(5;16)(q31;p13)[3]/46,XX[14]",,,,,,,,TRUE,FALSE,15-00027,negative,negative
15-00813,BA2851,2339,Female,Female,White,1,n,53,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",53,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Induction|Re-induction,Refractory,Standard Chemotherapy,4,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,7,Alive,Alive,FALSE,FALSE,,1,0,45,50,0,19.4,6.4,1.6,11.3,0,73,83,3.3,0.88,,29.4,9.6,"46,XX[20]",2008,109.3,Normal,33,"partial CD7, CD13, CD33, CD34, variable CD38, CD117, CD123, partial HLA-DR and dim MPO",6.8,137.54,FALSE,FALSE,,negative,negative
15-00786,BA2972,2322,Male,Male,White,1,y,40,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,40,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,HiDAC,Consolidation,5,Alive,Alive,FALSE,FALSE,,0,0,80,27.8,0,0,62.6,4.4,5.2,0,26,22,3.9,0.78,,37.6,13.2,"46,XY[20]",,91.7,normal,66,"dim CD7, CD13, CD33, CD34, CD38, partial CD56 (25%), CD58, dim CD64, CD117, dim CD123, HLA-DR, and MPO+.",7.4,2.68,FALSE,FALSE,,negative,negative
16-00094,BA2821,2501,Female,Female,White,1,n,37,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",37,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Hydroxyurea",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,8,Standard Chemotherapy,Azacitidine,Consolidation,-1,Alive,Alive,FALSE,FALSE,,0,1.7,95,74,2.5,0.8,13.6,14.4,10.2,0.4,23,14,3.1,0.46,,27.9,9.2,"46,XX[20]",,89.4,Normal,49,"variable CD11b, CD13, dim CD19, dim CD33, CD34, variable CD64, CD117, CD123, and HLA-DR",7,26.57,FALSE,FALSE,,negative,negative
16-00056,BA3001,2490,Female,Female,White,1,n,51,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,51,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"HiDAC|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,2,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,Alive,FALSE,FALSE,,0,0,95,95,0,0,7.8,0,3.1,0.1,22,12,2.9,0.93,,20.6,6.6,"46,XX[20]",189,112.6,Normal,57,"Immunophenotype: CD7, CD13, CD33, CD38, CD117, CD123 and MPO positive",6.5,25.02,FALSE,FALSE,,negative,positive
14-00542,BA3023,1710,Female,Female,HispNative,4,n,27,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,27,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,2,HiDAC|SWOG S1203 (7+3 +/- Vorinostat),2,Consolidation|Induction,Complete Response,Standard Chemotherapy,8,Standard Chemotherapy,HiDAC,Consolidation,137,Alive,Alive,TRUE,TRUE,14-00543,0,,69,68,,,,1,,,,,,,M2,,,"48,XX,+3,+10[2]/46,XX[18]",,,,,"CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7",,5.1,TRUE,TRUE,14-00543,negative,positive
16-00867,BA2704,4042,Female,Female,White,1,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,3,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Hydroxyurea,1,Induction,Unknown,Standard Chemotherapy,8,Standard Chemotherapy,Hydroxyurea,Induction,8,Dead,Dead-Unknown,FALSE,FALSE,,-5,0,93,85,0.8,0,16.5,0.8,1.6,0.2,19,21,2.7,0.78,,21.1,7.1,"46,XX[20]",360,84.4,Normal,43,"partial CD13, CD33, dim/partial CD56, CD58, dim CD117, CD123 and MPO",5.7,30.54,FALSE,FALSE,,positive,positive
15-00734,BA2226,2293,Female,Female,White,1,n,53,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,53,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,SWOG S1203 (7+3 +/- Vorinostat),1,Induction,Complete Response,Standard Chemotherapy,153,Standard Chemotherapy,SWOG S1203 (7+3 +/- Vorinostat),Induction,153,Alive,Alive,FALSE,FALSE,,0,0,93,80,0,1.7,19.3,20.2,13.2,0.6,47,37,3.1,0.79,M5,26.8,8.8,"46,XX[20]",977,92.1,Normal,36,"Blast immunophenotype: partial CD11b, CD13, CD33, CD38, CD58, partial CD64, partial CD117 and a subset with MPO - Blast/promonocyte immunophenotype: CD11b, CD13, partial CD14, CD15, CD33, CD38, CD58 and CD64",6,42.34,FALSE,FALSE,,negative,positive
16-01151,BA2984,4248,Male,Male,White,1,n,81,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,81,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Vidaza, BI836858 (anti-CD33)",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Vidaza, BI836858 (anti-CD33)",Induction,-1,Alive,Alive,TRUE,FALSE,16-01150,0,0,,80,0,7,7.8,0,6.9,0.5,31,42,3.2,1.3,,25.1,8.8,"46,XY[19]",665,85.1,Normal,16,"dim CD13, CD33, CD38, CD58, dim CD64, CD71, dim CD117 and CD123-positive",7.2,33.81,TRUE,FALSE,16-01150,negative,positive
16-00406,BA2528,2675,Male,Male,White,1,n,75,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",75,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,3,"Vidaza|7+3 (Cytarabine, Idarubicin)|Azacitidine",3,Induction|Frontline|Re-induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,Vidaza,Re-induction,-1,Alive,Alive,FALSE,FALSE,,0,0,23,,1,,51,11.2,36.8,,23,16,3.4,0.55,,27.1,9.1,"46,XY[19]",178,88,Normal,28,"CD13, CD33, CD34, CD38, CD117, CD123, dim HLA-DR, TdT, and MPO positive",6.4,1,FALSE,FALSE,,negative,negative
13-00354,BA2645,1163,Male,Male,Asian,4,n,73,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,73,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Decitabine|Stanford Protocol 9153 (TLI, ATG)",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Stanford Protocol 9153 (TLI, ATG)",Allogeneic - Mismatched Unrelated Donor,-1,Dead,Dead-Other,FALSE,FALSE,,0,,84,71,,,,6,,,,,,,,,,"46,XY[20]",,,,,""" CD4(subset), CD11c(partial), CD13(partial), CD14(partial), CD15(partial), CD33(subset), CD34(subset), CD38, CD64(subset), CD117(subset), HLA-DR and MPO""",,16.2,FALSE,FALSE,,negative,negative
13-00659,BA2023,1397,Male,Male,White,1,n,55,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,55,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide",4,Allogeneic - Sibling|Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,5,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Dead,Dead-Unknown,FALSE,FALSE,,0,0,54,54,0,,14,59.6,5.3,0,463,477,2.7,1.14,M4,19.3,6.6,"47,XY,+8[16]/46,XY[4]",,93.7,Trisomy 8,47,"partial CD13, CD15,  CD33, CD56, CD38, CD58, CD64, dimCD123, HLA-DR and MPO positive",5.7,16.66,FALSE,FALSE,,negative,negative
12-00023,BA2409,550,Female,Female,White,1,n,71,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,71,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",4,Allogeneic - Sibling|Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,7,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Sibling,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0,68,,1,,30,49,3,,14,18,3,0.85,M5,21.9,7.6,"46,XX[20]",313,102.9,Normal,125,"Blast Immunphenotype: CD13, CD33, CD34, CD38, dim CD45, CD117, CD123, and HLA-DR positive; Promonocyte Immunophenotype: CD11b, CD13, CD14, CD33, CD64, and HLA-DR",5.5,14.9,FALSE,FALSE,,negative,negative
14-00632,BA2081,1761,Female,Female,White,1,n,64,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,64,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,6,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |R-CHOP (Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine)",4,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)",Induction,3,Alive,Alive,FALSE,FALSE,,0,0,90,30,0,0,37.5,27.7,0,2.6,37,31,1.8,0.52,M4,23.5,7.7,"46,XX,del(17)(q25)[3]/46,sl,del(3)(q12q21)[cp17]",452,94.4,,56,"dim CD4, partial variable CD7, CD13, CD33, partial CD34, CD38, partial CD58, CD117, CD123, HLA-DR, TDT and partial MPO positive.",6.2,6.44,FALSE,FALSE,,negative,negative
16-01005,BA2361,4196,Female,Female,White,5,n,55,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,55,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin) plus Enasidenib|Busulfan, Cyclophosphamide",2,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,0,1,30,0,0,,31,4,6.8,,10,11,4.3,,,32.4,9.9,"46,XX,del(5)(q22q35)[2]/46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.2)[14]/46,XX[3]",,,Probe: 8 centromere/20q12,83,Negative,7.2,10.6,FALSE,FALSE,,negative,negative
12-00211,BA2865,764,Female,Female,White,1,n,50,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,50,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|HiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,27,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,0,0,90,82,0,,1,0,2,,19,30,2.8,0.86,,26.4,9.1,"46,XX,t(11;17)(q13;q21)[20]",1165,97.7,"While the chromosome 17 breakpoint is clearly within band 17q21 by metaphase chromosome analysis, these results suggest that it is not within the RARA gene",8,"dim CD4, CD13, dim CD15, dim CD33, CD38, CD58,CD64, CD117, CD123, dim HLA-DR, and cMPO",5.3,84.1,FALSE,FALSE,,negative,positive
14-00578,BA2962,1730,Male,Male,White,1,n,75,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,IntermediateOrAdverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,75,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Fludarabine, TBI|Decitabine",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, TBI",Allogeneic - Mismatched Unrelated Donor,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0,90,,0,0,6,2.6,0,0.1,18,49,2.6,0.94,M5,26.8,9.1,"46,XY[20]",1173,105.5,Normal,45,"dim partial CD11b, dim variable CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, CD123, HLA-DR, partial TdT, dim MPO positive",6.8,98.9,FALSE,FALSE,,positive,negative
13-00396,BA2546,1187,Male,Male,White,1,n,63,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,Decitabine,Consolidation,-1,Dead,Dead-Treatment,FALSE,FALSE,,-2,1.8,51,3.5,0.9,,41.2,37.7,11.4,0,20,20,3.2,1.37,M4,33.7,11,"42~45,XY,del(4)(q31q35),del(5)(q13q35),add(9)(q21),add(13)(p11.2),-16,-21[cp15]/40~46,sl,+9,-add(9)(q21),-15,+der(16)t(15;16)(q11.1;p13.3),-18,+mar[cp5]",,92.6,Extra MLL signal,24,"CD13, CD33, CD34, CD56, CD58, dim CD64, CD117 and partial HLA-DR.",7.1,5.23,FALSE,FALSE,,negative,negative
16-00278,BA2813,2597,Male,Male,White,5,n,64,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,64,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,41,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, Thiotepa, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1,Alive,Alive,FALSE,FALSE,,0,0,83,74,0,,13,0,13,,15,45,4,1.27,,25.2,8.7,"46,XY[20]",,,Normal,39,Positive,6,53.3,FALSE,FALSE,,positive,positive
14-00096,BA2808,1464,Male,Male,White,4,n,56,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,56,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Induction|Re-induction,Complete Response,Standard Chemotherapy,27,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Dead,Dead-Unknown,TRUE,FALSE,14-00098,0,,72,88,,,,1,,,,,,,,,,"40~43,XY,add(1)(p36),-2,-4,-5,-8,-12,-14,-15,-16,-17,?add(17)(p13),der(19)?t(8;19)(q11.2;p13),-20,-22,+7mar[cp18]",,,,,"CD34, CD38 (dim), CD13, CD33 (dim),CD64 (partial), CD11c, CD4 (partial), CD15, CD117, HLA-DR, and MPO(partial).",,12.9,TRUE,FALSE,14-00098,positive,negative
15-00900,BA2658,2420,Male,Male,White,1,n,24,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,24,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Decitabine|Busulfan, Cyclophosphamide",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Refractory,Standard Chemotherapy,7,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Mismatched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,0,,,1.8,0.9,23.9,23,7.9,0,37,28,3.7,0.95,,32.3,11.3,"46,XY[20]",243,92.8,Normal,102,,7.1,21.84,FALSE,FALSE,,negative,negative
14-00034,BA2156,1431,Male,Male,White,1,y,55,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,55,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Busulfan, Cyclophosphamide",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,0,50,25,0,,45.3,19.6,9.3,6,27,20,3.7,1.01,,30.6,10.1,"46,XY[20]",,98.4,Normal,15,"CD7, CD13, CD33, CD34, CD38, CD64, CD123, HLA-DR, and MPO",6.3,3.85,FALSE,FALSE,,negative,negative
14-00588,BA2688,1737,Female,Female,White,2,n,53,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute erythroid leukaemia,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute erythroid leukaemia,53,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin|Fludarabine, Cyclophosphamide, TBI ",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Allogeneic - Matched Unrelated Donor,-1,Dead,Dead-Treatment,FALSE,FALSE,,-1,0,9,4,0,,61,10,22,,14,40,3.3,0.65,,22.1,7.4,"46,XX,del(9)(q22q34)[20].",,93.4,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",38,"CD34 (partial +), CD2(partial dim +), CD13(dim +), CD33(variably to bright +), CD25(-), CD38(+), CD45(moderately +), CD15 (partial +), CD117(+), CD123(dim +), HLA-DR(partial +), MPO(+), TdT(-), other myeloid and lymphoid antigens (-)",5.8,2.1,FALSE,FALSE,,negative,negative
15-00237,BA2932,2028,Female,Female,White,1,n,29,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",IntermediateOrAdverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",29,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide|Transplant",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,24,Bone Marrow Transplant,Transplant,Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,0,95,78,0.9,0,11.7,0,13.5,1.8,20,25,3,0.54,,23,7.9,"46,XX[20]",1119,95.8,Normal,12,"dim CD2, dim CD7, CD13, dim CD19, dim CD20,      CD33, partial CD34, variable CD38, dim CD64, CD117, CD123, and HLA-DR      positive.",6.1,68.79,FALSE,FALSE,,positive,negative
14-00667,BA2044,1783,Male,Male,White,1,n,57,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,57,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, TBI",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,371,Bone Marrow Transplant,"Fludarabine, Melphalan, TBI",Allogeneic - Sibling,-1,Dead,Dead-Treatment,FALSE,FALSE,,-1,0.3,,,0,0.6,32.6,14.7,51.8,0,82,52,3.4,0.78,,29.6,10.1,"46,XY[20]",160,93.7,Normal,91,"CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+",7.5,3.53,FALSE,FALSE,,negative,negative
16-00303,BA2746,2611,Female,Female,HispNative,5,n,56,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,56,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI",4,Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,27,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Salvage,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0,1.5,2,0,,23,57,13,,67,33,3,1.87,,29,9.5,"46,XX[19]",,,Normal,28,Positive,7.5,58.7,FALSE,FALSE,,positive,positive
14-00567,BA2387,1723,Female,Female,White,1,n,71,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,71,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Mismatched Unrelated Donor,-1,Dead,Dead-Treatment,FALSE,FALSE,,-3,0,,,0,0,6.7,5.1,0,0.1,20,20,2.6,0.62,M5,21.4,7,"46,XX,idic(7)(q11.2)[20]",373,93.9,,19,"CD11b, CD13, CD33, partial CD34,      CD38, CD58, CD64, CD117, CD123, partial HLA-DR and cMPO positive",5.8,78.71,FALSE,FALSE,,negative,negative
14-00658,BA2893,1775,Female,Female,White,3,n,59,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Azacitidine, Sorafenib|Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Azacitidine, Sorafenib",Hypomethylating/Low Dose Cytarabine,-1,Dead,Dead-Disease,FALSE,FALSE,,-1,,51.5,72,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,"Large population of CD117 positive myeloblasts (predominantly CD34 negative, HLA-DR negative), representing approximately 71% of the leukocytes consistent with acute myeloid leukemia.",,89.17,FALSE,FALSE,,positive,positive
14-00725,BA2041,1814,Female,Female,White,2,n,32,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",32,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,Bu/Cy/ATG,Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,0,24,2,2,,54,0,44,,10,22,4.4,0.49,,25.9,9,"47,XX,+8[13]/46,XX[7].",125,97.1,"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[197],(D8Z2x3,D20S108x2)[101/200], (RUNX1T1x3,RUNX1x2)[91/200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[188], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]",67,"CD2(-), CD4(dim +), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD41(-), CD45(+), CD56(-), CD64(-), CD71(+), CD117(+), CD123(+), GLy-A(-), HLA-DR(partial + and variable), TdT(-), MPO(+).",7.1,1.4,FALSE,FALSE,,negative,negative
14-00537,BA2350,1708,Male,Male,HispNative,2,n,17,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",17,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,n,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Bu/Cy/ATG|ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC + Midostaurin|Etoposide, Cytarabine",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Unknown,Standard Chemotherapy,-1,Bone Marrow Transplant,Bu/Cy/ATG,Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,-3,,,,,,,,,,,,,,,,,"46,XY,t(11;19)(q23;p13.1)[19]/46,XY[1]",,,,,,,,FALSE,FALSE,,negative,negative
16-01210,BA2644,4263,Male,Male,White,3,n,63,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC",3,Consolidation|Induction|Allogeneic - Child,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Child,-1,Alive,Alive,FALSE,FALSE,,-17,,26.3,12,,,,,,,,,,,,,,"46,XY[11] ",,,Normal,69,,,9.28,FALSE,FALSE,,negative,negative
16-01216,BA2011,4263,Male,Male,White,3,n,63,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,1,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC",3,Consolidation|Induction|Allogeneic - Child,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Child,-1,Alive,Alive,TRUE,TRUE,16-01210,-18,,,,,,,,,,,,,,,,,"46,XY[11] ",,,Normal,,,,,TRUE,TRUE,16-01210,negative,negative
13-00232,BA2861,1101,Female,Female,White,1,n,22,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,22,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,0,55,29,2,,7,33,24,,67,16,2.2,0.64,M4,24,8,"46,XX[24]",373,95.2,normal,34,"CD7, CD13, CD33, CD34, CD38, CD56, partial CD64,     CD117,        dim CD123, HLA-DR and MPO+",6.5,29.4,FALSE,FALSE,,negative,negative
14-00690,BA2054,1800,Female,Female,White,3,n,49,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,49,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,-1,,54,3,,,,,,,,,,,M5,,,"46,XX,del(17)(p11.2)[15]/46,XX[5]",,,consistent with karyotype (68% del 17p13),,"Most of the atypical cells (data not shown) are myeloid blasts that express CD117, partial CD7 (about 30% positive), CD13, CD33, HLA-DR, weak CD4, and partial CD15 (about 50% positive), but do not express CD34, CD14(MO2), or CD64.",,,FALSE,FALSE,,negative,positive
15-00724,BA2020,2287,Male,Male,HispNative,3,n,51,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,51,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Allogeneic - Sibling|Consolidation|Induction,Refractory,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,0,,51,54,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,"CD13, partial CD15, CD33, CD117,  myeloperoxidase, and partial HLA-DR",,12,FALSE,FALSE,,positive,positive
15-00615,BA2000,2235,Female,Female,Asian,3,n,24,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,24,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,6,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)",5,Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,-1,Dead,Dead-Disease,FALSE,FALSE,,-3,,,,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,,,,FALSE,FALSE,,positive,negative
16-00951,BA2584,4075,Male,Male,White,3,n,42,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,42,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)",4,Allogeneic - Sibling|Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,-3,,,,,,,,,,,,,,,,,"45,XY,t(3;17)([21;q11.2),add(4)(q21),add(5)(p15),ins(10;11)(p12;q23q13),der(12;18)(q10;q10)[19]/46,XY[1]",,,11q23 rearrangement involving the  KMT2A (MLL) locus in 184/200 (92.0 percent) cells scored,,,,,FALSE,FALSE,,negative,negative
13-00165,BA3006,1060,Female,Female,White,3,n,33,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,33,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)",4,Allogeneic - Sibling|Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,-1,Dead,Dead-Treatment,FALSE,FALSE,,-2,,,,,,,,,,,,,,,,,"46,XX[7]",,,,,,,,FALSE,FALSE,,positive,positive
16-01121,BA2563,4239,Male,Male,White,3,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|IDAC plus Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Sorafenib",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,,86,89,,,,,,,,,,,,,,"46,XY[20]",,,Normal,57,,,115.15,FALSE,FALSE,,positive,positive
13-00563,BA2600,1343,Female,Female,White,4,n,64,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Fludarabine, BCNU, Melphalan|Decitabine, Midostaurin",2,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,249,Bone Marrow Transplant,"Fludarabine, BCNU, Melphalan",Allogeneic - Sibling,-1,Alive,Alive,TRUE,FALSE,13-00562,-2,,,,,,,,,,,,,,,,,"46,XX,t(2;3)(p13;q25~26)[2]/46,idem,i(14)(q10)[18]",,,,,,,,TRUE,FALSE,13-00562,positive,negative
15-00616,BA2425,2236,Female,Female,White,1,n,68,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,68,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1,Dead,Dead-Disease,FALSE,FALSE,,-14,2.6,,49,5.1,6.8,36.8,0.9,14.5,0.2,18,16,2.8,0.67,,21.9,7.5,"43-45,XX,del(5)(q16q33),der(7)t(7;12)(q11.1;q12)ins(7;?)(q11.1;?),-12,der(21;22)(q10;q10),+mar[cp20]/46,XX[1]",821,88.7,,8,"CD13, CD33, CD34, CD71, CD117, dimCD123, HLA-DR, and dim CD 64 positive",7.2,11.01,FALSE,FALSE,,negative,negative
15-00670,BA2035,2265,Male,Male,White,1,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",IntermediateOrAdverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",61,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea",4,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,-1,0,92,98,0,0.8,2.6,0,0,0.1,35,23,3.2,0.86,,19.9,6.8,"46,XY[7]",330,106.4,Normal,49,"dim CD33, CD34, CD38, dim CD45, CD117, and MPO",8,84.96,FALSE,FALSE,,positive,negative
16-00815,BA2778,4030,Female,Female,White,1,n,60,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea",4,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Complete Response,Standard Chemotherapy,18,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,-1,0,75,44,0,0.9,28.7,46.1,24.3,0,18,13,2.9,1.19,M5,26.4,8.8,"46,XX[20]",222,96.4,Normal,175,Positive,6.9,34.6,FALSE,FALSE,,negative,positive
14-00259,BA2110,1546,Female,Female,White,1,n,65,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Fludarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC",4,Consolidation|Salvage|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,Fludarabine,Consolidation,4,Dead,Dead-Disease,FALSE,FALSE,,0,0.1,70,,0.1,1.7,8.3,85.2,4.6,0.2,16,13,2.7,0.87,M4,30.4,9.6,"46,XX[20]",506,101.7,Normal,112,"CD11b, partial CD13, partial CD14, dim CD15, partial      CD16, CD33, CD38, CD58, CD64, partial CD123 and HLA-DR positive",7.4,58.86,FALSE,FALSE,,positive,positive
13-00602,BA2731,1370,Male,Male,White,2,y,63,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,-2,,,85,0,,9,3,3,,16,27,2.9,0.75,,,,"46,XY,del(11)(q14q23)[13]/46,XY[7].ishdel(11)(5'MLL-,3'MLL+)[2].",682,,"nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(5'MLLx1,3'MLLx2)(5'MLL con 3'MLLx1)[118/200]",,,6.6,33,FALSE,FALSE,,negative,negative
14-00092,BA2603,1461,Female,Female,White,1,n,63,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,63,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,1.7,13,14,0.8,,9.4,28.2,49.6,1.6,18,26,2.8,0.74,M4,21.2,7.3,"46,XX[20]",514,101.4,Normal,57,"CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive",6.1,63.75,FALSE,FALSE,,negative,positive
12-00051,BA3037,635,Female,Female,White,1,n,55,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,55,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,7,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0,88,93,0,,6,0,1,,19,26,3.4,0.88,,28.2,9.6,"46,XX[20]",678,99.9,Normal,19,"partial CD7, CD13, CD25, CD33, partial CD34, dim CD45, CD117, CD123, and partial HLA-DR positive",6.8,17.9,FALSE,FALSE,,positive,positive
13-00273,BA3043,1126,Female,Male,White,1,n,51,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,51,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,n,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",4,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Re-induction,3,Dead,Dead-Disease,FALSE,FALSE,,-2,2,,,0,,14,13,68,,31,20,3.1,0.95,,24.7,8.2,"46,XX[20]",,86.2,Normal,99,,6.8,21.7,FALSE,FALSE,,positive,positive
14-00787,BA2718,1848,Male,Male,White,1,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,0,0,90,90.5,0,0,8.2,2.2,0.9,0.8,22,43,3.1,1.21,M1,17.3,5.2,"46,XY[20]",1873,96.1,Normal,34,"CD7, CD13, CD33, CD34, CD117, HLA-DR, cMPO (+)",6.9,427.46,FALSE,FALSE,,negative,negative
16-00810,BA2098,4028,Female,Female,White,1,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,0,83,11.5,1.8,1.8,13.3,63.7,7.9,0.1,69,35,3,0.87,M5,34.7,11.6,"46,XX[20]",337,95.6,Normal,146,Positive,6.1,44.83,FALSE,FALSE,,negative,positive
15-00680,BA2201,2272,Male,Male,White,1,n,68,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,23,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,0.9,86,74.8,0,0,2.6,20.8,0.9,0.2,20,28,2.9,1.49,M5,33,10.8,"46,XY[20]",1211,95.9,Normal,83,"Variable CD13, variable CD14, CD33, variable CD64, CD117, CD123, and partial HLA-DR positive",7.2,134.36,FALSE,FALSE,,positive,positive
16-00519,BA2184,2713,Male,Male,White,1,n,47,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,47,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Bone Marrow Transplant,"Cyclophosphamide, Fludarabine, TBI",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,0,0,,72.9,0,0,20.3,3.4,3.4,6.9,49,21,3.5,1.08,,42.6,15,"46,XY[20]",353,86.8,Normal,34,"CD7, CD13, CD33, CD34, CD38, CD58, CD117, dim CD123 HLA-DR and MPO+ ,",7.4,8.98,FALSE,FALSE,,negative,negative
16-00525,BA3009,2715,Female,Female,Asian,1,n,26,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,26,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",4,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,"Cyclophosphamide, Fludarabine, TBI",Allogeneic - Mismatched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,0,95,40.2,0,0,45.5,9.8,4.5,0.2,32,58,3.1,0.69,,22.3,7.4,"46,XX,r(2)(p23q31),der(4)t(4;16)(q21;q12-13)del(16)(q22q22),der(16)t(4;16)(q21;q12-13),add(18)(p11.2),del(20)(q13.2)[16]/46,XX[4]",,97.8,"CBFB: 88% of cells were missing a signal for CBFB, consistent withdeletion associated with the unbalanced t(4;16) seen on chromosome analysis. No evidence for disruption. This probe will be useful in following this abnormal clone.",154,"CD13, partial CD15, CD34, CD38, partial CD56, CD58, partial CD117 and CD123+",5.8,9.27,FALSE,FALSE,,negative,negative
16-00027,BA2399,2473,Male,Male,AdmixedWhite,2,n,55,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",55,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI |7+3 (Cytarabine, Idarubicin) plus Crenolanib",4,Consolidation|Induction|Allogeneic - Child|Maintenance,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,Cyclophosphamide,Maintenance,1,Alive,Alive,FALSE,FALSE,,0,0,91,99.2,0,,0.8,0,0,,33,27,3,0.85,,18.8,6.2,"46,XY[29]",808,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",28,"CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(dim +), CD14(-), CD15(-/few dim +), CD16(-), CD33(+), CD34 (partial +), CD36(equivocal/small subset appears +), CD38(partial +), CD45(+), CD56(-), CD64(-/few dim +), CD117(+), HLA-DR(+ and variable), TDT(-), MPO(+)",6.1,181.08,FALSE,FALSE,,positive,negative
15-00610,BA2559,2233,Female,Female,White,5,n,42,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,42,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, TBI ",3,Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),Refractory,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Double Umbilical Cord Blood Transplant (DUCBT),-1,Alive,Alive,FALSE,FALSE,,0,,35,2,,,,,,,,,,,,,,"46,XX[20]",,,Normal,35,"The immature cells were positive for CD13, CD33, and many showed aberrant expression of CD7. The myeloblast portion was positive for CD34, CD117, and HLA-DR.  The immature monocyte portion was negative for CD34 and CD117, and expressed variable CD64 (including some cells with bright CD64), CD11b, an",,49.7,FALSE,FALSE,,positive,negative
15-00614,BA2093,2234,Male,Male,White,1,n,51,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,51,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,HiDAC|SWOG S1203 (7+3 +/- Vorinostat)|Bu/Cy/TBI,4,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,Bu/Cy/TBI,Allogeneic - Mismatched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,0,,,0,0,85.8,1.9,8.5,0,25,25,3,0.93,M0,25.1,8.2,"60~61<3n>,XYY,-1,-2,-3,-4,-5,del(5)(q13q33),-6,-7,+8,-9,+11,-12,+13,-15,-16,-17,-18,+21,+22[cp15]/70~73,idem,+Y,+1,+2,+5,+del(5)(q13q33),+6,+9,+11,+12,+20,+20[cp4]/46,XY[1]",634,81.8,"EGR-1/ D5S23, D5S721: 60/100 cells (60%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the first clone, above; 38 cells (38%) had a 2 red/ 4 green signal pattern, consistent with two copies of the deleted 5q in the second clone.",77,,6.5,0.5,FALSE,FALSE,,negative,negative
13-00625,BA2816,1378,Male,Male,White,4,n,21,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,21,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Bone Marrow Transplant,2,"SWOG S1203 (7+3 +/- Vorinostat)|Fludarabine, Cyclophosphamide, TBI ",2,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,177,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,0,,66,1,,,,17,,,,,,,M1,,,"45,XY,-7[6]/47,XY,+13[cp5]/46,XY[12]",,,,,"CD34, CD4, CD13, CD15, partial CD33, CD38, partial CD117, partial CD11c, HLA-DR, MPO and TdT",,2.1,FALSE,FALSE,,negative,negative
15-00279,BA2139,2087,Female,Female,White,3,n,48,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,48,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|TBI, VP-16",4,Consolidation|Induction|CNS|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"TBI, VP-16",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,TRUE,FALSE,15-00278;15-00322,0,,86,77,,,,,,,,,,,M5b,,,"46,XX",,,,,"Large population of atypical monocytic cells (weaker than  normal CD33, partial loss of CD13) including  promonocytes/monoblasts representing approximately 50% of  the leukocytes suggestive of acute monoblastic or monocytic  leukemia.",,81,TRUE,FALSE,15-00278;15-00322,positive,positive
15-00563,BA2031,2204,Female,Female,White,1,n,2,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,2,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide",3,Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,136,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,0,80,52.2,0,1.8,46,0,0,0.2,22,53,,0.24,M1,22,6.9,"46,XX,t(6;11)(q27;q23)[19]/46,XX[1]",,92.8,,40,"CD4, CD11b, variable CD13, CD15, CD33, variable CD56, CD58, CD64, lysozyme, and dim HLA-DR positive",,57.08,FALSE,FALSE,,negative,negative
16-00465,BA2272,2690,Male,Male,HispNative,1,n,12,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,12,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"Cytarabine|Sorafenib|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide",3,Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Refractory,Intrathecal,0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Mismatched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,1,0,70,85,0,1.8,14.7,51.4,8.3,50,28,150,3.7,0.64,M4,14.3,4.6,"47,XY,+8[19]/46,XY[1]",,132.4,RUNX1T1 signal consistent with the trisomy 8 clone ,49,"dimCD11b, dimCD13, CD14, dimCD33, CD64, variable CD123, HLA-DR CD13,dimCD33, dim variable CD34, CD117, CD123, HLA-DR",7.1,214.49,FALSE,FALSE,,positive,negative
15-00578,BA2066,2214,Female,Female,White,1,n,62,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Other,4,"3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea|Fludarabine, Melphalan, TBI, ATG",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Child,Complete Response,Standard Chemotherapy,7,Bone Marrow Transplant,"Fludarabine, Melphalan, TBI, ATG",Allogeneic - Child,-1,Alive,Alive,FALSE,FALSE,,0,0,95,67.25,0,0,9.5,23.3,0,0.1,54,57,3.3,0.78,M5,27.4,9.1,"46,XX,t(1;11)(p36.1;q23),add(9)(p22)[13]/46,sl,del(2)(p21p23),del(20)(q11.2-13.1)[4]/46,sl,add(12)(p11.2)[2]",861,93.2,"MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia",26,"CD4, partial CD11b, CD15, CD33, CD38, moderate CD45, partial CD56, CD64, CD123, partial CD117, and HLA-DR",6.8,87.72,FALSE,FALSE,,negative,negative
16-00373,BA2545,2653,Male,Male,White,1,n,37,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,37,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,3,Standard Chemotherapy|Bone Marrow Transplant|Other,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Radiation|Busulfan, Cyclophosphamide",4,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Supportive/Palliative Care,Unknown,Standard Chemotherapy,24,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Mismatched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,1.1,1,0,2.8,0.2,30.3,5.2,60.4,0,34,20,4.2,0.93,,39.2,14.4,"46,XY[20]",154,94.9,Normal,162,"dim/partial CD1a, dimCD4, dimCD5, CD33, CD43, dimCD45, CD56, CD68, CD117, and lysozyme positive with Ki67 activity >90%.",7.5,5.35,FALSE,FALSE,,negative,negative
15-00872,BA2662,2367,Female,Female,White,1,n,65,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Other,4,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea",4,Consolidation|Unknown|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,0,74,60,1.9,15.1,21.7,50,11.3,0,23,32,2.6,0.78,,21.6,7.2,"46,XX[20]",905,100.5,Normal,150,"partial variable CD7, subset CD11b (75%), CD13, CD33, partial CD14 (30%), partial CD64 (70%), CD38, CD58, partial CD117 (30%), CD123, HLA-DR, and partial (50%) MPO positive",6.7,84.69,FALSE,FALSE,,positive,positive
16-00067,BA2311,2496,Female,Female,HispNative,2,n,53,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,53,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI ",4,Consolidation|Induction|Allogeneic - Child|Maintenance,Complete Response,Standard Chemotherapy,-1,Supportive/Palliative Care,Cyclophosphamide,Maintenance,1,Alive,Alive,FALSE,FALSE,,-1,0,20,8,0,,37,20,30,,18,23,3.3,0.86,,20,6.2,"46,XX[20]",426,105.3,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",38,"CD34(+), CD13(dim +), CD15(partial +), CD33(dim to partial +), CD34(+), CD38(variably +), CD45(dim +), CD56(-), CD64 (small subset +), CD117(+), HLA-DR(partial +), other myeloid and lymphoid antigens(-).",7,6.63,FALSE,FALSE,,negative,negative
13-00384,BA2876,1181,Female,Female,White,4,n,71,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,3,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,3,"Cytarabine|Azacitidine|Stanford Protocol 9153 (TLI, ATG)",3,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,,,,Standard Chemotherapy,Cytarabine,Supportive/Palliative Care,9,Dead,Dead-Disease,TRUE,TRUE,13-00383,0,,34,8,,,,15,,,,,,,,,,"46,XX,t(8;19)(q24;q13),del(11)?(q14q23)[19]/46,XX[1]",,,,,"CD34, CD117, CD38, DIM CD13, CD33, HLA-DR, AND PARTIAL CD7",,4.2,TRUE,TRUE,13-00383,negative,negative
15-00979,BA2521,2455,Female,Female,White,1,n,44,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,44,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6,"Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea|Busulfan, Cyclophosphamide|7+3 (Cytarabine, Idarubicin) plus Dasatinib ",5,Allogeneic - Sibling|Induction|Experimental|Re-induction|Post-Transplant Relapse,Complete Response i,Standard Chemotherapy,28,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0,75,80,0,7.7,10.3,22.2,6.8,0,21,25,2.4,1.25,,22.9,7.4,"46,XX[20]",705,96.2,Normal,42,"CD13, CD33, subset CD34, variable CD117, CD123, HLA-DR, and variable MPO positive - Monocytic/blast equivalent immunophenotype: CD11b, CD13, subset CD14, variable CD16, CD33, CD64, dim CD123, and HLA-DR positive",6.2,69.84,FALSE,FALSE,,positive,positive
16-00271,BA2762,2594,Female,Female,White,2,n,22,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,22,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),3,"Fludarabine, Melphalan|Crenolanib|7+3 (Cytarabine, Idarubicin) plus Crenolanib",3,Allogeneic - Sibling|Induction|Experimental,Complete Response,Standard Chemotherapy,39,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,-1,0,63,42,0,,32.7,4.4,26.6,,27,39,3.1,0.68,,19.3,6,"46,XX[20]",,,"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[200]",176,"CD2(-), CD4(partial dim +), CD7(variably +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +).",6.3,22.01,FALSE,FALSE,,positive,positive
16-00143,BA2866,2532,Male,Male,HispNative,4,n,58,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,58,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),4,"Sorafenib|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Induction|Experimental,Refractory,Standard Chemotherapy,1,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,-1,,57,24,,,,,,,,,,,M2,,,"47,XY,t(8;22)(p11.2;q11.2),+19[20]",,,"t(8;22) clone observed, consistent with a neoplastic process ",,Positive,,100.2,FALSE,FALSE,,negative,negative
15-00479,BA2510,2167,Male,Male,White,5,n,65,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,65,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,4,"7+3 (Cytarabine, Idarubicin)|Azacitidine|Fludarabine, Cyclophosphamide, TBI |Venetoclax (ABT-199)",4,Hypomethylating/Low Dose Cytarabine|Experimental|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),,,,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Double Umbilical Cord Blood Transplant (DUCBT),-1,Dead,Dead-Disease,TRUE,FALSE,15-00478,-1,,95,62,,,,,,,,,,,,,,"48,XY,+8,der(11)t(11;?)(q23;?),+21[19]/46,XY[1]",,,Gain of 8q22 and 21q22 (88%),33,"positive for CD11b, CD13, CD33, CD38, dim CD45, dim CD56, CD64, and HLA-DR",,19.8,TRUE,FALSE,15-00478,negative,negative
13-00393,BA2357,1184,Male,Male,HispNative,2,n,52,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,52,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG",5,Consolidation|Salvage|Induction|Experimental|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,15,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG",Allogeneic - Matched Unrelated Donor,-1,Dead,Dead-Disease,FALSE,FALSE,,0,,21,5,,,68,4,23,,17,23,3.6,0.89,,28.3,8.5,"89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]",183,,"nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]",22,"partialCD4, partialCD15, dimCD33, CD34, CD38, dimCD45, CD117, HLA-DR, TdT, MPO",7.5,3.42,FALSE,FALSE,,negative,negative
15-00693,BA2955,2279,Female,Female,White,1,n,66,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",66,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,4,"Bortezomib|3+7 (Cytarabine, Daunorubicin)|MiDAC|Fludarabine, Cytarabine",4,Allogeneic - Sibling|Consolidation|Induction|Experimental,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Cytarabine",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,0,0,60,,0,0.9,29.8,54.4,1.8,0.5,23,19,2.5,0.84,,24.2,7.7,"47,XX,+6[6]/46,XX[19]",453,104.8,"IGH/MAF: 74/100 cells (74%) had variant abnormal 0-1 red/ 1-4 green/ 2-7 yellow signal patterns reflecting IGH/MAF fusion. The majority of cells (56%) were 0 red/ 1 green/ 3 yellow. IGH: 68/100 (68%) cells scored had signal patterns consistent with IGH rearrangement and the 14;16 translocation,above",92,"dimCD4, CD11b, CD13, dimCD14, CD33, CD56, CD58, CD64, dimCD123 and HLA-DR positive; Minor subset of blasts with immunophenotype: CD13, CD33, CD34, CD58, CD117, dimCD123, HLA-DR and MPO positive.",7.4,14.94,FALSE,FALSE,,positive,negative
14-00739,BA2541,1820,Male,Male,White,1,n,39,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",39,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Intrathecal,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Methotrexate",3,Induction|CNS|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,4,Dead,Dead-Disease,FALSE,FALSE,,0,0,,,0,0,28.3,17.7,3.5,0,19,14,3,0.97,,31.1,10.7,"46,XY,t(6;11)(q27;q23)[20]",,98.4,MLL: 80% of cells had a split signal pattern consistent with the disruption of MLL due to the t(6;11).,31,,6.2,21.12,FALSE,FALSE,,negative,negative
15-00855,BA2271,2360,Male,Male,HispNative,1,n,8,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid leukaemia associated with Down syndrome,Favorable,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid leukaemia associated with Down syndrome,8,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Intrathecal,2,"ADE (Cytarabine, Daunorubicin & Etoposide)|Cytarabine",2,Induction|CNS,Complete Response,Standard Chemotherapy,151,Intrathecal,Cytarabine,CNS,151,Alive,Alive,FALSE,FALSE,,-2,10.8,,,0,1.8,8.1,13.5,8.1,0,13,25,3.2,0.72,,26.8,9.3,"47,XY,+21c[20]",,90.5,RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis.,40,,8.2,67.53,FALSE,FALSE,,negative,positive
15-00556,BA2675,2202,Male,Male,White,1,n,10,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,IntermediateOrAdverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,10,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Intrathecal|Other,3,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|MiDAC",2,Induction|Re-induction,Refractory,Intrathecal,10,Standard Chemotherapy,MiDAC,Re-induction,31,Alive,Alive,FALSE,FALSE,,1,0,75,86,0,0,7.5,1.8,4.7,0.1,13,23,3.6,0.47,,21.6,6.9,"46,XY[20]",970,96,,42,"variable CD7, dim CD11b, CD13, CD33, partial CD34, dim CD64, CD117, CD123, HLA-DR, and dim MPO positive",7.8,133.63,FALSE,FALSE,,positive,negative
15-00276,BA2714,2059,Male,Male,White,1,n,60,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Other,3,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)",3,Salvage|Induction|Re-induction,Complete Response,Other,167,Standard Chemotherapy,Azacitidine,Salvage,6,Dead,Dead-Unknown,FALSE,FALSE,,0,0,90,39.6,1,4,47,10,1,0.1,30,26,2.4,1.17,M4,14,4.6,"46,XY[20]",612,104.5,Normal,80,"dim CD4, dim CD7, dim CD11b,      CD13, CD33, variable CD34, CD38, CD58, variable CD64, CD117, CD123, dim HLA-DR, MPO, and dim TdT",5.8,70.84,FALSE,FALSE,,negative,positive
16-00460,BA2926,2688,Male,Male,White,3,n,58,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",58,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine",3,Salvage|Induction|Symptom Control,Refractory,Standard Chemotherapy,10,Supportive/Palliative Care,Azacitidine,Symptom Control,-1,Dead,Dead-Disease,FALSE,FALSE,,-3,,,,,,,,,,,,,,,,,"[46,XY]",,,Normal,,,,4.17,FALSE,FALSE,,negative,negative
15-00261,BA2660,2052,Female,Female,White,1,n,43,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,43,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6,Supportive/Palliative Care,Cytarabine,Supportive/Palliative Care,125,Dead,Dead-Disease,FALSE,FALSE,,0,0,,,0,0,31.9,12.4,2.6,0.1,26,16,3,0.77,M4,22.1,7.5,"46,XY[20]",297,95.7,Normal,59,,6.5,22.95,FALSE,FALSE,,positive,negative
16-01049,BA2472,4207,Male,Male,Asian,2,n,78,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",78,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Decitabine|7+3 (Cytarabine, Idarubicin) plus Azacitidine|IDAC|Etoposide, Cytarabine",4,Induction|Re-induction|Maintenance|Supportive/Palliative Care,Refractory,Supportive/Palliative Care,-1,Standard Chemotherapy,"Etoposide, Cytarabine",Supportive/Palliative Care,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0,20,3.8,7.8,,40,5.2,40,,9,49,3.1,1.41,,25.7,8.5,"46,XY[20]",675,,"nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",30,"CD2(-), CD3(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(small subset+), CD16(-), CD19(-), CD20(-), CD33(+), CD34(+),CD36(-), CD38(dim+), CD45(dim +), CD56(-), CD64(variably+), CD117(+), HLA-DR(dim +), MPO(partial +), and TdT(-).",6.9,4.9,FALSE,FALSE,,negative,negative
14-00476,BA3013,1670,Male,Male,HispNative,4,n,47,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,47,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,3,Standard Chemotherapy|Supportive/Palliative Care|Intrathecal,5,"HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide",5,Consolidation|Induction|CNS|Re-induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,7,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,9,Dead,Dead-Disease,FALSE,FALSE,,0,,70,79,,,,2,,,,,,,M5,,,"46,XY,t(11;19)(q23;p13.1)[20]",,,,,"CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19",,261.2,FALSE,FALSE,,positive,negative
14-00488,BA2405,1675,Female,Female,White,3,n,44,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",44,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction,Unknown,Standard Chemotherapy,-1,Targeted Therapy - Kinase Inhibitor(s),Ponatinib,Experimental,-1,Dead,Dead-Unknown,TRUE,TRUE,14-00487,-1,,86.1,65,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,"Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia",,11.38,TRUE,TRUE,14-00487,positive,negative
14-00355,BA2935,1602,Male,Male,White,4,n,78,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,78,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3,"Azacitidine|Sorafenib|Decitabine, Midostaurin",3,Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,317,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,8,Dead,Dead-Disease,TRUE,FALSE,14-00356,-14,,,,,,,,,,,,,,,,,"46,XY[25]",,,,,,,,TRUE,FALSE,14-00356,positive,negative
16-00157,BA2477,2538,Male,Male,White,1,n,67,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,67,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,4,"AG-120|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC",4,Consolidation|Salvage|Induction|Experimental,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,-1,Alive,Alive,FALSE,FALSE,,0,0,93,94,0,0,1,2.8,1.9,0.1,20,30,2.4,1.23,,31.2,10.1,"46,XY[20]",,96.3,Normal,30,"partial CD7, CD13, dim CD15, CD33, CD38, CD58, CD117, dim CD123, HLA-DR and partial MPO+.",,125.16,FALSE,FALSE,,negative,positive
15-00201,BA2479,2016,Female,Female,White,5,n,71,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,71,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,n,y,n,n,2,Standard Chemotherapy|Targeted Therapy - Other,2,"Azacitidine|Venetoclax (ABT-199), Azacitidine",2,Induction|Experimental,Complete Response,Standard Chemotherapy,-1,Targeted Therapy - Other,"Venetoclax (ABT-199), Azacitidine",Experimental,115,Alive,Alive,TRUE,TRUE,15-00200,0,,65,,,,,,,,,,,,,,,"46,XX[20]",,,,96,"positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR",,1.6,TRUE,TRUE,15-00200,negative,positive
15-00464,BA2052,2147,Male,Male,White,2,n,71,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Supportive/Palliative Care,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Supportive/Palliative Care,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Dead,Dead-Unknown,FALSE,FALSE,,-3,0.9,,,2.8,,,,,,28,27,4.2,1.18,,29.3,9.8,"46,XY,inv(4)(p14p16.1)[3]/46,XY[16]",194,,"nuc ish(D5S2064,D5S630,EGR1)x4[32/200],(D7Z1,D7S522)x4[17/200],(D8Z2, D20S108)x4[27/200],(RUNX1T1,RUNX1)x4[32/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[21/200],(PML,RARA)x4 [34/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[35/200]",73,,7.1,,FALSE,FALSE,,negative,negative
15-00990,BA2885,2459,Female,Female,White,1,n,81,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,81,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Supportive/Palliative Care,1,Azacitidine,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Azacitidine,Supportive/Palliative Care,6,Dead,Dead-Disease,FALSE,FALSE,,0,0,90,70,0,0.8,6.1,72.2,12.2,0.4,62,50,2.9,4.22,M5,22.8,7.3,"46,XX[20]",262,90.8,Normal,29,"CD11b, variable CD13, variable CD14, CD33, CD56, CD64, dim CD123 and dim HLA-DR positive",5.8,97.26,FALSE,FALSE,,negative,positive
14-00012,BA2455,1406,Male,Male,White,4,n,72,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Supportive/Palliative Care,1,Hydroxyurea,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1,Dead,Dead-Disease,TRUE,FALSE,14-00013,0,,94,71,,,,0,,,,,,,M5,,,"48,XYY,+8[21]",,,,,"CD38, CD56, CD13(dim), CD64, CD11c, CD4, CD56, HLA-DR, and CD15",,24.2,TRUE,FALSE,14-00013,negative,positive
15-00073,BA2538,1963,Male,Male,White,2,n,81,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",81,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Supportive/Palliative Care|Targeted Therapy - Other,2,AG-221|Hydroxyurea,2,Experimental|Supportive/Palliative Care,,,,Targeted Therapy - Other,AG-221,Experimental,14,Dead,Dead-Disease,FALSE,FALSE,,-8,0,,12,0,,69,5,12,,30,41,3.3,0.76,,30.3,10.5,"46,XY[20]",227,85.6,"nuc ish(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(CCND1,IGH)x2[199]",117,,8.8,33.1,FALSE,FALSE,,negative,negative
14-00063,BA2871,1443,Female,Female,White,3,n,80,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,80,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Unknown,1,Bevacizumab,1,Unknown,,,,Unknown,Bevacizumab,Unknown,-1,Dead,Dead-Disease,FALSE,FALSE,,-4,,,,,,,,,,,,,,,,,"44-47,XX,del(5)(q13q33),der(14;18)(q10;q10),-20,-21,+1-4mar[cp15]",,,,,,,,FALSE,FALSE,,negative,negative
12-00294,BA2751,825,Male,Male,White,1,n,72,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,n,y,y,n,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,Dead-Other,FALSE,FALSE,,0,0,95,96,0,,3,0,1,,47,58,2.7,0.96,M4,16.5,5.6,"46,XY[20]",697,114,Normal,51,"Blasts: partial CD13, CD34, CD38, CD58, dim CD123, cTdT, HLA-DR, and partial/dim cMPO positive; Promonocyte/monoblast: CD11b, CD14, dim CD33, CD38, CD58, CD64, HLA-DR and dim cMPO positive",4.9,97,FALSE,FALSE,,positive,negative
13-00202,BA2782,1086,Male,Male,White,3,n,53,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,53,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,Dead-Other,FALSE,FALSE,,-1,,73,32,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,"atypical monocytic cells expressing weaker than   normal CD13 and CD33, with increased promonocytes/monoblasts representing approximately 44% of the leukocytes,",,22.79,FALSE,FALSE,,negative,positive
13-00406,BA2742,1190,Male,Male,White,1,n,62,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,62,0,Initial Acute Leukemia Diagnosis,Leukapheresis,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,Dead-Disease,FALSE,FALSE,,0,0,95,66.3,0,,9.5,1.9,4.8,0.2,93,104,3.2,1.85,M5,26.2,8.5,"46,XY[20]",2941,104.8,Normal,92,"CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38,      partial CD56, CD58, CD64, CD123, and HLA-DR positive",6.5,250.23,TRUE,TRUE,13-00409,positive,negative
13-00409,BA2316,1190,Male,Male,White,1,n,62,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,IntermediateOrAdverse,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,62,1,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,Dead-Disease,TRUE,TRUE,13-00406,0,0,95,95,0,,9.5,1.9,4.8,0.2,93,104,3.2,1.85,M5,26.2,8.5,"46,XY[20]",2941,104.8,Normal,92,"CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38, partial CD56, CD58, CD64, CD123, and HLA-DR positive",6.5,250.23,FALSE,FALSE,,positive,negative
16-00115,BA2621,2522,Male,Male,White,6,n,74,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",74,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,Dead-Disease,FALSE,FALSE,,0,,19,7,4,,12,2,51,,29,38,3.7,0.86,,24.2,7.8,"45,XY,-7,del(12)(p11.2p13)[20]",,90.6,Monosomy 7 is detected in 87% of cells.,35,,6.6,47.5,FALSE,FALSE,,negative,negative
15-00300,BA2440,2067,Male,Male,White,5,n,76,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,76,1,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,FALSE,FALSE,,0,,20,,,,,,,,,,,,,,,"41~42,XY,del(3)(p13p21),add(4)(q21),add(5)(q11.2),-7,-10,add(12)(p11.2),-15,add(15)(q21),add(17)(p11.2),-19,-20,-22,+2mar[cp6]/42~43,sl,+21[cp5]/42,sl,i(21)(q10)[cp2]/43~44,sl,+add(7)(p11)[cp2]/43~46,sl,+add(7)(p11),+21[cp4]/81~87<4n>,slx2[cp2]",,,"Loss of chromosome 5q31 sequences (73.5%)                Loss of chromosome 7 sequences (monosomy 7) (61.5%)                Gain of 21q22 (AML1) sequences (11.5%)                Polysomy for 8, 20q (7.5%), 11q, 15q, 16q and 17q sequences",91,,,5.6,FALSE,FALSE,,negative,negative
16-00354,BA2300,2632,Male,Female;Male,White,3,n,79,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,79,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,FALSE,FALSE,,-1,,86,87,,,,,,,,,,,,,,"43-45,X,-Y,del(5)(q22q35),del(7)(q22),+8,-9,add(9)(p13),+11,-13,-14,add(16)(q24),-17,-18,del(20)(q11.2q13.2),+2-3mar[cp21]",,,5q31 (EGR1): deletion present  8q22 (RUNX1T1): gain present  11q23 (KMT2A; also known as MLL): gain present ,27,,,70.01,FALSE,FALSE,,negative,negative
16-01093,BA2082,4229,Male,Male,White,2,n,61,FALSE,TRUE,FALSE,None,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",61,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,,FALSE,FALSE,,0,0,48,6,0,,31,14,47,,27,27,4.2,0.86,,36.9,12.6,"47,XY,t(8;19)(q24.1;q13.1),+10[17]/46,XY[3]",294,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",175,,7,2.43,FALSE,FALSE,,negative,negative
13-00260,BA2947,1117,Male,Male,White,1,n,14,FALSE,TRUE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,14,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,1,"COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)",1,Induction,Complete Response,Standard Chemotherapy,133,Standard Chemotherapy,"COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)",Induction,133,Alive,Alive,FALSE,FALSE,,0,0,62,64,0,,28,1,7,,15,9,4.1,0.58,M2,18.5,6.3,"45,X,-Y,t(8;21)(q22;q22)[4]/45,idem,del(9)(q12q22)[13]/46,XY[3]",486,105.8,"RUNX1T1/ RUNX1 fusion and t(8;21),",63,"CD13, CD33, CD34, dim CD45, partial CD56, CD58, dim CD117, HLA-DR, MPO, and partial TdT-positive",7.9,13.3,FALSE,FALSE,,negative,negative
13-00245,BA2909,1108,Male,Male,Asian,1,n,8,FALSE,TRUE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,8,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",2,Induction|Intensification,Complete Response,Standard Chemotherapy,11,Standard Chemotherapy,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",Intensification,62,Alive,Alive,FALSE,FALSE,,0,0,30,17,0,,33,17,20,,,,,0.53,M2,29.3,10.3,"46,XY,t(8;21)(q22;q22)[5]/46,idem,der(7)t(7;8)(q22;q11.2)[13]/46,XY[2]",,93.5,t(8;21),109,"dim CD7, CD13, CD33, CD34, CD38, partial CD56,CD58, CD117, CD123, dim HLA-DR, and MPO",,19.5,FALSE,FALSE,,negative,negative
13-00146,BA2449,1046,Female,Female,White,1,n,7,FALSE,TRUE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,7,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,n,y,y,n,y,1,Standard Chemotherapy,1,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,9,Standard Chemotherapy,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",Re-induction,-1,Dead,Dead-Other,FALSE,FALSE,,0,0,85,30,0,,42,0,27,,18,19,3.9,0.41,,27.7,9.4,"46,XX,t(8;21)(q22;q22)[19]/46,XX[1]",747,90.5,"AML/ETO fusion, t(8;21)",71,"CD13, CD33, CD34, CD56, CD71, CD117, HLA-DR, MPO-positive",7.3,4.8,FALSE,FALSE,,negative,negative
13-00615,BA2294,1375,Female,Male,HispNative,4,n,62,FALSE,TRUE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,62,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Induction,-1,Alive,Alive,FALSE,FALSE,,0,,52,57,,,,6,,,,,,,,,,"46,XY,t(8;21)(q22;q22)[14]",,,,,"CD34, PARTIAL CD38, CD33, CD13, CD64, PARTIAL CD11C, PARTIAL CD19, HLA-DR, PARTIAL CD15, CD117, AND MPO",,12.9,FALSE,FALSE,,negative,negative
16-00474,BA2306,2694,Male,Male,AdmixedBlack,6,n,50,FALSE,TRUE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,50,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Unknown,Standard Chemotherapy,20,Standard Chemotherapy,HiDAC,Consolidation,182,Alive,Alive,FALSE,FALSE,,-1,,70,91,0,,7,2,0,,23,25,2.4,0.66,,26.6,8.7,"46,XY,t(8;21)(q22;q22)[20]",,94.7,,28,,6.3,71.1,FALSE,FALSE,,negative,negative
15-00756,BA2121,2305,Male,Male,White,1,n,36,FALSE,TRUE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Intermediate,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,36,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Hydroxyurea",2,Consolidation|Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,103,Alive,Alive,FALSE,FALSE,,0,0,25,38,0,3.4,29.1,2.6,23.9,0,32,39,2.3,0.7,,21,7.5,"45,X,-Y,t(8;2;21)(q22;p21;q22)[20]",,104.5,RUNX1T1/RUNX1: (92%),29,"CD13, CD33, partial CD34, CD64, CD19 dim, CD71, CD117 partial, HLA-DR, dim CD123, CD58 and MPO",6.7,24.98,FALSE,FALSE,,negative,negative
14-00643,BA2354,1763,Male,Male,Asian,1,n,37,FALSE,TRUE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,37,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Busulfan, Cyclophosphamide",4,Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,0,Alive,Alive,FALSE,FALSE,,0,0.8,,,0,7.5,17.5,0,37.5,0.4,22,13,3,0.89,M2,15.8,5.5,"45,X,-Y,t(8;21)(q22;q22)[20]",411,100.6,"RUNX1T1/RUNX1:  94% of cells had the dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.",42,"dim CD7, CD13, dim CD33, CD34, CD38, CD56, dim partial      CD64, CD117, dim CD123, HLA-DR, MPO, dim TdT positive",7,8.15,FALSE,FALSE,,negative,negative
15-00763,BA2944,2307,Male,Male,White,3,n,23,FALSE,TRUE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,23,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin)|Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)",2,Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,-4,,,,,,,,,,,,,,,,,"46,XY,add(6)(q23),del(7)(q33),t(8;21)(q22;q22)[2]/46,sl,add(17)(p11.1)[5]/46,sdl1,add(16)(p11.2)[2]/46,sdl2,add(3)(q21)[8]/46,sdl3,add(20)(q11.2)[3]",,,62% t(8;21) (RUNX1T1;RUNX1) translocation present,,,,,FALSE,FALSE,,negative,negative
15-00807,BA2978,2333,Female,Female,HispNative,1,n,14,FALSE,TRUE,FALSE,RUNX1-RUNX1T1,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Adverse,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,14,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Busulfan, Cyclophosphamide",2,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,189,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,Alive,FALSE,FALSE,,-3,,,,,,,,,,,,,,,,,"46,XX,t(8;21)(q21.3;q22)[17]/49,sl,+4,+15,+der(21)t(8;21)[2]/53,sdl,-4,+13,+18,+19,+20,+21[4]",,,"All twenty-three metaphase cells examined were abnormal, with t(8;21), leading to RUNX1/RUNX1T1 fusion.   Two subclones, comprising 6 cells total, had an additional copy of the der(21).",,,,,FALSE,FALSE,,negative,negative
14-00175,BA2567,1508,Male,Male,White,3,n,46,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,46,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,3,DLI|Standard Chemotherapy|Bone Marrow Transplant,8,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Clofarabine|ODSH (2 O, 3-O Desulfated Heparin) ",6,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Post-Transplant Relapse,Complete Response,Standard Chemotherapy,-1,DLI,Donor Lymphocyte Infusion,Post-Transplant Relapse,-1,Dead,Dead-Disease,TRUE,FALSE,14-00176,0,,25.9,0.5,,,,,,,,,,,M5,,,,,,Normal,,"Increased atypical CD56 positive, weak CD117 positive myelomonocytic cells representing approximately 23% of the leukocytes",,3.6,TRUE,FALSE,14-00176,negative,negative
14-00023,BA2325,1409,Female,Female,White,1,n,74,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,74,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,n,y,y,n,y,1,Standard Chemotherapy,1,"3+7 (Cytarabine, Daunorubicin)",1,Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,6,Alive,Alive,FALSE,FALSE,,0,0.9,,,0,,11.4,44.7,35.1,7.1,17,28,2.6,0.79,,28.1,9.4,,645,98.3,,71,,6.2,35.91,FALSE,FALSE,,negative,positive
15-00302,BA2036,2068,Female,Female,White,3,n,65,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,UNKNOWN,Standard Chemotherapy,-1,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,-1,Dead,Dead-Other,FALSE,FALSE,,0,,,,,,,,,,,,,,,,,,,,,,"Large population of atypical myeloblasts (CD56 positive,  weak CD117 positive, CD34 negative, HLA-DR negative),  representing approximately 87% of the leukocytes,  consistent with acute myeloid leukemia",,,FALSE,FALSE,,negative,positive
15-00961,BA2109,2444,Female,Female,White,1,n,52,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,52,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,8,Standard Chemotherapy,HiDAC,Consolidation,81,Alive,Alive,FALSE,FALSE,,0,0,,,30,13,9,21,19,0.1,54,50,2.2,0.84,,18.8,6.5,,,98.9,,21,,6.5,65.58,FALSE,FALSE,,negative,negative
13-00253,BA2653,1113,Female,Female,White,1,n,42,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,42,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,4,Dead,Dead-Disease,FALSE,FALSE,,0,0,70,9,0,,43,6,38,,36,28,3.5,0.81,M7,34.8,12,,762,85.2,"Extra signals were observed for BCR (22q11.2), PML (15q22), MLL (11q23),     RUNX1T1 (8q21.3) and RUNX1 (21q22) in roughly 45-60% of interphase cells.     These results suggest the presence of a hyperdiploid clone.",13,"CD7, CD13, CD33, CD58, partial CD61, CD71, and Factor 8 positive",6.8,7.9,FALSE,FALSE,,negative,negative
16-00498,BA2022,2706,Female,Female,White,3,n,33,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,33,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"ATRA, Arsenic Trioxide",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Consolidation,-1,Alive,Alive,FALSE,FALSE,,0,,,,,,,,,,,,,,,,,,,,This analysis showed evidence of a PML-RARA rearrangement in 177/200 (88.5 percent) interphase cells scored.,26,"Large population of CD117pos, CD34neg, HLA-DR neg myeloblasts, representing 78% of leukocytes consistent w/AML.",,12.75,FALSE,FALSE,,positive,negative
15-00471,BA2868,2142,Male,Male,White,3,y,69,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,69,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Dead,Dead-Disease,FALSE,FALSE,,0,,60,,,,,,,,,,,,,,,,,,,,"weak  CD7, CD13, partial CD15, weak CD33, CD34, weak CD64, CD117,  myeloperoxidase, and HLA-DR, but do not express CD14(MO2),  CD42b, or CD61.",,33,FALSE,FALSE,,negative,negative
14-00078,BA2227,1450,Male,Male,White,1,n,17,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",17,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,n,y,y,n,1,Standard Chemotherapy,3,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Clofarabine, Cyclophosphamide, Etoposide|HAM (Cytarabine, Mitoxantrone)",2,Induction|Re-induction,Refractory,Standard Chemotherapy,74,Standard Chemotherapy,"Clofarabine, Cyclophosphamide, Etoposide",Re-induction,5,Dead,Dead-Disease,FALSE,FALSE,,0,0,,,0,,48.5,0.6,1.2,1.6,18,11,3.5,0.7,,25.6,9.1,,,87.4,Normal,25,,6.9,4.34,FALSE,FALSE,,negative,negative
16-01100,BA2456,4231,Male,Male,White,2,n,65,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Cytarabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Cytarabine,Supportive/Palliative Care,-1,Dead,Dead-Unknown,FALSE,FALSE,,0,,,,,,,,,,,,,,,,,,,,"nuc ish (PML,RARA)x2[199]",,,,,FALSE,FALSE,,negative,positive
16-00269,BA2400,2593,Female,Female,White,1,n,44,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,44,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,8,Standard Chemotherapy,HiDAC,Consolidation,99,Alive,Alive,TRUE,FALSE,16-00268,0,0,65,11.2,3.5,0,76.7,0,8.6,0,19,11,2.8,0.53,,23.7,7.8,,197,100.4,Normal,222,"CD13, CD33, CD117, CD123, dim HLA-DR and MPO",6.1,2.41,FALSE,FALSE,,negative,positive
15-00123,BA2806,1969,Male,Male,White,2,n,42,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,Intermediate-I,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,42,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5,Bone Marrow Transplant,Bu/Cy/ATG,Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,,81,85,,,4,7,4,,89,50,3,0.94,,27.8,9.5,,945,95.5,,39,"partialCD4, partial/dimCD7, partialCDllb, CD13, partialCD15, partialCD22, partialCD25, brightCD33, partialCD34, CD38, CD45, CD117, partialCD123, HLA-DR, partialMPO, partialTdT",5.7,48.03,FALSE,FALSE,,positive,positive
15-00965,BA2242,2447,Female,Female,White,1,n,61,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC",4,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,Alive,FALSE,FALSE,,0,0,,,0,0,89.9,9.3,0.8,0,43,31,2.4,0.5,,19.5,6.5,,313,92.4,normal,32,,5.8,67.36,FALSE,FALSE,,negative,positive
14-00832,BA2620,1868,Female,Female,White,1,n,65,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,IntermediateOrAdverse,Intermediate-II,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,65,0,Initial Acute Leukemia Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,0,Alive,Alive,FALSE,FALSE,,0,0.8,,30,0,12.5,24.2,28.3,18.4,0,23,29,3,0.78,,22.4,7.4,,561,107.2,,60,"CD7, minor subset CD11b, CD13, minor subset CD14,      dim CD33, CD34, CD38, CD58, minor subset CD64, CD117, CD123, HLA-DR, subset      myeloperoxidase positive",6.6,31.66,FALSE,FALSE,,positive,negative
13-00466,BA2063,1566,Male,Male,White,2,n,71,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,n,y,y,n,2,Standard Chemotherapy|Targeted Therapy - Other,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|BL-8040",4,Consolidation|Salvage|Induction|Experimental,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,Cytarabine,Salvage,-1,Dead,Dead-Disease,FALSE,FALSE,,0,0.5,,0,2.5,,56.8,2.6,37.6,,21,27,3.9,0.93,,33.4,11.2,,195,,,89,,6.9,2,FALSE,FALSE,,negative,negative
15-00892,BA2512,2421,Female,Female,White,3,n,72,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,Not Enough Information,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,0,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Targeted Therapy - Other,1,SGN-CD33A,1,Experimental,,,,Targeted Therapy - Other,SGN-CD33A,Experimental,-1,Dead,Dead-Disease,FALSE,FALSE,,0,,,,,,,,,,,,,,,,,,,,Normal,,,,,FALSE,FALSE,,negative,positive
14-00126,BA2812,1451,Male,Male,White,3,n,46,FALSE,TRUE,FALSE,Unknown,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",Intermediate,Not Enough Information,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",46,14,Initial Acute Leukemia Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Alive,Alive,FALSE,FALSE,,0,,,,,,,,,,,,,,,,,,,,,,,,,FALSE,FALSE,,negative,negative
